## **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup>:
C07D 213/65, 213/68, 295/108, 295/13, 409/04

(11) International Publication Number:

WO 98/00402

(43) International Publication Date:

8 January 1998 (08.01.98)

(21) International Application Number:

PCT/KR97/00128

A1

(22) International Filing Date:

28 June 1997 (28.06.97)

(30) Priority Data:

Lifting Dam.		
1996/25825	29 June 1996 (29.06.96)	KR
1996/25826	29 June 1996 (29.06.96)	KR
1996/25827	29 June 1996 (29.06.96)	KR
1996/40596	18 September 1996 (18.09.96)	KR
1997/22984	3 June 1997 (03.06.97)	KR
1997/22985	3 June 1997 (03.06.97)	KR
1997/23192	4 June 1997 (04.06.97)	KR
1997/23193	4 June 1997 (04.06.97)	KR

(71) Applicant (for all designated States except US): SAMJIN PHARMACEUTICAL CO., LTD. [KR/KR]; 338-8, Seokyo-dong, Mapo-ku, Seoul 121-739 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHO, Eui-Hwan [KR/KR]; #105-101, Hyndai 1st Apt., Kaepo-dong, Kangnam-ku, Seoul 135-240 (KR). CHUNG, Sun-Gan [KR/KR]; #131-904, Mokhwa Apt., 850, Keumjeong-dong, Kunpo, Kyungki-do 435-050 (KR). LEE, Sun-Hwan [KR/KR]; #105-403, Daelim Apt., Dokkok-dong, Pangtak, Kyungki-do 459-100 (KR). KWON, Ho-Seok [KR/KR];

#506-1105, Sinddonga Apt., 1274, Kwonsun-dong, Kwonsun-ku, Suweon, Kyungki-do 441-390 (KR). LEE, Jae-Eung [KR/KR]; 390-3, Sinjang-dong, Hannam, Kyungki-do 465-032 (KR). KANG, Dong-Wook [KR/KR]; #268-203, Jookong Apt., Wonmoon-dong, Kwachon, Kyungki-do 465-032 (KR). JOO, Jeong-Ho [KR/KR]; 289-83, Noryangjin 2-dong, Dongjak-ku, Seoul 156-052 (KR). LEE, Young-Hee [KR/KR]; 866-5, Bono 1-dong, Ansan, Kyungki-do 425-181 (KR).

(74) Agent: PARK, Sa-Ryong; 823-5, Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).

(81) Designated States: AU, BG, BR, CA, CN, CZ, HU, JP, MX, NO, NZ, PL, RO, RU, SG, SK, TR, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

#### Published

With international search report.

(54) Title: PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

#### (57) Abstract

The present invention relates to novel compound having strong antitumor activities of general formula (I), wherein  $R_1$  and  $R_2$  are independently hydrogen, substituted or unsubstituted  $C_1$ - $C_6$  cycloalkyl, substituted or unsubstituted  $C_2$ - $C_6$  unsaturated alkyl, ketone, substituted or unsubstituted aryl, substituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted or unsubstituted arylhydroxy, substituted or unsubstituted arithmet.  $C_1$ - $C_4$  lower thioester, thiol, substituted or unsubstituted crunsubstituted crunsubstit

$$\begin{array}{c|c}
R_3 & R_4 \\
R_1 & A & Z
\end{array}$$

$$\begin{array}{c|c}
R_3 & R_4 \\
R_7 & R_6
\end{array}$$

$$\begin{array}{c|c}
R_1 & R_6
\end{array}$$

$$\begin{array}{c|c}
R_1 & R_6
\end{array}$$

stituted or unsubstituted C<sub>1</sub>-C<sub>4</sub> lower thioalkoxy; or R<sub>1</sub> and R<sub>2</sub> are fused to form C<sub>3</sub>-C<sub>4</sub> saturated or unsubstituted chain; R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are independently hydrogen, halogen, hydroxy, nitro, C<sub>1</sub>-C<sub>4</sub> lower ester, C<sub>1</sub>-C<sub>4</sub> lower alkyl, C<sub>1</sub>-C<sub>4</sub> lower thioalkyl, substituted or unsubstituted aryl, substituted or unsubstituted lower arylalkoxy, substituted or unsubstituted lower alkylamino, or lower alkyl substituted or unsubstituted carbamate; or among R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub>, two adjacent groups are bonded with each other to form 1,2-phenylene or 2,3-naphthylene; X is oxygen, sulfur, or substituted or unsubstituted imino; Y is bonded at the 3-position or 4-position of the aromatic ring part wherein Y is oxygen or -NR<sub>8</sub>- (wherein, R<sub>8</sub> is the same with the above-mentioned R<sub>3</sub>); Z is hydroxy, C<sub>1</sub>-C<sub>4</sub> lower alkoxy, C<sub>1</sub>-C<sub>4</sub> lower thioalkoxy, substituted or unsubstituted aryloxy, C<sub>1</sub>-C<sub>4</sub> lower alkylamino, substituted or unsubstituted cycloamino containing 1-5 nitrogen atoms; A is nitrogen or -CH=; its pharmaceutically acceptable acid addition salts and process for the preparation thereof.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	E8	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	Pl	Pinland	LT	Lithumia	SIC	Slovekia
AT	Austria	FR	Prance	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	8Z	Swaziland
AZ	Azerbailan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Hersegovina	GB	Georgia	MD	Republic of Moldova	TG	Togo
33	Barbados	GH	Chana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Paso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Himgary	ML	Mali	TT	Trinidad and Tobago
BJ	Benja	12	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL.	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	18	iceland	MW	Malawi	US	United States of America
CA	Canada	п	haly	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP.	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KB	Kenya	NL	Netherlands	YU	Yugoslavia .
CH	Switzerland	KG	Kyrgyzatan	NO	Norway	ZW	Zimbebwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Carnescon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
Ċΰ	Cuba	KZ	Kazakstan	RO	Romanie		
cz	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	u	Liechteastein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	82	Sweden		
ER	Estonia	LR	Liberia	SG	Singapore		
]							
1							

# Piperazine derivatives and process for the preparation thereof

The present invention relates to new piperazine derivatives of the general formula (I)

5

wherein R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C2-C8 unsaturated alkyl, ketone, substituted or unsubstituted aryl, substituted or unsubstituted C<sub>1</sub>-C<sub>4</sub> alkoxy, substituted or unsubstituted arylhydroxy, substituted or unsubstituted amino, C1-C4 lower ester, C1-C4 lower thioester, thiol, substituted or unsubstituted carboxyl, epoxy, substituted or unsubstituted C1-C4 lower thioalkoxy; or R<sub>1</sub> and R<sub>2</sub> are fused to form C<sub>3</sub>-C<sub>4</sub> saturated or unsaturated chain; R3, R4, R5, R6 and R7 are independently hydrogen, halogen, hydroxy, nitro, C1-C4 lower ester, C1-C4 lower alkyl, C1-C4 lower thioalkyl, substituted or unsubstituted C3-C6 cycloalkyl, C1-C4 lower alkoxy, C1-C4 lower thioalkoxy, substituted or unsubstituted aryl, substituted or unsubstituted lower arylalkoxy, substituted or unsubstituted lower alkylamino, or lower alkyl substituted or unsubstituted carbamate; or among R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub>, two adjacent groups are bonded with each other to form 1,2-phenylene or 30 2,3-naphthylene; X is oxygen, sulfur, or substituted or unsubstituted imino; Y is bonded at the 3-position or 4-position of the aromatic ring part wherein Y is oxygen or -NRs- (wherein, Rs is the same with the above-mentioned R<sub>3</sub>.); Z is hydroxy, C<sub>1</sub>-C<sub>4</sub> lower alkoxy, C<sub>1</sub>-C<sub>4</sub> lower thioalkoxy, substituted or unsubstituted aryloxy, C1-C4 lower alkylamino, 35 substituted or unsubstituted cycloamino containing 1-5 nitrogen atoms; A is nitrogen or -CH=; its pharmaceutically acceptable acid addition

salts and process for the preparation thereof.

In the above definitions, C1-C8 alkyl means straight or branched alkyl group such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl,

tert-butyl, pentyl, iso-pentyl, hexyl, heptyl, octyl, 2-methylpentyl or the like.

C<sub>1</sub>-C<sub>4</sub> lower alkyl means methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl.

Substituted or unsubstituted C3-C6 cycloalkyl means substituted or 10 unsubstituted cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, substituted cyclopropyl, substituted cyclopentyl, substituted cyclohexyl or the like.

C<sub>1</sub>-C<sub>4</sub> lower ester means a carboxyl group esterified by a lower alkyl group.

15 C<sub>1</sub>-C<sub>4</sub> lower alkoxy means methoxy, ethoxy, propoxy, isopropoxy, butyloxy, isobutyloxy, tert-butyloxy group or the like. C<sub>1</sub>-C<sub>4</sub> lower thioalkoxy means methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, tert-butylthio group or the like. C<sub>1</sub>-C<sub>4</sub> lower alkylamino means methylamino, ethylamino, propylamino,

20 butylamino group or the like. Aryloxy means phenoxy, substituted phenoxy, naphthyloxy or

substituted naphthyloxy or the like.

Cycloamino group containing 1-5 nitrogen atoms means pyrrolidinyl, pyrrolinyl, imidazolyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, piperazinyl or the like.

The present inventors had studied for a long time to find compounds having intensive antitumor activity. As the results, now we have finally found out the facts that the present compounds of the general

30 formula(I) and acid addition salts thereof have not only prominent antitumor activities but very low toxicities.

Accordingly, the one object of the present invention is to provide the novel compounds of the general formula(I) and acid addition salts thereof having not only prominent antitumor activities but very low 35 toxicities.

The other object of the present invention is to provide a process for

15

20

25

30

the preparation of the compounds of general formula(I) and acid addition salts thereof.

The compounds of the present invention can be mixed with pharmaceutically acceptable vehicles by a known method to give pharmaceutical compositions and the pharmaceutical compositions can be used to prevent or treat with various kinds of tumors of human beings or mammals.

Therefore, another object of the present invention is to provide pharmaceutical compositions containing the compounds of the general formula(I) or acid addition salts thereof as active ingredients. Acids which can be reacted with the compounds of the general formula(I) to form acid addition salts are pharmaceutically acceptable inorganic or organic acids; for example, inorganic acids such as hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid; organic acids such as formic acid, acetic acid, propionic acid, succinic acid, citric acid, maleic acid, malonic acid, glycolic acid, lactic acid; amino acids such as glycine, alanine, valine, leucine, isoleucine, serine, cysteine, cystine, asparaginic acid, glutamic acid, lysine, arginine, tyrosine, proline, sulfonic acids such as methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, toluene sulfonic acid; or the like. Vehicles which can be used in the preparation of pharmaceutical compositions containing the compounds of the general formula(I) as active ingredients are sweetening agent, binding agent, dissolving agent, aids for dissolution, wetting agent, emulsifying agent, isotonic agent, adsorbent, degrading agent, antioxident, antiseptics, lubricating agent, filler, perfume or the like, such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, silica, talc, stearic acid, stearin, magnesium stearate, calcium stearate, magnesium aluminum silicate, starch, gelatine, tragacanth gum, glycine, silica, alginic acid, sodium alginate, methyl cellulose, sodium carboxy methyl cellulose, agar, water, ethanol, polyethylenglycol, polyvinyl pyrrolidone, sodium chloride, potassium chloride, orange essence, strawberry essence, vanila aroma or the like. Daily dosage of the compound of the general formula(I) may be varied depending on age, sex of patient and the degree of disease. Daily dosage is 1.0mg to 5,000mg may be administered one to several times.

The compounds of the general formula (I) according to the present invention may be prepared by the following scheme I.

## Scheme I

10

15

25

30

35

 $R_1$  A Z  $R_1$  A Z  $R_2$   $R_3$   $R_4$   $R_7$   $R_6$ 

 $\begin{array}{c|c}
R_2 & X & R_3 & R_4 \\
\hline
R_1 & A & Z & R_7 & R_6
\end{array}$ 20 (I)

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, A, X, Y and Z are as defined above, and Lie is a leaving group such as halogen atom, sulfonyl or the like.

The above process comprises reacting a compound of the general formula(a) with a -C(=X)- group-providing agent in organic solvent to obtain a compound of the general formula(b) and successively reacting the compound of the general formula(b) with a compound of the general formula(c) to give the compound of the general formula(I). The used -C(=X)-group-providing agent preferably be selected from 1,1-carbonyldiimidazole, 1,1-carbonylthiodiimidazole, phosgene, thiophosgene, carbonyldiphenoxide, phenylchloroformate or the like. The reaction may be carried out in conventional organic solvent such as, for example, tetrahydrofuran, dichloromethane, chloroform,

acetonitrile.

And also the reaction is preferably carried out in the presence of coupling agent such as conventional inorganic or organic base. Such conventional inorganic or organic base used in the reaction means sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, triethylamine, pyridine, DBU or the like, and 1-1.5 equivalent, preferably 1-1.1 equivalent thereof may be used.

The reaction may be carried out between 3°C and boiling point of the solvent used, preferably at 50°C-100°C for 5 - 48 hours, preferably for 10 - 24 hours.

-C(=X)-group-providing agent may be used in an amount of 1 - 1.5 equivalent, preferably 1-1.1 equivalent to the starting compound.

A compound of the general formula(I) wherein Y is  $-NR_s-$  may be prepared by the following scheme II

Scheme II.

20

15

15

30

wherein, R1, R2, R3, R4, R5, R6, R7, R8, A, X and Z are as defined above.

A compound of the general formula(Ib) above may be prepared effectively by introducing R<sub>8</sub> providing agent into a compound of the general formula(Ia).

Rs providing agent preferably used in the above reaction is  $C_1$ - $C_R$  lower alkylhalogen,  $C_1$ - $C_8$  lower alkyl sulfonate, substituted or unsubstituted  $C_3$ - $C_8$  cycloalkylhalogen, arylhalogen, substituted or unsubstituted  $C_3$ - $C_R$  cycloalkyl sulfonate, arylsulfonate, or the like.

C<sub>1</sub>-C<sub>8</sub> lower alkylhalogen means methylchloride, methylbromide, methyliodide, ethylchloride, ethylbromide, ethyliodide, propylchloride, propylbromide, butylchloride, butylbromide, butylbromide, pentylbromide, penty

 $C_1$ - $C_8$  lower alkyl sulfonate means methylsulfonate, ethylsulfonate, propylsulfonate, butylsulfonate, pentylsulfonate, or the like.

Substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkylhalogen cyclopropylchloride, cyclopropylbromide, cyclopropyliodide, cyclobutylchloride, cyclobutylbromide, cyclobutyliodide, cyclopentylchloride, cyclopentylbromide, cyclopentyliodide, cyclopentylchloride, cyclopentylbromide, cyclopentyliodide, cyclopropyl methylchloride, cyclopropyl methylchloride, cyclobutyl methylchloride, cyclobutyl methylchloride, cyclobutyl methylchloride, cyclopentyl methylc

Arylhalogen means benzylchloride, benzylbromide, benzyliodide, benzoylchloride, benzoylbromide, benzoyliodide, toluylchloride, toluylbromide, toluyliodide, or the like.

35 Substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl sulfonate means cyclopropyl sulfonate, cyclobutyl sulfonate, cyclopentyl sulfonate,

cyclohexyl sulfonate, methylcyclopropyl sulfonate, methylcyclobutyl sulfonate, methylcyclopentyl sulfonate, methylcyclohexyl sulfonate, or the like.

5 Arylsulfonate means benzyl sulfonate, benzoyl sulfonate, toluyl sulfonate, or the like.

More particularly, a compound of the general formula (1a) may be reacted with an alkylating agent or arylating agent in a solvent at the temperature of 25-80°C, for 30 minutes - 20 hours to give the object compound of the general formula(Ib).

An alkylating agent or arylating agent may be used in amount of 1.0 - 1.5 equivalent.

Conventional organic solvent such as for example tetrahydrofuran, dichloromethane, acetonitrile, dimethylformamide may be used in the above reaction.

In the above reactions, if any acid material is formed, any basic material may be preferably added as scavenger in order to eliminate the acid material from the reaction phase. Such basic material may be alkali metal hydroxide, alkali earth metal hydroxide, alkali metal oxide, alkali earth metal oxide, alkali earth metal carbonate, alkali earth metal carbonate, alkali metal hydrogen carbonate, alkali earth metal hydrogen carbonate such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium oxide, potassium carbonate, sodium carbonate, calcium carbonate, magnesium carbonate, sodium bicarbonate, calcium bicarbonate or the like, or organic amines.

- 30 The compound of the general formula(a) is described in prior art ( J. Med. Chem., 1992, 35, 3784, 3792 ) or may be prepared in a similar method to the art.
- Hereinafter the present invention will be described in more details with reference to following examples but it is not intended to limit the scope

of the invention thereinto.

Compounds of the general formula(I) and formula(Ib) are prepared in following examples according to the above-mentioned process.

5

$$\begin{array}{c} X \\ X \\ R_1 \end{array} \qquad \begin{array}{c} X \\ Y - C - N \end{array} \qquad \begin{array}{c} R_3 \\ R_7 \end{array} \qquad \begin{array}{c} R_4 \\ R_6 \end{array}$$

15

10

$$R_2$$
 $R_1$ 
 $R_2$ 
 $R_3$ 
 $R_4$ 
 $R_6$ 
 $R_6$ 

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, A, X, Y, Z are the same above.

25

30

	Est				T		Τ		T	т—	<del></del>	7	т
	Ex. No.	Rı	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	A	Х	Y	z	Y
	1	Me	Me	SMe	Н	Н	Н	Н	N	0	NH	OMe	3-N
5	2	Ме	Me	人	Н	Н	Н	Н	N	0	NH	ОМе	3-N
	3	Me	Me	Me	Ме	Н	Me	Me	N	0	NH	OMe	3-N
	4	Me	Et	SMe	H	Н	H	Н	N	0	NH	OMe	3-N
10	5	Me	Et	人	Н	Н	Н	Н	N	0	NH	OMe	3-N
	6	Me	Et	Me	Ме	Н	Me	Me	N	0	NH	OMe	3-N
	7	Me	Et	H	SH	Н	Н	Н	N	0	NH	OMe	3-N
15	8	Me	nPr	Н	OMe	H	OMe	Н	N	0	NH	OMe	3-N
15	9	Me	nPr	Н	Me	H	Me	Н	N	0	NH	OMe	3-N
	10	Me	nPr	H	F	H	F	Н	N	0	NH	OMe	3-N
	11	Me	nPr	OMe	H	H	Н	Н	N	0	NH	OMe	3-N
20	12	Et	Me	H	OMe	Н	OMe	Н	N	0	NH	OMe	3-N
20	13	Et	Me	Н	Me	Н	Me	Н	N	0	NH	OMe	3-N
Į	14	Et	Me	Н	OH	Н	Н	Н	N	0	NH	OMe	3-N

Ex. No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	Ro	R <sub>7</sub>	A	x	Y	Z	Y
15	nPr	Me	Н	OMe	Н	OMe	Н	N	0	NH	OMe	3-N
16	nPr	Me	Н	Me	Н	Me	Н	N	0	NH	<del></del>	3-N
17	nPr	Me	H	ОН	Н	Н	Н	N	0	NH	<del> </del>	3-N
18	-(C	H <sub>2</sub> ) <sub>3</sub> -	Н	ОМе	Н	OMe	Н	N	0	NH	<del> </del>	3-N
19	-(C	H <sub>2</sub> ) <sub>3</sub> -	Н	Me	Н	Me	Н	N	0	NH	<del> </del>	3-N
20	-(C	H <sub>2</sub> ) <sub>4</sub> -	Н	OMe	H	OMe	Н	N	0	NH	<del> </del>	3-N
21	-(CI	H <sub>2</sub> ) <sub>4</sub> -	Н	Me	Н	Me	Н	N	0	<del> </del>	<del> </del>	3-N
22	Me	Me	H	Me	Н	Me	Н	N	S	<del> </del>	<del> </del>	3-N
23	Me	Me	Н	F	Н	F	Н	N	S	<del> </del>	<del> </del>	3-N
24	Me	Me	Н	OH	Н	Н	Н	N	S		<del> </del>	3-N
25	Me	nPr	Н	OMe	Н	OMe	Н	N	S		<del> </del> -	3-N
26	nPr	Me	H	OMe	Н	OMe	Н	N	S	NH	<del> </del>	3-N
27	nPr	Me	H	Me	Н	Me	Н	N	S		<del></del>	3-N
28	nPr	Me	H	OH	H.	Н	Н	7	S		<del> </del>	3-N
29	-(CI	I <sub>2</sub> ) <sub>3</sub> -	Н	OMe	Н	OMe	Н	Ν	S	NH		3-N
30	-(CI	I <sub>2</sub> ) <sub>3</sub> -	Н	Me	Н	Me	Н	N	S	NH		3-N
31	-(CF	2)4-	Н	OMe	Н	OMe	Н	N	S	NH		3-N
32	-(CH	2)4-	Н	Me	Н	Me	Н	N	S	NH		3-N
33	Me	Me	Н	ОМе	Н	OMe	Н	N	0			3-N
34	Ме	Me	Н	Me	Н	Me	Н	N	0			
35	Me	Et	H	Me	Н	Me	Н	N	0			
36	-(CH	2)3-	Н	ОМе	Н	OMe	Н	N	0			
37	-(CH	2)3-	H	Me	Н	Me	Н	N	0			<del></del> i
38	Me	Me	Н	OMe	Н	OMe	Н	N				3-N
39	Me	Ме	Н	Me	Н	Me	Н	N	0			3-N
	No. 15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31   32   33   34   35   36   37   38	No.       R1         15       nPr         16       nPr         17       nPr         18       -(C)         20       -(C)         21       -(C)         22       Me         23       Me         24       Me         25       Me         26       nPr         27       nPr         28       nPr         29       -(C)         31       -(C)         32       -(C)         33       Me         34       Me         35       Me         36       -(C)         37       -(C)         38       Me	No.       R1       R2         15       nPr       Me         16       nPr       Me         17       nPr       Me         18       -(CH₂)₃-         20       -(CH₂)₄-         21       -(CH₂)₄-         22       Me       Me         23       Me       Me         24       Me       Me         25       Me       nPr         26       nPr       Me         27       nPr       Me         28       nPr       Me         29       -(CH₂)₃-         30       -(CH₂)₃-         31       -(CH₂)₄-         32       -(CH₂)₄-         33       Me       Me         34       Me       Me         35       Me       Et         36       -(CH₂)₃-       3         37       -(CH₂)₃-       3         38       Me       Me	No.       R1       R2       R3         15 $nPr$ Me       H         16 $nPr$ Me       H         17 $nPr$ Me       H         18 $-(CH_2)_3-$ H         20 $-(CH_2)_4-$ H         21 $-(CH_2)_4-$ H         22       Me       Me       H         23       Me       Me       H         24       Me       Me       H         25       Me       nPr       H         26 $nPr$ Me       H         27 $nPr$ Me       H         28 $nPr$ Me       H         29 $-(CH_2)_3-$ H         30 $-(CH_2)_3-$ H         31 $-(CH_2)_4-$ H         32 $-(CH_2)_4-$ H         33       Me       Me       H         34       Me       Me       H         35       Me       Et       H         36 $-(CH_2)_3-$ H         36 $-(CH_2)_3-$ H	No.       R1       R2       R3       R4         15       nPr       Me       H       OMe         16       nPr       Me       H       Me         17       nPr       Me       H       OMe         18       -(CH2)3-       H       OMe         19       -(CH2)4-       H       OMe         20       -(CH2)4-       H       Me         21       -(CH2)4-       H       Me         22       Me       Me       H       Me         23       Me       Me       H       OMe         24       Me       Me       H       OMe         25       Me       nPr       H       OMe         26       nPr       Me       H       OMe         27       nPr       Me       H       OMe         28       nPr       Me       H       OMe         30       -(CH2)3-       H       Me         31       -(CH2)4-       H       Me         32       -(CH2)4-       H       Me         33       Me       Me       H       OMe         34       Me	No.       R₁       R₂       R₃       R₄       R₅         15       nPr       Me       H       OMe       H         16       nPr       Me       H       Me       H         17       nPr       Me       H       OMe       H         18       -(CH₂)₃-       H       OMe       H         19       -(CH₂)₃-       H       Me       H         20       -(CH₂)₄-       H       OMe       H         21       -(CH₂)₄-       H       Me       H         22       Me       Me       H       Me       H         23       Me       Me       H       OH       H         24       Me       Me       H       OH       H         25       Me       nPr       H       OMe       H         26       nPr       Me       H       OMe       H         27       nPr       Me       H       OH       H         29       -(CH₂)₃-       H       OMe       H         30       -(CH₂)₃-       H       Me       H         31       -(CH₂)₃-       H       Me	No.         R₁         R₂         R₃         R₄         R₅         R₆           15         nPr         Me         H         OMe         H         OMe           16         nPr         Me         H         Me         H         Me           17         nPr         Me         H         OH         H         H           18         -(CH₂)₃-         H         OMe         H         OMe           19         -(CH₂)₃-         H         Me         H         OMe         H         OMe           20         -(CH₂)₃-         H         Me         H         OMe         H         OMe           21         -(CH₂)₃-         H         Me         H         Me         H         Me           22         Me         Me         H         P         H         Me         Me         Me         H         OMe         H         OMe         H         OMe         Me         Me         H         Me         H         Me         Me         H         Me </td <td>No.         R₁         R₂         R₃         R₄         R₅         R₀         R₁           15         nPr         Me         H         OMe         H         OMe         H           16         nPr         Me         H         OMe         H         Me         H           17         nPr         Me         H         OMe         H         OMe         H           18         -(CH₂)₃-         H         OMe         H         OMe         H           19         -(CH₂)₃-         H         OMe         H         OMe         H           20         -(CH₂)₃-         H         OMe         H         OMe         H           21         -(CH₂)₃-         H         Me         H         Me         H           22         Me         Me         H         Me         H         Me         H           23         Me         Me         H         OH         H         H         H           24         Me         Me         H         OH         H         H         H           25         Me         nPr         H         OMe         H         OMe<td>No.         R₁         R₂         R₃         R₄         R₅         R₆         R₁         A           15         nPr         Me         H         OMe         H         OMe         H         N           16         nPr         Me         H         OMe         H         Me         H         N           17         nPr         Me         H         OMe         H         OMe         H         N           18         -(CH₂)₃-         H         OMe         H         OMe         H         N           19         -(CH₂)₃-         H         OMe         H         OMe         H         N           20         -(CH₂)₃-         H         OMe         H         Me         H         N           21         -(CH₂)₃-         H         Me         H         Me         H         Me         H         N           22         Me         Me         H         Me         H         Me         H         N           23         Me         Me         H         OH         H         H         N           25         Me         nPr         H         OMe</td><td>  No.   R1   R2   R3   R4   R5   R6   R7   A   X     15   nPr   Me   H   OMe   H   OMe   H   N   O     16   nPr   Me   H   OMe   H   Me   H   N   O     17   nPr   Me   H   OMe   H   OMe   H   N   O     18   -(CH2)3-   H   OMe   H   OMe   H   N   O     19   -(CH2)4-   H   OMe   H   OMe   H   N   O     20   -(CH2)4-   H   OMe   H   OMe   H   N   O     21   -(CH2)4-   H   Me   H   Me   H   N   O     22   Me   Me   H   Me   H   Me   H   N   S     23   Me   Me   H   OMe   H   OMe   H   N   S     24   Me   Me   H   OMe   H   OMe   H   N   S     25   Me   nPr   H   OMe   H   OMe   H   N   S     26   nPr   Me   H   OMe   H   OMe   H   N   S     27   nPr   Me   H   OMe   H   OMe   H   N   S     28   nPr   Me   H   OMe   H   OMe   H   N   S     29   -(CH2)3-   H   OMe   H   OMe   H   N   S     30   -(CH2)4-   H   OMe   H   OMe   H   N   S     31   -(CH2)4-   H   OMe   H   OMe   H   N   S     32   -(CH2)4-   H   OMe   H   OMe   H   N   O     33   Me   Me   H   OMe   H   OMe   H   N   O     34   Me   Me   H   OMe   H   OMe   H   N   O     35   Me   Me   H   OMe   H   OMe   H   N   O     36   -(CH2)3-   H   OMe   H   OMe   H   N   O     37   -(CH2)3-   H   OMe   H   OMe   H   N   O     38   Me   Me   H   OMe   H   OMe   H   N   O     39   Me   Me   H   OMe   H   OMe   H   N   O     39   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   Me   H   OMe   H   OMe   H   N   O     31   Me   Me   Me   H   OMe   H   OMe   H   N   O     32   Me   Me   Me   H   OMe   H   OMe   H   N   O     33   Me   Me   Me   H   OMe   H   OMe   H   N   O     34   Me   Me   Me   H   OMe   H   OMe   H   N   O     35   Me   Me   Me   H   OMe   H   OMe   H   N   O     36   Me   Me   Me   H   OMe   H   OMe   H   N   O     37   Me   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O     38   Me   Me   Me   Me   Me   Me   Me   M</td><td>  No.   R1   R2   R3   R4   R5   R6   R7   A   X   Y     15   nPr   Me   H   OMe   H   OMe   H   N   O   NH     16   nPr   Me   H   OMe   H   Me   H   N   O   NH     17   nPr   Me   H   OMe   H   OMe   H   N   O   NH     18   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     19   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     20   -(CH2)4-   H   OMe   H   OMe   H   N   O   NH     21   -(CH2)4-   H   Me   H   Me   H   N   S   NH     22   Me   Me   H   Me   H   Me   H   N   S   NH     23   Me   Me   H   OHe   H   H   N   S   NH     24   Me   Me   H   OHe   H   OHe   H   N   S   NH     25   Me   nPr   H   OMe   H   OMe   H   N   S   NH     26   nPr   Me   H   OMe   H   OMe   H   N   S   NH     27   nPr   Me   H   OMe   H   OMe   H   N   S   NH     28   nPr   Me   H   OMe   H   OMe   H   N   S   NH     29   -(CH2)3-   H   OMe   H   OMe   H   N   S   NH     30   -(CH2)4-   H   OMe   H   OMe   H   N   S   NH     31   -(CH2)4-   H   OMe   H   OMe   H   N   S   NH     32   -(CH2)4-   H   OMe   H   OMe   H   N   O   NH     33   Me   Me   H   OMe   H   OMe   H   N   O   NH     34   Me   Me   H   OMe   H   OMe   H   N   O   NH     35   Me   Et   H   Me   H   Me   H   N   O   NH     36   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     37   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     38   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     30   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     30   Me   Me   H   OMe   H   OMe   H   N   O   NH     31   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     32   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O   NH     34   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O   NH     35   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O   NH     36   Me   Me   H   OMe   H   OMe   H  </td><td>  No.   R1   R2   R3   R4   R5   R6   R7   A   X   Y   Z    </td></td>	No.         R₁         R₂         R₃         R₄         R₅         R₀         R₁           15         nPr         Me         H         OMe         H         OMe         H           16         nPr         Me         H         OMe         H         Me         H           17         nPr         Me         H         OMe         H         OMe         H           18         -(CH₂)₃-         H         OMe         H         OMe         H           19         -(CH₂)₃-         H         OMe         H         OMe         H           20         -(CH₂)₃-         H         OMe         H         OMe         H           21         -(CH₂)₃-         H         Me         H         Me         H           22         Me         Me         H         Me         H         Me         H           23         Me         Me         H         OH         H         H         H           24         Me         Me         H         OH         H         H         H           25         Me         nPr         H         OMe         H         OMe <td>No.         R₁         R₂         R₃         R₄         R₅         R₆         R₁         A           15         nPr         Me         H         OMe         H         OMe         H         N           16         nPr         Me         H         OMe         H         Me         H         N           17         nPr         Me         H         OMe         H         OMe         H         N           18         -(CH₂)₃-         H         OMe         H         OMe         H         N           19         -(CH₂)₃-         H         OMe         H         OMe         H         N           20         -(CH₂)₃-         H         OMe         H         Me         H         N           21         -(CH₂)₃-         H         Me         H         Me         H         Me         H         N           22         Me         Me         H         Me         H         Me         H         N           23         Me         Me         H         OH         H         H         N           25         Me         nPr         H         OMe</td> <td>  No.   R1   R2   R3   R4   R5   R6   R7   A   X     15   nPr   Me   H   OMe   H   OMe   H   N   O     16   nPr   Me   H   OMe   H   Me   H   N   O     17   nPr   Me   H   OMe   H   OMe   H   N   O     18   -(CH2)3-   H   OMe   H   OMe   H   N   O     19   -(CH2)4-   H   OMe   H   OMe   H   N   O     20   -(CH2)4-   H   OMe   H   OMe   H   N   O     21   -(CH2)4-   H   Me   H   Me   H   N   O     22   Me   Me   H   Me   H   Me   H   N   S     23   Me   Me   H   OMe   H   OMe   H   N   S     24   Me   Me   H   OMe   H   OMe   H   N   S     25   Me   nPr   H   OMe   H   OMe   H   N   S     26   nPr   Me   H   OMe   H   OMe   H   N   S     27   nPr   Me   H   OMe   H   OMe   H   N   S     28   nPr   Me   H   OMe   H   OMe   H   N   S     29   -(CH2)3-   H   OMe   H   OMe   H   N   S     30   -(CH2)4-   H   OMe   H   OMe   H   N   S     31   -(CH2)4-   H   OMe   H   OMe   H   N   S     32   -(CH2)4-   H   OMe   H   OMe   H   N   O     33   Me   Me   H   OMe   H   OMe   H   N   O     34   Me   Me   H   OMe   H   OMe   H   N   O     35   Me   Me   H   OMe   H   OMe   H   N   O     36   -(CH2)3-   H   OMe   H   OMe   H   N   O     37   -(CH2)3-   H   OMe   H   OMe   H   N   O     38   Me   Me   H   OMe   H   OMe   H   N   O     39   Me   Me   H   OMe   H   OMe   H   N   O     39   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   Me   H   OMe   H   OMe   H   N   O     31   Me   Me   Me   H   OMe   H   OMe   H   N   O     32   Me   Me   Me   H   OMe   H   OMe   H   N   O     33   Me   Me   Me   H   OMe   H   OMe   H   N   O     34   Me   Me   Me   H   OMe   H   OMe   H   N   O     35   Me   Me   Me   H   OMe   H   OMe   H   N   O     36   Me   Me   Me   H   OMe   H   OMe   H   N   O     37   Me   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O     38   Me   Me   Me   Me   Me   Me   Me   M</td> <td>  No.   R1   R2   R3   R4   R5   R6   R7   A   X   Y     15   nPr   Me   H   OMe   H   OMe   H   N   O   NH     16   nPr   Me   H   OMe   H   Me   H   N   O   NH     17   nPr   Me   H   OMe   H   OMe   H   N   O   NH     18   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     19   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     20   -(CH2)4-   H   OMe   H   OMe   H   N   O   NH     21   -(CH2)4-   H   Me   H   Me   H   N   S   NH     22   Me   Me   H   Me   H   Me   H   N   S   NH     23   Me   Me   H   OHe   H   H   N   S   NH     24   Me   Me   H   OHe   H   OHe   H   N   S   NH     25   Me   nPr   H   OMe   H   OMe   H   N   S   NH     26   nPr   Me   H   OMe   H   OMe   H   N   S   NH     27   nPr   Me   H   OMe   H   OMe   H   N   S   NH     28   nPr   Me   H   OMe   H   OMe   H   N   S   NH     29   -(CH2)3-   H   OMe   H   OMe   H   N   S   NH     30   -(CH2)4-   H   OMe   H   OMe   H   N   S   NH     31   -(CH2)4-   H   OMe   H   OMe   H   N   S   NH     32   -(CH2)4-   H   OMe   H   OMe   H   N   O   NH     33   Me   Me   H   OMe   H   OMe   H   N   O   NH     34   Me   Me   H   OMe   H   OMe   H   N   O   NH     35   Me   Et   H   Me   H   Me   H   N   O   NH     36   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     37   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     38   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     30   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     30   Me   Me   H   OMe   H   OMe   H   N   O   NH     31   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     32   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O   NH     34   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O   NH     35   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O   NH     36   Me   Me   H   OMe   H   OMe   H  </td> <td>  No.   R1   R2   R3   R4   R5   R6   R7   A   X   Y   Z    </td>	No.         R₁         R₂         R₃         R₄         R₅         R₆         R₁         A           15         nPr         Me         H         OMe         H         OMe         H         N           16         nPr         Me         H         OMe         H         Me         H         N           17         nPr         Me         H         OMe         H         OMe         H         N           18         -(CH₂)₃-         H         OMe         H         OMe         H         N           19         -(CH₂)₃-         H         OMe         H         OMe         H         N           20         -(CH₂)₃-         H         OMe         H         Me         H         N           21         -(CH₂)₃-         H         Me         H         Me         H         Me         H         N           22         Me         Me         H         Me         H         Me         H         N           23         Me         Me         H         OH         H         H         N           25         Me         nPr         H         OMe	No.   R1   R2   R3   R4   R5   R6   R7   A   X     15   nPr   Me   H   OMe   H   OMe   H   N   O     16   nPr   Me   H   OMe   H   Me   H   N   O     17   nPr   Me   H   OMe   H   OMe   H   N   O     18   -(CH2)3-   H   OMe   H   OMe   H   N   O     19   -(CH2)4-   H   OMe   H   OMe   H   N   O     20   -(CH2)4-   H   OMe   H   OMe   H   N   O     21   -(CH2)4-   H   Me   H   Me   H   N   O     22   Me   Me   H   Me   H   Me   H   N   S     23   Me   Me   H   OMe   H   OMe   H   N   S     24   Me   Me   H   OMe   H   OMe   H   N   S     25   Me   nPr   H   OMe   H   OMe   H   N   S     26   nPr   Me   H   OMe   H   OMe   H   N   S     27   nPr   Me   H   OMe   H   OMe   H   N   S     28   nPr   Me   H   OMe   H   OMe   H   N   S     29   -(CH2)3-   H   OMe   H   OMe   H   N   S     30   -(CH2)4-   H   OMe   H   OMe   H   N   S     31   -(CH2)4-   H   OMe   H   OMe   H   N   S     32   -(CH2)4-   H   OMe   H   OMe   H   N   O     33   Me   Me   H   OMe   H   OMe   H   N   O     34   Me   Me   H   OMe   H   OMe   H   N   O     35   Me   Me   H   OMe   H   OMe   H   N   O     36   -(CH2)3-   H   OMe   H   OMe   H   N   O     37   -(CH2)3-   H   OMe   H   OMe   H   N   O     38   Me   Me   H   OMe   H   OMe   H   N   O     39   Me   Me   H   OMe   H   OMe   H   N   O     39   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   Me   H   OMe   H   OMe   H   N   O     30   Me   Me   Me   H   OMe   H   OMe   H   N   O     31   Me   Me   Me   H   OMe   H   OMe   H   N   O     32   Me   Me   Me   H   OMe   H   OMe   H   N   O     33   Me   Me   Me   H   OMe   H   OMe   H   N   O     34   Me   Me   Me   H   OMe   H   OMe   H   N   O     35   Me   Me   Me   H   OMe   H   OMe   H   N   O     36   Me   Me   Me   H   OMe   H   OMe   H   N   O     37   Me   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O     38   Me   Me   Me   Me   Me   Me   Me   M	No.   R1   R2   R3   R4   R5   R6   R7   A   X   Y     15   nPr   Me   H   OMe   H   OMe   H   N   O   NH     16   nPr   Me   H   OMe   H   Me   H   N   O   NH     17   nPr   Me   H   OMe   H   OMe   H   N   O   NH     18   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     19   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     20   -(CH2)4-   H   OMe   H   OMe   H   N   O   NH     21   -(CH2)4-   H   Me   H   Me   H   N   S   NH     22   Me   Me   H   Me   H   Me   H   N   S   NH     23   Me   Me   H   OHe   H   H   N   S   NH     24   Me   Me   H   OHe   H   OHe   H   N   S   NH     25   Me   nPr   H   OMe   H   OMe   H   N   S   NH     26   nPr   Me   H   OMe   H   OMe   H   N   S   NH     27   nPr   Me   H   OMe   H   OMe   H   N   S   NH     28   nPr   Me   H   OMe   H   OMe   H   N   S   NH     29   -(CH2)3-   H   OMe   H   OMe   H   N   S   NH     30   -(CH2)4-   H   OMe   H   OMe   H   N   S   NH     31   -(CH2)4-   H   OMe   H   OMe   H   N   S   NH     32   -(CH2)4-   H   OMe   H   OMe   H   N   O   NH     33   Me   Me   H   OMe   H   OMe   H   N   O   NH     34   Me   Me   H   OMe   H   OMe   H   N   O   NH     35   Me   Et   H   Me   H   Me   H   N   O   NH     36   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     37   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     38   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     39   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     30   Me   Me   Me   H   OMe   H   OMe   H   N   O   NH     30   Me   Me   H   OMe   H   OMe   H   N   O   NH     31   -(CH2)3-   H   OMe   H   OMe   H   N   O   NH     32   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O   NH     34   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O   NH     35   Me   Me   H   OMe   H   OMe   H   OMe   H   N   O   NH     36   Me   Me   H   OMe   H   OMe   H	No.   R1   R2   R3   R4   R5   R6   R7   A   X   Y   Z

	Ex No	1 1 1	R <sub>2</sub>	R <sub>3</sub>	R4	Rs	R <sub>6</sub>	R <sub>7</sub>	A	X	Y	Z	Y
	40	Me	Et	Н	OMe	Н	OMe	Н	N	0	NH	H_ks.	· 3-N
5	41	Me	Et	Н	Me	Н	Me	Н	N	0	NH	N N80	
J	42	Me	Me	H	OMe	Н	OMe	Н	N	0	NH	1 ( ) (H	
	43	Me	Ме	Н	Me	Н	Me	Н	N	0	NH		3-N
	44	Me	Et	Н	OMe	Н	OMe	Н	N	0	NH		3-N
10	45	Me	Et	H	Me	Н	Me	Н	N	0	NH	10m	3-N
10	46	Me	Ac	Н	ОМе	Н	OMe	Н	N	0	NH	OMe	<del></del>
	47	Me	Ac	H	Me	Н	Me	Н	N	0	NH	OMe	
	48	Me	Ac	Н	F	Н	F	Н	N	0	NH	OMe	
15	49	Me	Ac	Н	CI	Ĥ	CI	Н	N	0	NH	OMe	3-N
	50	Me	Ac	Me	Me	Н	Н	Н	N	0	NH	OMe	3-N
	51	Me	Ac	ОМе	Н	Н	Н	Н	N	0	NH	OMe	3-N
	52	Me	Ac	Н	ОН	Н	Н	Н	N	0	NH	OMe	3-N
20	53	Me	Ac	Н	OMe	Н	ОМе	Н	N	S	NH	OMe	3-N
	54	Me	Ac	Н	Me	H	Me	Н	N	S	NH	OMe	3-N
	55	Me	Ac	Н	ОН	Н	Н	Н	N	S	NH	OMe	3-N
	56	Me	<b>○</b> *	Н	ОМе	Н	OMe	H	N	0	NH		3-N
25	57	Me	OH	H	Me	Н	Me	Н	N	0	NH	OMe	3-N
	58	Ме	OH _	Me	Me	Н	Н	Н	N	0	NH	OMe	3-N
	59	Me	× ×	Н	F	Н	F	Н	N	0	NH		3-N
30	60	Ме	<u>~</u>	Н	Cl	Н	CI	Н	N	0	NH	OMe	
30	61	Ме	<u>o</u>	QMe	Н	Н	Н	Н	N	0	NH	OMe	
	62	Me	OH _	Н	ОН	Н	Н	н	N	0	NH	OMe	
	63	Ме	OH	Н	OMe	Н	OMe	Н	N	S	NH	OMe	
35	64	Ме	<u></u>	Н	Me	Н	Me	Н	N	S	NH	OMe	
					-						<del></del> -L		

	Ex No.	, ,	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	A	x	Y	Z	Y
	65	Me	×°*	Н	OMe	Н	OMe	Н	N	0	NH	OMe	3-N
5	66	Me	×°H	Н	Me	Н	Me	Н	N	0	NH		3-N
	67	Me	× OH	Н	OMe	Н	OMe	Н	N	0	NH	<del> </del>	3-N
	68	Me	×on	Н	Me	Н	Me	Н	N	0	NH	┼	3-N
10	69	Me	SCHOEM,	Н	ОМе	Н	OMe	Н	N	0	NH	<del> </del>	3-N
	70	Me	EMOEH,	Н	Me	Н	Me	Н	N	0	NH	<del> </del>	3-N
	71	Me	***	Н	OMe	Н	OMe	Н	N	0	NH	┼	3-N
15	72	Me	3H	Н	Me	Н	Me	Н	N	0	NH	OMe	<del> </del>
	73	Me	Vinyl	Н	OMe	Н	OMe	Н	N	0	NH	OMe	<del> </del> -
	74	Me	Vinyl	Н	Me	Н	Me	Н	N	0	NH	OMe	<del> </del> -
20	75	Me	Vinyl	Н	F	Н	F	Н	N	0	NH	OMe	
20	76	Me	人	Н	OMe	Н	OMe	Н	N	0	NH	OMe	3-N
	77	Me	人	Н	Me	Н	Me	Н	N	0	NH	OMe	3-N
25	78	Ме	ocu Loei	Н	ОМе	н	OMe	Н	N	0	NH	ОМе	
	79	Ме	ocu Žoti	Н	ОМе	Н	ОМе	Н	N	0	NH	ОМе	3-N
30	80	Me	oca žoti	Н	Me	Н	Me	Н	N	0	NH	ОМе	3-N
							-						

	Ex.	T	1	<del></del>	т—	7						
	No.	D and D.	R <sub>3</sub>	R4	Rs	R <sub>6</sub>	R	7 Re	A	X	Z	Y
	81	-СН=СН-СН=СН-	H	OMe	Н	ОМе	Н	Н	N	0	ОМе	3-N
5	82	-СН=СН-СН=СН-	Н	Me	Н	Me	H	Н	N	0	+	3-N
·	83	-СН=СН-СН=СН-	Me	Me	Н	Н	Н	Н	N	0		3-N
	84	-СН=СН-СН=СН-	Н	F	Н	F	Н	Н	N	+-	+	3-N
	85	-СН=СН-СН=СН-	Н	CI	Н	Cl	Н	Н	N	+-	<del> </del>	3-N
10	86	-СН=СН-СН=СН-	F	Н	Н	Н	Н	Н	N	+-	<del> </del>	3-N
10	87	-СН=СН-СН=СН-	Cl	Н	Н	Н	Н	Н	N	0	+	3-N
	88	-СН=СН-СН=СН-	Н	CI	Н	Н	Н	Н	N	0	OMe	<del> </del>
,	89	-СН=СН-СН=СН-	Н	ОН	Н	Н	Н	H	N	0	<del>i</del>	3-N
15	90	-СН=СН-СН=СН-	ОМе	Н	Н	Н	Н	Н	N	0	ОМе	
	91	-СН=СН-СН=СН-	SMe	Н	Н	Н	Н	Н	N	0	OMe	
	92	-СН=СН-СН=СН-	Н	°\	Н	Н	Н	H	N	0	OMe	
	93	-СН=СН-СН=СН-	Н	0 ح∕ ٥	Н	Н	Н	Н	N	0	ОМе	3-N
20	94	-СН=СН-СН=СН-	OMe	Н	Н	Me	Н	Н	N	0	OMe	3-N
	95	-СН=СН-СН=СН-	ОМе	Н	Н	Ph	Н	Н	N	0	OMe	
	96	-СН=СН-СН=СН-	Me	Н	Н	OMe	Н	Н	N	0	OMe	
	97	-СН=СН-СН=СН-	-Be	nzo-	Н	Н	Н	Н	N	0	OMe	
25	98	-СН=СН-СН=СН-	H	OMe	Н	OMe	Н	Me	N	0	OMe	
	99	-СН=СН-СН=СН-	Н	ОМе	Н	ОМе	Н	Et	N	0	OMe	
	100	-СН=СН-СН=СН-	Н	OMe	Н	OMe	Н	iPr	N		ОМе	
30	101	-СН=СН-СН=СН-	Н	ОМе	Н	ОМе	Н	Δ	N		ОМе	
30	102	-СН=СН-СН=СН-	Н	OMe	Н	OMe	Н	Benzyl	N	0	OMe	3-N
	103 -	-СН=СН-СН=СН-	Н	Me	Н	Me	Н	Me	N		ОМе	
	104 -	-СН=СН-СН=СН-	Н	Me	Н	Me	Н	Et	N		OMe	
35	105 -	СН=СН-СН=СН-	Н	Me	H a	Me	Н	iPr	N		OMe	
50												

	<u> </u>			· · · · ·	,							
	Ex.	R <sub>1</sub> and R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	R <sub>8</sub>	A	х	Z	Y
	106	-CH=CH-CH=CH-	H	Me	Н	Me	Н	Ben zyl	N	0	OMe	3-N
5	107	-СН=СН-СН=СН-	H	$ $ $^{\circ}$ $\vee$	Н	Н	Н	Me	N	0	OMe	3-N
	108	-CH=CH-CH=CH-	Н	°Y	Н	Н	Н	Et	N	0	OMe	3-N
	109	-СН=СН-СН=СН-	Н	OMe	Н	ОМе	Н	Н	N	S	OMe	3-N
	110	-СН=СН-СН=СН-	Н	Me	Н	Me	Н	Н	N	S	OMe	3-N
10	111	-CH=CH-CH=CH-	Н	F	Н	F	Н	Н	N	S	OMe	3-N
	112	-СН=СН-СН=СН-	Н	CI	Н	Cl	Н	Н	N	S	OMe	3-N
	113	-СН=СН-СН=СН-	Н	ОМе	Н	Н	Н	Н	N	S	OMe	3-N
	114	-СН=СН-СН=СН-	Н	ОМе	Н	ОМе	Н	Н	N	0	Me	3-N
15	115	-CH=CH-CH=CH-	Н	Me	Н	Me	Н	Н	N	0	Me	3-N
	116	-CH=CH-CH=CH-	Me	Me	Н	Н	Н	Н	N	0	Me	3-N
	117	-CH=CH-CH=CH-	Н	F	Н	F	Н	Н	N	0	Me	3-N
	118	-СН=СН-СН=СН-	H	Cl	Н	Cl	Н	Н	N	0	Me	3-N
20	119	-CH=CH-CH=CH-	OMe	Н	H	Н	Н	Н	N	0	Me	3-N
	120	-CH=CH-CH=CH-	F	Н	Н	Н	H	Н	N	0	Me	3-N
	121	-CH=CH-CH=CH-	CI	Н	H	Н	Н	Н	N	0	Me	3-N
	122	-CH=CH-CH=CH-	SMe	Н	Н	H	Н	Н	N	0	Me	3-N
25	123	-CH=CH-CH=CH-	OMe	Н	Н	Me	Н	Н	N	0	Me	3-N
	124	-CH=CH-CH=CH-	-Be	nzo-	Н	Н	Н	Н	N	0	Me	3-N
	125	-СН=СН-СН=СН-	Н	ОМе	Н	OMe	Н	Н	N	S	Me	3-N
	126	-СН=СН-СН=СН-	H	Me	Н	Me	Н	Н	N	S	Me	3-N
30	127	-СН=СН-СН=СН-	Н	F	Н	F	Н	Н	N	S	Me	3-N
	128	-СН=СН-СН=СН-	H	OMe	Н	ОМе	Н	Н	N	0	2-Py	4-N
	129	-СН=СН-СН=СН-	H	ОМе	Н	OMe	Н	Н	N	0	3-Ру	4-N
	130	-СН=СН-СН=СН-	Н	OMe	Н	OMe	Н	Н	N	0	2-Thienyl	
35	131	-СН=СН-СН=СН-	Н	Me	Н	Me	Н	Н	N	0	3-Py	4-N
											<del></del>	i

X	T	T
1	Z	Y
0	OMe	3-N
	0 0 0 0 0 0 0 0	O OMe

	Ex. No.	Rı	R <sub>2</sub>	R <sub>3</sub>	R4	R <sub>5</sub>	R <sub>6</sub>	R	R <sub>8</sub>	A	x	Z	Y
	146	Me	nPr	Н	OMe	Н	OMe	Н	Me	N	0	OMe	3-N
5	147	Et	Me	H	OMe	Н	ОМе	Н	Me	N	0	OMe	<del> </del>
	148	nPr	Me	H	OMe	Н	ОМе	Н	Me	N	0	OMe	+
	149	Me	Ac	Н	OMe	Н	OMe	Н	Me	N	0	OMe	3-N
	150	Me	Ac	H	OMe	H	ОМе	Н	Et	N	0	OMe	3-N
10	151	Me	Ac	H	Ме	Н	Me	Н	Me	N	0	OMe	3-N
	152	Me	**************************************	H	OMe	H	ОМе	Н	Me	N	0	OMe	3-N
	153	Me	* <del>\</del>	Н	ОМе	Н	OMe	Н	Et	N	0	OMe	3-N
	154	Me	× ×	H	Me	Н	Me	Н	Me	N	0	OMe	3-N
15	155	Me	X <sub>OH</sub>	Н	OMe	Н	OMe	Н	Me	N	0	OMe	3-N
	156	Me	∕⁄ <sub>OH</sub>	Н	Me	Н	Me	Н	Me	N	0	OMe	3-N
	157	Ме	och,	Н	OMe	Н	OMe	Н	Me	N	0	OMe	3-N
20	158	Me	Vinyl	Н	OMe	Н	OMe	Н	Me	N	0	OMe	3-N
	159	Me	Vinyl	Н	Me	Н	Me	Н	Me	N	0	OMe	3-N
	160	Me	Vinyl	Н	ОМе	Н	OMe	Н	Et	N	0	OMe	3-N
	161	Me	人	H	OMe	Н	OMe	Н	Me	N	0	OMe	3-N
25	162	Me	人	Н	Me	Н	Me	Н	Me	N	0	OMe	3-N
	163	Me	Ac	н	OMe	Н	OMe	H	CH, COE1	N	0	ОМе	3-N
	164	Me	Ac	Н	Me	Н	Me	H	-				
	165	Me	Ac	Н					CHICOEI	N	0	ОМе	3-N
30		+			OMe	H	OMe	H	сн,Сон	N	0	OMe	3-N
	166	Me	<b>○H</b>	Н	OMe	H	OMe	H	CHICOE	N	0	OMe	3-N
	167	Me	<u></u>	H	OMe	H	OMe	Н	сн <b>,</b> сон	N	0	OMe	3-N
	168	Me	<b>OII</b>	Н	Me	Н	Me	Н	O CH, 00E1	N	0	OMe	3-N
35	169	Me	Ç,	Н	Me	Н	Me	Н.	о сн,сон	N	-	OMe	3-N
			<u>.</u>		L								

		<del></del>				<b>,</b>							
	Ex. No.	Rı	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	R <sub>8</sub>	A	x	Z	Y
	170	Me	Me	H.	Н	Н	Н	Н	Н	СН	0	OMe	3-N
5	171	Me	Me	Н	OMe	Н	OMe	Н	Н	CH	0	OMe	3-N
	172	Me	Me	Н	Me	Н	Me	Н	H	СН	0	OMe	3-N
	173	Me	Me	Me	Me	Н	Н	Н	Н	СН	0	OMe	3-N
	174	Me	Ме	Me	Me	Н	Me	Me	Н	СН	0	OMe	3-N
10	175	Me	Me	Н	F	Н	F	Н	Н	СН	0	OMe	3-N
	176	Me	Me	Cl	Н	Н	Н	Н	Н	CH	0	OMe	3-N
	177	Me	Me	Н	CI	Н	Н	Н	Н	СН	0	<del> </del>	3-N
	178	Me	Ме	ОН	Н	H	Н	Н	Н	СН	0		3-N
15	179	Me	Me	Н	OH	Н	Н	Н	Н	СН	0		3-N
	180	Me	Me	Н	SH	Н	Н	Н	Н	CH	0		3-N
	181	Me	Me	OAc	Н	Н	Н	Н	Н	CH	0		3-N
	182	Me	Me	Н	OAc	Н	Н	Н	Н	СН	0		3-N
20	183	Me	Me	OMe	Н	Н	Н	Н	Н	СН	0		3-N
	184	Me	Me	Н	Me	Н	Н	ОМе	Н	CH	0	OMe	3-N
	185	Me	Me	Н	ОМе	H	Н	Me	Н	CH	0	OMe	3-N
	186	Me	Me	H	ОМе	Н	Н	Ph	Н	СН	0	OMe	3-N
25	187	Me	Me	人	Н	H	Н	Н	Н	СН	0	OMe	3-N
	188	Me	Me	Be	nzo	Н	Н	Н	Н	CH	0		3-N
ļ	189	Me	Ме	Nar	ohto	Н	Н	Н	Н	СН	0	OMe	
1	190	Me	Me	Ħ	ОМе	Н	ОМе	Н	Me	СН	0	OMe	
30	191	Me	Me	Н	Me	Н	Me	Н	Me	CH	0	OMe	
	192	Me	Me	H	F	Н	F	Н	Me	CH	0	OMe	
	193	Me	Me	Н	OMe	Н	ОМе	Н	Et	СН	0	OMe	
	194	Me	Me	Н	Me	Н	Me	Н	Et	CH	0	OMe	
35													

	Ex. No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	R <sub>8</sub>	A	Х	Z	Y
	195	Me	Me	Н	F	Н	F	H	Et	СН	0	OMe	3-N
_	196	Me	Me	Н	F	Н	F	Н	iPr	CH	0	OMe	-
5	197	Me	Me	Н	OMe	H	OMe	Н	Н	СН	S	OMe	+
	198	Me	Me	Н	Me	Н	Me	Н	H	СН	S	OMe	+
	199	Me	Me	Me	Me	Н	Н	Н	Н	СН	S	OMe	
	200	Me	Me	Н	F	Н	F	Н	Н	CH	S	OMe	+
10	201	Me	Me	H	Cl	H	Cl	Н	H	CH	S	OMe	
10	202	Me	Me	F	Н	H	Н	Н	H	CH	S	OMe	
	203	Me	Me	Cl	Н	H	Н	Н	Н	СН	S	OMe	
	204	Me	Me	ОМе	Н	Н	Н	Н	Н	СН	S	OMe	3-N
	205	Me	Me	SMe	Н	Н	Н	H	Н	СН	S	OMe	3-N
15	206	Me	Me	Н	ОН	Н	Н	Н	Н	СН	S	OMe	3-N
	207	Me	Me	OPh	Н	Н	Н	Н	Н	CH	S	OMe	3-N
	208	Me	Me	人	Н	Н	Н	Н	Н	СН	S	OMe	
	209	Me	Me	Н	ОМе	Н	H	Me	H	СН	S	OMe	2 N
20	210	Me	Me	Be	nzo	Н	Н	Н	Н	CH	S		
	211	Me	Acetyl	Н	ОМе	Н	OMe	H	Н	CH	0	OMe	
	212	Me	Acetyl	Н	Me	Н	Me	Н	Н	CH	0	OMe	3-N
	213	Me	Acetyl	Н	Cl	Н	Cl	Н	H	CH		OMe	3-N
25	214	Ме	<b>*</b>	Н	ОМе	Н	ОМе	Н	н	СН	0	OMe OMe	3-N
	215	Ме	OH _	Н	Ме	н	Ме	Н	Н	СН	0	OMe	3-N
	216	Me	Vinyl	Н	OMe	Н	ОМе	Н	H	CH	0	OMe	3-NI
30	217	Me	Vinyl	Н	Me	Н	Me	Н	Н	CH	0	OMe	
Į	218	Me	Acetyl	Н	OMe	Н	OMe	Н	Н	CH	S		
	219	Me	Acetyl	Н	Me	H	Me	H	H	CH	S	OMe	
	220	Me	Acetyl	Н	Cl	Н	Cl	Н	H			OMe	
35	221	Me	OH _	Н	OMe		OMe	Н	Н	CH	S S	OMe OMe	3-N

		<del></del>											
	Ex. No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>	R <sub>8</sub>	A	X	Z	Y
5	222	Me	, OH	Н	Me	Н	Ме	Н	Н	СН	s	OMe	3-N
	223	Me	**************************************	н	CI	н	CI	Н	Н	СН	s	ОМе	3-N
10	224	Me	Me	Н	ОМе	H	OMe	Н	O CH <sub>2</sub> COEt	СН	0	ОМе	3-N
	225	Me	Ме	Н	Me	н	Me	Н	CH2COE1	СН	0	OMe	3-N
15	226	Ме	Ме	Н	ОМе	Н	OMe	Н	сн <b>₁</b> сон	СН	0	OMe	3-N
	227	Ме	Me	Н	Me	·H	Me	Н	сн*сон О	СН	0	ОМе	3-N
	228	Ме	Me	Н	ОМе	Н	OMe	Н	Н	СН	0	ОН	3-N
	229	Ме	Me	Н	Me	H	Me	Н	Н	СН	0	ОН	3-N
	230	Me	Me	Н	F	Н	F	Н	Н	СН	0		3-N
20	231	Me	Me	Н	Cl	Н	Cl	Н	Н	СН	0	ОН	3-N

### Example 1

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methylthiophenyl) piperazine:

a) Phenyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate: 3-Amino-5,6-dimethyl-2-methoxypyridine(1.52g, 0.01mol) and phenylchloroformate(1.56g, 0.01mol) were dissolved in dichloromethane and was stirred at room temperature for 2 hours. The mixture was concentrated under the reduced pressure to remove the solvent. The concentrate was purified by column chromatography(ethylacetate: hexane = 1:6) to obtain the titled compound.

yield: 92 %

 $^{1}$ H-NMR(CDCl<sub>3</sub>)  $\delta$ : 2.18(3H,s), 2.36(3H,s), 4.00(3H,s), 7.31(5H,m), 8.07(1H,s)

15

b) 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methyl thiophenyl)piperazine:

Phenyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate(136mg, 0.5mmol) and 1-(2-methylthiophenyl)piperazine(104mg, 0.5mmol) were dissolved in anhydrous tetrahydrofuran and DBU(76mg, 0.5mmol) was added. The mixture was stirred at room temperature for 2 hours and concentrated under the reduced pressure to remove tetrahydrofuran. The concentrate was purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

25 yield: 59%

m.p.: 167-169°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.21(3H,s), 2.43(6H,s), 3.06(4H,t), 3.68(4H,t), 4.09(3H,s), 6.89(1H,s), 7.06(1H,m), 7.14(3H,s), 8.26(1H,s)

## 30 Example 2

1-[(5,6-Dimethyl=2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-isopropenyl)phenyl)piperazine:

Phenyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and 1-(2-isopropenylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 62 %

m.p.: 139-140°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.20(3H,s), 2.21(6H,s), 3.10(4H,t), 3.64(4H,t), 3.84(3H,s), 5.07(1H,s), 5.13(1H,s), 6.64(1H,s), 6.98(1H,s), 7.04(3H,dd), 7.18(1H,d), 7.91(1H,s)

5

### Example 3

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2,3,5,6-tetramethylphenyl)piperazine:

Phenyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and 1-(2,3,5,6-tetramethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 71%

m.p.: 190-192°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.21(15H,s), 2.42(3H,s), 3.17(4H,t), 3.61(4H,t),

15 4.08(3H,s), 6.84(1H,s), 6.89(1H,s), 8.26(1H,s)

### Example 4

1-[(5-Ethyl-6-methyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methylthiophenyl)piperazine:

20 Phenyl N-(5-ethyl-6-methyl-2-methoxypyridin-3-yl)carbamate and 1-(2-methylthiophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 56%

m.p.: 160-161°C

25 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.19(3H,t), 2.43(3H,s), 2.50(3H,s), 2.58(2H,q), 3.07(4H,t), 3.69(4H,t), 4.15(3H,s), 6.93(1H,s), 7.06(1H,m), 7.14(3H,m), 8.35(1H,s)

Mass(EI) m/z: Calcd for C21H22N4O2 400.1932, found 400.1925

## 30 Example 5

1-[(5-Ethyl-6-methyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-isopropenylphenyl)piperazine:

Phenyl N-(5-ethyl-6-methyl-2-methoxypyridin-3-yl)carbamate and 1-(2-isopropenylphenyl)piperazine were reacted by the same way with

35 the example 1 to obtain the titled compound.

yield: 51%

m.p.: 185-187°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) &: 1.18(3H,t), 2.21(3H,s), 2.42(3H,s), 2.56(2H,q), 3.08(4H,t), 3.62(4H,t), 4.03(3H,s), 5.08(1H,s), 5.13(1H,s), 6.90(1H,s), 7.02(3H,m), 7.18(1H,d), 8.25(1H,s)

5

## Example 6

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2,3,5,6-tetramethylphenyl) piperazine:

Phenyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(2,3,5,6-tetramethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 69%

m.p.: 176-177°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.19(3H,t), 2.21(12H,s), 2.44(3H,s), 2.57(2H,q),

15 3.17(4H,t), 3.62(4H,t), 4.06(3H,s), 6.84(1H,s), 6.92(1H,s), 8.30(1H,s)

## Example 7

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-thiophenyl)piperazine:

20 Phenyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(3-thiophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield : 63%

m.p.: 108-110°C

25 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.17(3H,t), 2.37(3H,s), 2.49(2H,q), 3.28(4H,t), 3.60(4H,t), 3.98(3H,s), 6.87(4H,m), 6.98(1H,s), 8.18(1H,s)

### Example 8

1-[(2-Methoxy-6-methyl-5-propylpyridin-3-yl)aminocarbonyl]-4-(3,5-30 dimethoxyphenyl)piperazine:

Phenyl N-(2-methoxy-6-methyl-5-propylpyridin-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 67%

35 m.p.: 82-84℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 0.94(3H,t), 1.58(2H,m), 2.37(3H,s), 2.49(2H,q),

3.25(4H,t), 3.66(4H,t), 3.78(6H,s), 3.99(3H,s), 6.07(3H,m), 6.88(1H,s), 8.16(1H,s)

Mass(EI) m/z : Calcd for Cz3Hz2N4O1 428.2423, found 428.2447

## 5 Example 9

1-[(2-Methoxy-6-methyl-5-propylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl) piperazine

Phenyl N-(2-methoxy-6-methyl-5-propylpyridin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with

10 the example 1 to obtain the titled compound.

yield: 64%

m.p.: 145-146°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 0.95(3H,t), 1.59(2H,m), 2.29(6H,s), 2.41(3H,s), 2.49(2H,q), 3.24(4H,t), 3.67(4H,t), 3.98(3H,s), 6.59(3H,m), 6.89(1H,s),

15 8.17(1H.s)

Mass(EI) m/z: Calcd for C23H32N4O4 428.2423, found 428.2385

### Example 10

1-[(2-Methoxy-6-methyl-5-propylpyridin-3-yl)aminocarbonyl]-4-(3,5-diffuserally and )

20 difluorophenyl)piperazine:

Phenyl N-(2-methoxy-6-methyl-5-propylpyridin-3-yl)carbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 57%

25 m.p.: 121-123°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 0.95(3H,t), 1.59(2H,m), 2.38(3H,s), 2.50(2H,q), 3.29(3H,t), 3.66(3H,t), 4.00(3H,s), 6.28(1H,m), 6.36(2H,d), 6.87(1H,s), 8.17(1H,s)

## 30 Example 11

1-[(2-Methoxy-6-methyl-5-propylpyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

Phenyl N-(2-methoxy-6-methyl-5-propylpyridin-3-yl)carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 71%

m.p.: 109-110°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 0.95(3H,t), 1.59(2H,m), 2.37(3H,s), 2.49(2H,q), 3.12(4H,t), 3.70(4H,t), 3.89(3H,s), 3.97(3H,s), 6.91(4H,m), 6.95(1H,s),

5 8.19(1H,s)

## Example 12

1-[(6-Ethyl-2-methoxy-5-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

Phenyl N-(6-ethyl-2-methoxy-5-methylpyridin-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 65%

m.p.: 115-116°C

15 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.21(3H,t), 2.21(3H,s), 2.65(2H,q), 3.27(4H,t), 3.64(4H,t), 3.79(6H,s), 3.98(3H,s), 6.09(3H,m), 6.86(1H,s), 8.12(1H,s) Mass(EI) m/z: Calcd for C<sub>22</sub>H<sub>30</sub>N<sub>4</sub>O<sub>4</sub> 414.2267, found 414.2240

### Example 13

20 1-[(6-Ethyl-2-methoxy-5-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dim ethylphenyl)piperazine:
Phenyl N-(6-ethyl-2-methoxy-5-methylpyridin-3-yl)carbamate and

1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

25 yield: 61%

m.p.: 135-136°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.22(3H,t), 2.21(3H,s), 2.29(6H,s), 2.65(2H,q), 3.24(4H,t), 3.66(4H,t), 3.98(3H,s), 6.59(3H,m), 6.87(1H,s), 8.12(1H,s) Mass(EI) m/z: Calcd for C<sub>22</sub>H<sub>30</sub>N<sub>4</sub>O<sub>2</sub> 382.2368, found 382.2376

## Example 14

30

1-[(6-Ethyl-2-methoxy-5-methylpyridin-3-yl)aminocarbonyl]-4-(3-hydroxyphenyl)piperazine:

Phenyl N-(6-ethyl-2-methoxy-5-methylpyridin-3-yl)carbamate and

35 1-(3-hydroxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 56%

m.p.: 168-170℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.21(3H,t), 2.20(2H,s), 2.63(2H,t), 3.28(4H,t), 3.68(4H,t),

3.98(3H,s), 6.41(1H,d), 6.55(1H,d), 6.84(1H,m), 6.87(1H,s), 7.13(1H,t),

5 8.10(1H.s)

Mass(EI) m/z: Calcd for C20H26N4O3 370.2004, found 370.1992

## Example 15

1-[(2-Methoxy-5-methyl-6-propylpyridin-3-yl)aminocarbonyl]-4-(3,5-

10 dimethoxyphenyl)piperazine:

Phenyl N-(2-methoxy-5-methyl-6-propylpyridin-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 57%

15 m.p: 121-122℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 0.96(3H,t), 1.67(2H,m), 2.21(3H,s), 2.58(2H,t), 3.26(4H,t), 3.68(4H,t), 3.79(6H,s), 3.97(3H,s), 6.14(3H,m), 6.89(1H,s), 8.11(1H,s)

Mass(EI) m/z : Calcd for C23H32N4O4 428.2423, found 428.2423

20

### Example 16

 $1\hbox{-}[(2\hbox{-}Methoxy\hbox{-}5\hbox{-}methyl\hbox{-}6\hbox{-}propylpyridin}\hbox{-}3\hbox{-}yl) a minocarbonyl]\hbox{-}4\hbox{-}(3,5\hbox{-}dimethylphenyl) piperazine:}$ 

Phenyl N-(2-methoxy-5-methyl-6-propylpyridin-3-yl)carbamate and

25 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 54%

, ----

m.p. : 138−139℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 0.96(3H,t), 1.72(2H,m), 2.21(6H,s), 2.30(3H,s),

0 2.59(2H,t), 3.28(4H,t), 3.76(4H,t), 3.97(3H,s), 6.70(3H,m), 6.87(1H,s), 8.11(1H,s)

Mass(EI) m/z: Calcd for C23H32N4O2 396.2525, found 396.2432

### Example 17

35 1-[(2-Methoxy-5-methyl-6-propylpyridin-3-yl)aminocarbonyl]-4-(3-hydroxyphenyl)piperazine:



Phenyl N-(2-methoxy-5-methyl-6-propylpyridin-3-yl)carbamate and 1-(3-hydroxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 52%

5 m.p.: 153-155℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 0.95(3H,t), 1.69(2H,m), 2.19(3H,s), 2.59(2H,t), 3.22(4H,t), 3.68(4H,t), 3.97(3H,s), 6.42(1H,d), 6.52(1H,d), 6.87(1H,s), 7.12(1H,t), 8.09(1H,s)

Mass(EI) m/z : Calcd for  $C_{21}H_{28}N_4O_3$  384.2161, found 384.2153

10

### Example 18

1-[N-(2-Methoxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl) aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

Phenyl N-(2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl) 15 carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the

same way with the example 1 to obtain the titled compound. yield: 59%

m.p.: 143-144°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.10(2H,m), 2.87(4H,m), 3.12(4H,t), 3.70(4H,t),

3.78(6H,s), 4.00(3H,s), 6.08(3H,m), 6.90(1H,s), 8.24(1H,s)

## Example 19

1-[N-(2-Methoxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl) aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

25 Phenyl N-(2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl) carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound. yield: 55%

m.p.: 183-185℃

30 H NMR(CDCl<sub>3</sub>) δ: 2.08(2H,m), 2.28(6H,s), 2.87(4H,m), 3.22(4H,t), 3.67(4H,t), 4.00(3H,s), 6.57(3H,m), 6.89(1H,s), 8.24(1H,s)

## Example 20

1-[(2-Methoxy-5,6,7,8-tetrahydroquinolin-3-yl)aminocarbonyl]-4-(3,5dimethoxyphenyl)piperazine:

Phenyl N-(2-methoxy-5,6,7,8-tetrahydroquinoline-3-yl)carbamate and

1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 54%

m.p.: 161-163°C

5 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.75(2H,m), 1.84(2H,m), 2.67(2H,t), 2.73(2H,t), 3.27(4H,t), 3.71(4H,t), 3.79(6H,s), 3.97(3H,s), 6.10(3H,m), 6.90(1H,s), 8.07(1H,s)

## Example 21

10 1-[(2-Methoxy-5,6,7,8-tetrahydroquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethyphenyl)piperazine:

Phenyl N-(2-methoxy-5,6,7,8-tetrahydroquinolin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

15 yield: 51%

m.p.: 143-144°C

<sup>1</sup>H NMR(CDCL) δ: 1.75(2H,m), 1.84(2H,m), 2.30(6H,s), 2.68(2H,t), 2.72(2H,t), 3.26(4H,t), 3.67(4H,t), 3.97(3H,s), 6.61(3H,m), 6.91(1H,s), 8.07(1H,s)

20

### Example 22

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

Phenyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)thiocarbamate(200mg,

- 0.7mmol) and 1-(3,5-dimethylphenyl)piperazine(154mg, 0.7mmol) were dissolved in anhydrous tetrahydrofuran and DBU(106mg) was added thereto. The mixture was stirred at room temperature for 2 hours and concentrated under the reduced pressure to remove the solvent. The concentrate was purified by column chromatography( ethylacetate:
- 30 hexane = 1:2) to obtain the titled compound.

yield: 50%

m.p.: 192-193°C

<sup>1</sup>H NMR(CDCI<sub>3</sub>) δ: 2.21(3H,s), 2.29(6H,s), 2.36(3H,s), 3.33(4H,t), 3.96(3H,s), 4.09(4H,t), 6.57(3H,m), 7.33(1H,s), 8.11(1H,s)

35 Mass(EI) m/z: Calcd for  $C_{21}H_{28}N_4O_1S_1$  384.1983, found 384.1992

## Example 23

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl)piperazine:

Phenyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)thiocarbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 22 to obtain the titled compound.

yield: 47%

m.p.: 60-62°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.21(3H,s), 2.36(3H,s), 3.39(4H,t), 3.96(3H,s),

10 4.10(3H,t), 6.29(3H,m), 7.33(1H,s), 8.14(1H,s)

### Example 24

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3-hydroxyphenyl)piperazine:

Phenyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)thiocarbamate and 1-(3-hydroxyphenyl)piperazine were reacted by the same way with the example 22 to obtain the titled compound.

yield: 43%

m.p.: 185-186°C

20 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.14(3H,s), 2.36(3H,s), 3.25(4H,t), 3.89(3H,s), 4.09(4H,t), 6.30(1H,d), 6.36(2H,m), 7.03(1H,t), 7.48(1H,s), 8.56(1H,s)

#### Example 25

1-[(2-Methoxy-6-methyl-5-propylpyridin-3-yl)aminothiocarbonyl]-4-(3,5 -dimethoxyphenyl)piperazine:

Phenyl N-(2-methoxy-6-methyl-5-propylpyridin-3-yl)thiocarbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 22 to obtain the titled compound.

yield: 55%

30 m.p.: 143-144°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) &: 0.93(3H,t), 1.66(2H,m), 2.17(3H,s), 2.65(2H,t), 3.38(4H,t), 3.79(6H,s), 3.98(3H,s), 4.15(4H,t), 6.11(3H,m), 7.43(1H,s), 8.25(1H,s)

### 35 Example 26

1-[(2-Methoxy-5-methyl-6-propylpyridin-3-yl)aminothiocarbonyl]-4-(3,5

-dimethoxyphenyl)piperazine:

Phenyl N-(2-methoxy-5-methyl-6-propylpyridin-3-yl)thiocarbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 22 to obtain the titled compound.

5 yield: 52%

m.p.: 183-184°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 0.98(3H,t), 1.72(2H,m), 2.17(3H,s), 2.62(2H,t), 3.39(4H,t), 3.79(6H,s), 3.96(3H,s), 4.19(4H,t), 6.15(3H,m), 7.42(1H,s), 8.08(1H,s)

10 Mass(EI) m/z: Calcd for C23H32N4O3S1 444.2195, found 444.2171

### Example 27

1-[(2-Methoxy-5-methyl-6-propylpyridin-3-yl)aminothiocarbonyl]-4-(3,5 -dimethylphenyl)piperazine:

15 Phenyl N-(2-methoxy-5-methyl-6-propylpyridin-3-yl)thiocarbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 22 to obtain the titled compound.

yield: 49%

m.p.: 195-197℃

20 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 0.98(3H,t), 1.73(2H,m), 2.18(6H,s), 2.34(3H,s), 2.62(2H,t), 3.47(4H,t), 3.96(3H,s), 4.01(4H,t), 6.59(3H,m), 7.02(1H,s), 7.99(1H,s)

Mass(EI) m/z: Calcd for C23H32N4O1S1 412.2296, found 412.2266

### 25 Example 28

1-[(2-Methoxy-5-methyl-6-propylpyridin-3-yl)aminothiocarbonyl]-4-(3hydroxyphenyl)piperazine:

Phenyl N-(2-methoxy-5-methyl-6-propylpyridin-3-yl)thiocarbamate and 1-(3-hydroxyphenyl)piperazine were reacted by the same way with the

30 example 22 to obtain the titled compound.

yield: 48%

m.p.: 160-162°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 0.98(3H,t), 1.72(2H,m), 2.22(3H,s), 2.61(3H,t), 3.31(4H,t), 3.95(3H,s), 4.10(4H,t), 6.45(3H,m), 7.12(1H,t), 7.41(1H,s),

8.08(1H.s)35

Mass(EI) m/z: Calcd for C<sub>21</sub>H<sub>28</sub>N<sub>4</sub>O<sub>2</sub>S<sub>1</sub> 400.1932, found 400.1969

## Example 29

1-[N-(2-Methoxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl)aminothiocar bonyl]-4-(3,5-dimethoxyphenyl)piperazine:

5 Phenyl N-(2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl) thiocarbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 22 to obtain the titled compound. yield: 55%

m.p.: 169-170℃

10  $^{1}$ H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.10(2H,m), 2.89(4H,m), 3.30(4H,t), 3.77(6H,s), 3.98(3H,s), 4.20(4H,t), 6.05(3H,m), 7.37(1H,s), 8.25(1H,s)

## Example 30

1-[N-(2-Methoxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl)aminothiocar

15 bonyl]-4-(3,5-dimethylphenyl)piperazine:

Phenyl N-(2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl) thiocarbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 22 to obtain the titled compound.

yield: 53%

20 m.p.: 159-161℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.09(2H,m), 2.28(6H,s), 2.87(4H,m), 3.67(4H,t), 4.00(3H,s), 4.21(4H,t), 6.57(3H,m), 6.93(1H,s), 8.24(1H,s)

## Example 31

25 1-[(2-Methoxy-5,6,7,8-tetrahydroquinolin-3-yl)aminothiocarbonyl]-4-(3,5dimethoxyphenyl)piperazine:

Phenyl N-[(2-methoxy-5,6,7,8-tetrahydroquinolin-3-yl)thiocarbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 22 to obtain the titled compound.

30 yield: 56%

m.p.: 160-161°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.77(2H,m), 1.83(2H,m), 2.70(2H,t), 2.76(2H,t), 3.38(4H,t), 3.79(6H,s), 3.96(3H,s), 4.16(4H,t), 6.12(3H,m), 7.45(1H,s), 8.03(1H.s)

35

Example 32

1-[(2-Methoxy-5,6,7,8-tetrahydroquinolin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

Phenyl N-(2-methoxy-5,6,7,8-tetrahydroquinolin-3-yl)thiocarbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 22 to obtain the titled compound.

yield: 54%

m.p.: 200-201°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.77(2H,m), 1.84(2H,m), 2.34(6H,s), 2.71(3H,t), 2.75(3H,t), 3.47(4H,t), 3.97(3H,s), 4.42(4H,t), 6.35(3H,m), 6.91(1H,s),

10 7.91(1H,s)

### Example 33

1-[(5,6-Dimethyl-2-methylaminopyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

Phenyl N-(5,6-dimethyl-2-methylaminopyridin-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 53%

m.p.: 150-151°C

20 <sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.29(3H,s), 2.48(3H,s), 3.29(4H,t), 3.45(3H,s), 3.77(6H,s), 3.79(4H,t), 6.10(3H,m), 7.40(1H,s)

#### Example 34

1-[(5,6-Dimethyl-2-methylaminopyridin-3-yl)aminocarbonyl]-4-(3,5-

25 dimethylphenyl)piperazine:

Phenyl N-(5,6-dimethyl-2-methylaminopyridin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 52%

30 m.p.: 160-162°C

<sup>1</sup>H NMR(CDC<sub>3</sub>) δ: 2.30(9H,s), 2.48(3H,s), 3.31(4H,t), 3.46(3H,s), 3.78(4H,t), 6.60(3H,m), 7.41(1H,s)

### Example 35

35 1-[(5-Ethyl-6-methyl-2-methylaminopyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

Phenyl N-(5-ethyl-6-methyl-2-methylaminopyridin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 56%

5 m.p.: 143-145°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.22(3H,t), 2.28(6H,s), 2.52(3H,s), 2.72(2H,q), 3.29(4H,t), 3.45(3H,s), 3.78(4H,t), 6.59(3H,m), 7.41(1H,s)

### Example 36

10 1-[(2-Methylamino-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl) aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:
Phenyl N-(2-methylamino-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl) carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

15 yield: 49%

m.p.: 148-150°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) &: 2.09(2H,m), 2.95(4H,m), 3.30(4H,t), 3.47(3H,s), 3.77(4H,t), 3.80(6H,s), 6.10(3H,m), 7.49(1H,s)

### 20 Example 37

1-[(2-Methylamino-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl) aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:
Phenyl N-(2-methylamino-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl) carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the

25 same way with the example 1 to obtain the titled compound.

yield: 48%

m.p.: 185-187°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.14(2H,m), 2.29(6H,s), 2.95(4H,m), 3.32(4H,t), 3.47(3H,s), 3.79(4H,t), 6.59(3H,m), 7.48(1H,s)

## Example 38

30

1-{[5,6-Dimethyl-2-(4'-t-butoxycarbonylpiperazinyl)pyridin-3-yl] aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine:
Phenyl N-[5,6-dimethyl-2-(4'-t-butoxycarbonylpiperazinyl)pyridin-3-yl]

35 carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 58% m.p.: 74-75°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.46(9H,s), 2.20(3H,s), 2.21(3H,s), 2.90(4H,t), 3.20(4H,t), 3.55(4H,t), 3.65(4H,t), 3.98(3H,s), 6.02(3H,m), 8.20(1H,s)

5

### Example 39

1-{[5,6-Dimethyl-2-(4'-t-butoxycarbonylpiperazinyl)pyridin-3-yl] aminocarbonyl}-4-(3,5-dimethylphenyl)piperazine:

Phenyl N-[5,6-dimethyl-2-(4'-butoxycarbonylpiperazinyl)pyridin-3-yl]

carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 56%

m.p.: 155-156℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.48(9H,s), 2.22(3H,s), 2.29(6H,s), 2.35(3H,s),

15 2.95(4H,t), 3.25(4H,t), 3.57(4H,t), 3.67(4H,t), 6.59(3H,m), 8.21(1H,s)

## Example 40

1-{[5-Ethyl-6-methyl-2-(4'-t-butoxycarbonylpiperazinyl)pyridin-3-yl] aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine:

Phenyl N-[5-ethyl-6-methyl-2-(4'-t-butoxycarbonylpiperazinyl) pyridin-3-yl]carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 52%

25 m.p.: 119-120°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.25(3H,t), 1.48(9H,s), 2.38(3H,s), 2.51(2H,q), 2.96(4H,t), 3.27(4H,t), 3.58(8H,m), 3.78(6H,s), 6.08(3H,m), 8.24(1H,s)

### Example 41

30 1-{[5-Ethyl-6-methyl-2-(4'-t-butoxycarbonylpiperazinyl)pyridin-3-yl] aminocarbonyl}-4-(3,5-dimethylphenyl)piperazine:

Phenyl N-[5-ethyl-6-methyl-2-(4'-t-butoxycarbonylpiperazinyl) pyridin-3-yl]carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled

35 compound.

yield: 50%

m.p.: 126-128°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.20(3H,t), 1.49(9H,s), 2.29(6H,s), 2.39(3H,s), 2.52(2H,q), 2.98(4H,t), 3.23(4H,t), 3.59(8H,m), 6.59(3H,m), 7.58(1H,s), 8.26(1H,s)

5

## Example 42

1-[(5,6-Dimethyl-2-piperazinylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-{[5,6-Dimethyl-2-(4'-t-butoxycarbonylpiperazinyl)pyridin-3-yl]
aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine(0.218g, 0.4mmol) was
dissolved in dichloromethane: nitromethane = 2:1(10ml) and
anisole(0.26g, 2.4mmol) and aluminum chloride(0.3g, 2,4mmol) were
added slowly thereto. The mixture was stirred at room temperature for
20min. Distilled water(50ml) was added into the mixture and the
mixture was made basic with saturated NaHCO3 and extracted with
dichloromethane and then concentrated under the reduced pressure to
remove the solvent. The concentrate was purified by column
chromatography(methanol: dichloromethane = 8:1) to obtain the titled

compound. 20 yield: 89%

m.p. : oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.21(3H,s), 2.35(3H,s), 3.02(4H,t), 3.34(4H,t), 3.59(4H,t), 3.62(4H,t), 3.78(6H,s), 6.08(3H,m), 8.18(1H,s)

### 25 Example 43

1-[(5,6-Dimethyl-2-piperazinylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

1-{[5,6-Dimethyl-2-(4'-t-butoxycarbonylpiperazinyl)pyridin-3-yl] aminocarbonyl}-4-(3,5-dimethylphenyl)piperazine was reacted by the

30 same way with the example 42 to obtain the titled compound.

yield: 85%

m.p.: 103-105℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.16(3H,s), 2.24(6H,s), 2.40(3H,s), 3.30(4H,t), 3.44(4H,t), 3.50(4H,t), 3.81(4H,t), 6.95(3H,m), 7.72(1H,s)

1-[(5-Ethyl-6-methyl-2-piperazinylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-{[5-Ethyl-6-methyl-2-(4'-t-butoxycarbonylpiperazinyl)pyridin-3-yl] aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 42 to obtain the titled compound.

yield: 88%

m.p.: 68-70℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.20(3H,t), 2.40(3H,s), 2.52(2H,q), 2.75(4H,t), 3.32(4H,t), 3.70(8H,m), 3.78(6H,s), 6.09(3H,m), 7.68(1H,s), 8.23(1H,s)

10

## Example 45

1-[(5-Ethyl-6-methyl-2-piperazinylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

1-([5-Ethyl-6-methyl-2-(4'-t-butoxycarbonylpiperazinyl)pyridin-3-yl]
aminocarbonyl}-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 42 to obtain the titled compound.

yield: 85%

m.p. : 100-102℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.20(3H,t), 2.28(6H,s), 2.39(3H,s), 2.65(2H,q),

20 2.76(4H,t), 3.00(4H,t), 3.23(4H,t), 3.70(4H,t), 6.58(3H,m), 7.66(1H,s), 8.24(1H,s)

#### Example 46

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)carbamate(200mg, 0.67mmol) and 1-(3,5-dimethoxyphenyl)piperazine(150mg, 0.67mmol) were dissolved in anhydrous tetrahydrofuran(15ml) and DBU(100mg, 0.67mmol) was added. The mixture was stirred at room temperature for

30 2 hrs and concentrated under the reduced pressure to remove tetrahydrofuran. The concentrate was purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

yield: 83%

35 m.p.: 149-151℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.57(3H,s), 2.65(3H,s), 3.28(4H,t,J=4.65Hz), 3.70(4H,t,

J=4.65Hz), 3.79(6H,s), 4.06(3H,s), 6.09(1H,s), 6.14(2H,d),6.94(1H,s), 8.87(1H,s)

### Example 47

5 1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 46 to obtain the titled compound.

10 yield: 82%

m.p.: 66-69°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.31(6H,s), 2.57(3H,s), 2.65(3H,s), 3.08(4H,t), 3.30(4H,t), 4.10(3H,s), 6.71(2H,d), 6.94(1H,s), 8.89(1H,s)

### 15 Example 48

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 46 to obtain the titled compound.

yield: 77%

m.p.: 180-181°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.57(3H,s), 2.65(3H,s), 3.33(4H,t,J=5.0Hz), 3.74(4H,t,J=5.0Hz), 4.07(3H,s), 6.37(1H,s), 6.46(2H,d), 6.93(1H,s), 8.85(1H,s)

25

### Example 49

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 30 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 46 to obtain the titled compound.

yield: 81%

m.p.: oil phase

<sup>1</sup>H NMR(CDC<sub>b</sub>)  $\delta$ : 2.57(3H,s), 2.65(3H,s), 3.34(4H,t), 3.78(4H,t),

35 4.04(3H,s), 6.93(3H,m), 8.80(1H,s)

### Example 50

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2,3-dimethylphenyl)piperazine:

Pheny N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(2,3-dimethylphenyl)piperazine were reacted by the same way with the example 46 to obtain the titled compound.

yield: 81%

m.p.: 173-174°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.29(6H,s), 2.58(3H,s), 2.65(3H,s), 2.98(4H,t),

10 3.70(4H,t), 4.06(3H,s), 6.91(1H,d), 6.97(1H,s), 7.10(1H,t), 8.89(1H,s)

### Example 51

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 46 to obtain the titled compound.

yield: 79%

m.p.: 153-154°C

20 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.58(3H,s), 2.65(3H,s), 3.15(4H,t), 3.73(4H,t), 3.90(3H,s), 4.06(3H,s), 6.91(1H,d), 6.96(1H,d), 6.97(1H,s), 7.10(1H,t), 8.89(1H,s)

#### Example 52

25 1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-hydroxyphenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(3-hydroxyphenyl)piperazine were reacted by the same way with the example 46 to obtain the titled compound.

30 yield: 76%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.60(3H,s), 2.72(3H,s), 3.34(4H,t), 3.79(4H,t), 3.98(3H,s), 6.45(3H,m), 6.98(1H,m), 8.97(1H,s)

### 35 Example 53

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5

-dimethoxyphenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)thiocarbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 22 to obtain the titled compound.

5 yield: 77%

m.p.: 167-169°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.58(3H,s), 2.68(3H,s), 3.47(4H,t), 3.81(6H,s), 4.05(3H,s), 4.36(4H,t), 6.42(3H,m), 7.49(1H,s), 9.05(1H,s)

### 10 Example 54

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5 -dimethylphenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)thiocarbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with

15 the example 22 to obtain the titled compound.

yield: 75%

m.p.: 176-177℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.34(6H,s), 2.58(3H,s), 2.68(3H,s), 3.48(4H,t), 4.06(3H,s), 4.43(4H,t), 7.05(3H,m), 7.52(1H,s), 9.04(1H,s)

20

## Example 55

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3-hydroxyphenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)thiocarbamate and 1-(3-hydroxyphenyl)piperazine were reacted by the same way with the example 22 to obtain the titled compound.

yield: 71%

m.p.: 114-115℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.56(3H,s), 2.75(3H,s), 3.68(4H,t), 4.05(3H,s),

30 4.45(4H,t), 7.30(4H,m), 9.03(1H,s)

Mass(EI) m/z: Calcd for C23H30N4O4S1 458.1987, found 458.2527

#### Example 56

1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl}

35 -4-(3,5-dimethoxyphenyl)piperazine:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-

dimethoxyphenyl)piperazine(100mg, 0.23mmol) was dissolved in anhydrous ethanol(15ml) and NaBH4(8.66mg) was added. The reaction solution was stirred at room temperature for 2 hours. The mixture was concentrated under the reduced pressure to remove ethanol and purified by column chromatography (ethylacetate: hexane = 2:1) to obtain the

by column chromatography (ethylacetate: hexane = 2:1) to obtain the titled compound.

yield: 97%

m.p.: 124-126°C

<sup>1</sup>H NMR(CDC<sub>b</sub>)  $\delta$ : 1.48(3H,d), 2.42(3H,s), 3.27(4H,t), 3.69(4H,t),

10 3.79(6H,s), 3.99(3H,s), 5.03(1H,q), 6.09(1H,s), 6.15(2H,d), 6.90(1H,s), 8.46(1H,s)

Mass(EI) m/z : Calcd for C<sub>22</sub>H<sub>30</sub>N<sub>4</sub>O<sub>5</sub> 430.2216, found 430.2265

## Example 57

15 1-([5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl) -4-(3,5-dimethylphenyl)piperazine:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 56 to obtain the titled compound.

20 yield: 95%

m.p.: 153-154°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.48(3H,d), 2.30(6H.s), 2.42(3H,s), 3.26(4H,t), 3.68(4H,t), 3.99(3H,s), 5.05(1H,q), 6.71(2H,d), 6.96(1H,s), 8.46(1H,s) Mass(EI) m/z: Calcd for C<sub>22</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub> 398.2317, found 398.2343

25

#### Example 58

1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl} -4-(2,3-dimethylphenyl)piperazine:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl]-4-(2,3-30 dimethylphenyl)piperazine was reacted by the same way with the example 56 to obtain the titled compound.

yield: 96%

m.p.: 100-102°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.47(3H,d), 1.59(3H,s), 2.25(3H,s), 2.28(3H,s), 2.43(3H,s), 2.93(4H,t), 3.66(4H,t), 3.99(3H,s), 5.05(1H,q), 6.93(3H,m), 7.11(1H,m), 8.48(1H,s)

## Example 59

1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl} -4-(3,5-difluorophenyl)piperazine:

5 1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 56 to obtain the titled compound.

yield: 97%

m.p.: 184-186°C

10 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ : 1.48(3H,d), 2.50(3H,s), 3.30(4H,t), 3.70(4H,t), 4.11(3H,s), 5.06(1H,q), 6.33(1H,s), 6.42(2H,d), 6.92(1H,s), 8.54(1H,s)

### Example 60

1-([5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl}

15 -4-(3,5-dichlorophenyl)piperazine:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)piperazine was reacted by the same way with the example 56 to obtain the titled compound.

vield: 95%

20 m.p.: 197-200℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.46(3H,d), 2.41(3H,s), 3.28(4H,t), 3.66(4H,t), 3.96(3H,s), 5.20(1H,q), 7.02(3H,m), 8.42(1H,s)

### Example 61

25 1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl} -4-(2-methoxyphenyl)piperazine:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine was reacted by the same way with the example 56 to obtain the titled compound.

30 yield: 97%

m.p.: 88-90°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.47(3H,d), 2.42(3H,s), 3.11(4H,t), 3.70(4H,t), 3.89(3H,s), 3.99(3H,s), 5.03(1H,q), 6.89(3H,m), 6.94(1H,s), 7.05(1H,m), 8.48(1H,s)

35

Example 62

1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl} -4-(3-hydroxyphenyl)piperazine:

1-[5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-hydro xyphenyl)piperazine was reacted by the same way with the example 56 to obtain the titled compound.

yield: 87%

m.p.: 194-196°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.47(3H,d), 2.41(3H,s), 3.27(4H,t), 3.79(4H,t), 3.98(3H,s), 5.04(1H,q), 6.57(3H,m), 6.90(1H,s), 7.13(1H,t), 8.41(1H,s)

10

## Example 63

1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminothio carbonyl}-4-(3,5-dimethoxyphenyl)piperazine:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5

15 -dimethoxyphenyl)piperazine was reacted by the same way with the example 56 to obtain the titled compound.

yield: 89%

m.p. : 189-190°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.47(3H,d), 2.43(3H,s), 3.35(4H,t), 3.78(6H,s),

20 3.97(3H,s), 4.09(4H,t), 5.05(1H,q), 6.07(3H,m), 7.35(1H,s), 8.42(1H,s)

### Example 64

1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminothio carbonyl}-4-(3,5-dimethylphenyl)piperazine:

25 1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5 -dimethylphenyl)piperazine was reacted by the same way with the example 56 to obtain the titled compound.

yield: 88%

m.p.: 170-172°C

30 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.46(3H,d), 2.29(6H,s), 2.43(3H,s), 3.43(4H,t), 3.97(3H,s), 4.10(4H,t), 5.06(1H,q), 6.60(3H,m), 7.37(1H,s), 8.40(1H,s)

#### Example 65

1-{[5-(1-Hydroxy-1-methylethyl)-2-methoxy-6-methylpyridin-3-yl]

aminocarbonyl)-4-(3,5-dimethoxyphenyl)piperazine:
1-{(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-

dimethoxyphenyl)piperazine(214mg, 0.50mmol) was dissolved in tetrahydrofuran(10ml) and CH<sub>3</sub>MgBr(0.50ml, 1.50mmol) was added slowly. The mixture solution was refluxed for 15 hrs and concentrated under the reduced pressure to remove the solvent and extracted with ethylacetate, dried and filtered. The resultant was purified by column chromatography(ethylacetate: hexane = 1: 2) to obtain the titled compound.

yield: 84%

m.p.: 146-148°C

10 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.64(6H,s), 2.64(3H,s), 3.25(4H,t), 3.67(4H,t), 3.78(6H,s), 3.99(3H,s), 6.07(3H,m), 6.86(1H,s), 8.47(1H,s)

#### Example 66

1-{[5-(1-Hydroxy-1-methylethyl)-2-methoxy-6-methylpyridin-3-yl] 15 aminocarbonyl}-4-(3,5-dimethylphenyl)piperazine:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 65 to obtain the titled compound.

yield: 81%

20 m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.64(6H,s), 2.29(6H,s), 2.65(3H,s), 3.24(4H,t), 3.67(4H,t), 3.99(3H,s), 6.59(3H,m), 7.05(1H,s), 8.48(1H,s)

## Example 67

- 25 1-{[5-(1-Hydroxy-1-methylpropyl)-2-methoxy-6-methylpyridin-3-yl] aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine:
  1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine(214mg, 0.50mmol) was dissolved in tetrahydrofuran(10ml) and C<sub>2</sub>H<sub>5</sub>MgBr(0.50mg, 1.50mmol) was added
  30 slowly. The mixture solution was referred to 1.50mmol) was added
- 30 slowly. The mixture solution was refluxed for 15 hours and concentrated under the reduced pressure to remove the solvent and extracted with ethylacetate, dried and filtered. The resultant was purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

35 yield: 76%

m.p.: 127-129°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 0.83(3H,t), 1.63(3H,s), 1.94(2H,m), 2.61(3H,s), 3.26(4H,t), 3.68(4H,t), 3.79(6H,s), 3.99(3H,s), 6.08(3H,m), 6.86(1H,s), 8.44(1H,s)

### 5 Example 68

1-{[5-(1-Hydroxy-1-methylpropyl)-2-methoxy-6-methylpyridin-3-yl] aminocarbonyl}-4-(3,5-dimethylphenyl)piperazine:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 67 to obtain the titled compound.

yield: 74%

m.p.: 164-165°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 0.83(3H,t), 1.60(3H,s), 1.95(2H,m), 2.29(6H,s), 2.61(3H,s), 3.23(4H,t), 3.67(4H,t), 3.99(3H,s), 6.59(3H,m), 6.87(1H,s),

15 8.45(1H,s)

### Example 69

1-[5-(([4-(3,5-Dimethoxyphenyl)piperazino]carbonyl)amino)-6-methoxy-2-methylpyridin-3-yl]ethyl ethanthioate:

- Triphenylphosphine(262mg, 1.0mmol) was dissolved in tetrahydrofuran(15ml) and diethyl azodicarboxylate(157μl, 1.0mmol) was added and then the mixture was stirred at 0°C for 30min.

  1-([5-(1-Hydroxyethyl)-2-methoxy-6-methylpuridin-2-millority and the statement of the statement
  - 1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl) -4-(3,5-dimethoxyphenyl)piperazine(213mg, 0.5mmol) and thioacetic
- acid(72μl, 1.0mmol) were dissolved in tetrahydrofuran and was added into the above solution. The mixture solution was stirred at 0°C for 1hour and at room temperature for 1hour and then was concentrated under the reduced pressure to remove the solvent. The concentrate was purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

30 obtain the fitted com

yield: 62%

35

m.p.: oil phase

<sup>1</sup>H NMR(CDC<sub>3</sub>) δ: 1.55(3H,d), 2.20(3H,s), 2.39(3H,s), 3.15(4H,t), 3.57(4H,t), 3.69(6H,s), 3.90(3H,s), 4.74(1H,q), 6.01(3H,m), 6.89(1H,s), 8.33(1H,s)

## Example 70

1-[5-({[4-(3,5-Dimethylphenyl)piperazino]carbonyl}amino)-6-methoxy-2-methylpyridin-3-yl]ethyl ethanthioate:

1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl}
5 -4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 69 to obtain the titled compound.

yield: 60%

m.p.: oil phase

¹H NMR(CDCl<sub>3</sub>) δ: 1.60(3H,d), 2.26(6H,s), 2.52(3H,s), 3.20(4H,t),

3.64(4H,t), 3.96(3H,s), 4.80(1H,q), 6.56(3H,m), 6.91(1H,s), 8.38(1H,s)

### Example 71

1-{[2-Methoxy-6-methyl-5-(1-sulfanylmethyl)]aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine:

- 15 1-[5-(([4-(3,5-Dimethoxyphenyl)piperazino]carbonyl]amino)-6-methoxy-2 -methylpyridin-3-yl]ethyl ethanthioate(180mg, 0.37mmol) was dissolved in tetrahydrofuran(15ml) and LiAlH4(15mg, 0.4mmol) was added and then the mixture was stirred at 0°C for 20min. 2N-HCl was added the above solution. The mixture was concentrated under the reduced
- pressure to remove the solvent and extracted with dichloromethane, dried and filtered. The resultant was concentrated under the reduced pressure and purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

vield: 88%

25 m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.42(3H,d), 2.39(3H,s), 3.25(4H,t), 3.66(4H,t), 3.76(6H,s), 3.96(3H,s), 5.02(1H,q), 6.17(3H,m), 6.87(1H,s), 8.41(1H,s)

#### Example 72

- 30 1-([2-Methoxy-6-methyl-5-(1-sulfanylmethyl)]aminocarbonyl}-4-(3,5-dimethyl)piperazine:
  - 1-[5-({[4-(3,5-Dimethylphenyl)piperazino]carbonyl}amino)-6-methoxy-2-methylpyridin-3-yllethyl ethanthioate was reacted by the same way with the example 71 to obtain the titled compound.
- 35 yield: 87%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.43(3H,d), 2.28(6H,s), 2.40(3H,s), 3.25(4H,t), 3.72(4H,t), 5.03(1H,q), 6.64(3H,m), 6.88(1H,s), 8.42(1H,s)

#### Exmaple 73

5 1-[(2-Methoxy-6-methyl-5-vinylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-{[5-(1-Hydroxyethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine was dissolved in chloroform(15ml) and pyridinum p-toluensulfonate(60mg, 0.23mmol) was added and then

the mixture solution was refluxed 16hours. The above solution was concentrated under the reduced pressure to remove chloroform and purified by column chromatography to obtain the titled compound, yield: 93%

m.p.: 140-141°C

15 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.43(3H,s), 3.27(4H,t), 3.69(4H,t), 3.79(6H,s), 4.00(3H,s), 5.25(1H,d), 5.65(1H,d), 6.08(1H,s), 6.13(2H,d), 6.82(1H,d), 6.91(1H,s), 8.53(1H,s)

Mass(EI) m/z : Calcd for C22H28N4O4 412.2110, found 412.2119

#### 20 Example 74

1-[(2-Methoxy-6-methyl-5-vinylpyridin-3-yl)aminocarbonyl]-4-(3.5-dimethylphenyl)piperazine:

1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl}-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with

25 the example 73 to obtain the titled compound.

yield: 94%

m.p.: 131-132°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.57(3H,s), 2.31(6H,s), 2.43(1H,s), 3.25(4H,t), 3.68(4H,t), 4.00(3H,s), 5.25(1H,d), 5.65(1H,d) 6.60(3H,m), 6.82(1H,dd),

30 6.92(1H,s), 8.53(1H,s)

Mass(EI) m/z: Calcd for C22H28N4O2 380.2212, found 380.2236

#### Example 75

1-[(2-Methoxy-6-methyl-5-vinylpyridin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)piperazine:

1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl}

-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 73 to obtain the titled compound.

yield: 93%

m.p.: 160-161°C

5 <sup>t</sup>H NMR(CDCl<sub>3</sub>) δ: 2.44(3H,s), 3.30(4H,t,J=5.5Hz), 3.68(4H,t,J=5.5Hz), 4.01(3H,s), 5.26(1H,d), 5.65(1H,d), 6.30(1H,s), 6.39(2H,d), 6.81(1H,dd), 8.53(1H,s)

Mass(EI) m/z : Calcd for C22H28N4O4 412.2110, found 412.2102

## 10 Example 76

1-[(5-Isopropenyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3.5-dimethoxyphenyl)piperazine:

-{[5-(1-Hydroxy-1-methylethyl)-2-methoxy-6-methylpyridin-3-yl) aminocarbonyl]}-4-(3,5-dimethoxyphenyl)piperazine was reacted by the

same way with the example 73 to obtain the titled compound. yield: 96%

, icia : 5076

m.p.: 83-85°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.01(3H,s), 2.38(3H,s), 3.25(4H,t), 3.66(4H,t), 3.78(6H,s), 3.99(3H,s), 4.86(1H,s), 5.30(1H,s), 6.11(3H,m), 6.90(1H,s), 8.18(4H,s)

20 8.18(1H,s)

## Example 77

1-[(5-Isopropenyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3.5-dimethylphenyl)piperazine:

25 1-{[5-(1-Hydroxy-1-methylethyl)-2-methoxy-6-methylpyridin-3-yl]amin ocarbonyl}-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with example 73 to obtain the titled compound.

yield: 93%

m.p.: 140-142°C

30 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.01(3H,s), 2.29(6H,s), 2.28(3H,s), 3.23(4H,t), 3.66(4H,t), 3.99(3H,s), 4.86(1H,s), 5.18(1H,s), 6.59(3H,m), 6.91(1H,s), 8.18(1H,s)

#### Example 78

Ethyl 2-{1-[5-({[4-(3,5-dimethoxyphenyl)piperazino]carbonyl}amino)-6-methoxy-2-methylpyridin-3-yl]ethoxy)acetate:

1-{[5-(1-Hydroxy)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine(0.5mmol) was dissolved in dimethylformamide(15ml) and NaH(18.5mg, 0.5mmol) was added and then the mixture solution was stirred at room temperature for 15min.

Ethylbromoacetate(83.5mg, 0.5mmol) was added into the above mixture and stirred at room temperature for 3hours. The mixture was concentrated under the reduced pressure to remove the solvent and purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

10 yield: 89%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.25(3H,t), 1.34(3H,d), 2.42(3H,s), 3.00(4H,t), 3.29(4H,t), 3.74(6H,s), 3.97(3H,s), 4.16(4H,s), 4.53(1H,q), 6.03(3H,m), 7.58(1H,s)

15

## Example 79

4-{1-[5-({[4-(3,5-Dimethoxyphenyl)piperazino}carbonyl}amino)-6-methox y-2-methylpyridin-3-yl]ethoxy}-4-oxobutanoic acid:

1-{[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl}

-4-(3,5-dimethoxyphenyl)piperazine(107mg, 0.25mmol) and dimethylaminopyridine(3mg, 0.025mmol) were dissolved in pyridine and anhydrous succinic acid(50mg, 0.5mmol) was added. The mixture was stirred at room temperature for 5hrs. Distilled water was added into the above mixture. The above solution was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the organic phase washed with 1N-HCl and then concentrated under the reduced pressure to remove the solvent. The concentrate was purified by column chromatography(dichloromethane: methanol = 20:1) to obtain the titled compound.

yield: 78%

3.010 . 1070

30 m.p.: 158-160°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.42(3H,d), 2.43(3H,s), 2.61(4H,m), 3.24(4H,t), 3.66(4H,t), 3.76(6H,s), 3.95(3H,s), 5.94(1H,q), 6.04(3H,m), 6.89(1H,s), 8.13(1H,s)

35 Example 80

4-{1-[5-({[4-(3,5-Dimethylphenyl)piperazino]carbonyl}amino)-6-methoxy-

2-methylpyridin-3-yl]ethoxy)-4-oxobutanoic acid:

1-{[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl}-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 79 to obtain the titled compound.

5 yield: 76%

m.p.: 138-140°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.43(3H,d), 2.27(6H,s), 2.55(3H,s), 2.65(4H,m), 3.24(4H,t), 3.69(4H,t), 3.95(3H,s), 5.95(1H,q), 6.60(3H,m), 6.88(1H,s), 8.11(1H,s)

10

## Example 81

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl) piperazine:

a) Phenyl N-(2-methoxyquinolin-3-yl)carbamate:
3-Amino-2-methoxyquinoline(4g, 23mmol) and phenyl
chloroformate(4.04g, 25mmol) were dissolved in dichloromethane and
stirred at room temperature for 2 hours. The above mixture was
concentrated under the reduced pressure to remove dichloromethane and
purified by column chromatography(hexane: ether =8:1) to obtain the
titled compound.

yield: 75%

m.p.: oil phase

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 4.01(3H,s), 7.30(5H,s), 7.41(1H,t), 7.70(1H,d),

25 7.71(1H,d), 8.71(1H,s)

b) 1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate(148mg, 0.5mmol) and 1-(3,5-dimethoxyphenyl)piperazine(112mg, 0.5mmol) were dissolved in anhydrous tetrahydrofuran and DBU(117mg, 0.75mmol) was added. The solution was stirred at room temperature for 2 hours. The mixture was concentrated under the reduced pressure to remove tetrahydrofuran and purified by column chromatography(hexane: ether = 5:1) to obtain the titled compound.

yield: 81%

m.p. : 200-201°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.31(4H,t,J=5.0Hz), 3.74(4H,t), 3.79(6H,s), 4.17(3H,s), 6.09(1H,s), 6.17(2H,s), 7.35(1H,t), 7.49(1H,t), 7.71(1H,d), 7.78(1H,d), 8.78(1H,s)

5 Mass(EI) m/z: Calcd for C23H26N4O4 422.1954, found 422.1952

## Example 82

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound. yield: 79%

m.p.: 143-145°C

15 H NMR (CDCl<sub>3</sub>): δ 2.30(6H,s), 3.29(4H,t), 3.80(4H,t), 4.18(3H,s), 6.62(3H,m), 7.36(1H,t), 7.49(1H,t), 7.71(1H,d), 7.78(1H,d), 8.79(1H,s) Mass(EI) m/z : Calcd for C<sub>23</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> 390.2055, found 390.2066

## Example 83

20 1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(2,3-dimethylphenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and 1-(2,3-dimethylphenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

25 yield: 83%

m.p.: 174-175℃

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.20(3H,s), 2.39(3H,s), 3.28(4H,t), 3.69(4H,t), 3.93(3H,s), 5.98(1H,s), 6.30(1H,t), 6.37(1H,s), 6.39(1H,s), 6.63(1H,s)

#### 30 Example 84

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

yield: 78%

m.p. : 158-159℃

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  3.32(4H,t,J=5.0Hz), 3.72(4H,t,J=5.0Hz), 4.19(3H,s), 6.29(1H,s), 6.39(2H,d), 7.36(1H,t), 7.50(1H,t), 7.71(1H,d), 7.81(1H,d), 8.78(1H.s)

5

## Example 85

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and

10 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

yield : 56%

m.p.: 156-158°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  3.33(4H,t), 3.73(4H,t), 4.21(3H,s) 6.79(1H,s),

6.83(1H,d), 6.93(1H,t), 7.26(1H,t), 7.38(1H,t), 7.52(1H,t), 7.71(1H,d), 7.83(1H,d)

Mass(EI) m/z: Calcd for C21H20N4O2Cl1 430.0963, found 430.0977

### Example 86

20 1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(2-fluorophenyl)piperazine: Phenyl N-(2-methoxyquinolin-3-yl)carbamate and 1-(2-fluorophenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

yield: 81%

25 m.p.: 156-158°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.18(4H,t), 3.74(4H,t), 4.18(3H,s), 6.99(2H,q), 7.07(2H,m), 7.35(2H,m), 7.50(1H,t), 7.70(1H,d), 7.77(1H,d)

## Example 87

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(2-chlorophenyl)piperazine: Phenyl N-(2-methoxyquinoline-3-yl)carbamate and 1-(2-chlorophenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound. yield: 78%

m.p.: 79-80°C <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  3.32(4H,t), 3.74(4H,t), 4.20(3H,s), 6.82(2H,q), 6.94(2H,m), 7.34(2H,m), 7.48(1H,d), 7.70(1H,d), 7.78(1H,d)

## Example 88

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3-chlorophenyl)piperazine:

5 Phenyl N-(2-methoxyquinolin-3-yl)carbamate and 1-(3-chlorophenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

yield: 73%

m.p.: 97-98°C

10 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.31(4H,t), 3.73(4H,t), 4.18(3H,s), 6.82(1H,d), 6.87(1H,d), 6.92(1H,s), 7.21(1H,t), 7.32(1H,s), 7.37(1H,t), 7.51(1H,t), 7.70(1H,d), 7.78(1H,d), 8.80(1H,s)

## Example 89

15 1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3-hydroxyphenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and 1-(3-hydroxyphenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

20 yield: 75%

m.p.: 190-191°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.33(4H,t), 3.80(4H,t), 4.19(3H,s), 6.47(1H,s), 6.62(2H,s), 7.16(1H,t), 7.32(1H,s), 7.37(1H,t), 7.51(1H,t), 7.72(1H,d), 7.78(1H,d), 8.78(1H,s)

25

## Example 90

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and

30 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

yield: 88%

m.p.: 159-161°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  3.28(4H,t), 3.71(4H,t), 3.81(3H,s), 4.18(3H,s),

35 6.52(2H,s), 6.62(1H,s), 7.23(1H,t), 7.31-7.53(3H,m), 7.72(2H,m), 8.81(1H,s)

## Example 91

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(2-methylthiophenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and

5 1-(2-methylthiophenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

yield: 78%

m.p.: 147-149°C

'H NMR (CDCl<sub>3</sub>): δ 2.44(3H,s), 3.07(4H,t), 3.75(4H,t), 4.18(3H,s),

7.13(3H,m), 7.18(1H,d), 7.39(2H,m), 7.70(3H,m), 8.81(1H,s)

### Example 92

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3-isopropoxyphenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and 1-(3-isopropoxyphenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

yield: 93%

m.p. : 111-113℃

20 H NMR (CDCl<sub>3</sub>): δ 1.34(6H,d), 3.30(4H,t), 3.74(4H,t), 4.18(3H,s), 4.55(1H,m), 6.49(2H,s), 7.05(1H,s), 7.20(1H,t), 7.32(1H,s), 7.37(1H,t), 7.50(1H,t), 7.70(1H,d), 7.77(1H,d), 8.80(1H,s)

## Example 93

25 1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3-cyclopropylmethoxy phenyl)piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and 1-(3-cyclopropylmethoxyphenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

30 yield: 90%

m.p.: 146-147°C ;

<sup>1</sup>H NMR (CDC<sub>b</sub>): 8 0.36(2H,t), 0.65(2H,m), 1.28(1H,m), 3.31(4H,t), 3.75(4H,t), 3.80(2H,d), 4.18(3H,s), 6.50(1H,s), 6.60(2H,s), 7.19(1H,t), 7.32(1H,s), 7.37(1H,t), 7.50(1H,t), 7.70(1H,d), 7.77(1H,d), 8.79(1H,s)

35

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(2-methoxy-5-methyl phenyl)piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and

1-(2-methoxy-5-methylphenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

yield: 76%

m.p.: 115-116°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.30(3H,s), 3.14(4H,t), 3.75(4H,t), 3.87(3H,s), 4.18(3H,s), 6.79(2H,m), 6.84(1H,d), 7.35(2H,m), 7.50(1H,t), 7.72(1H,d),

10 7.77(1H,d), 8.82(1H,s)

## Example 95

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(2-methoxy-5-phenyl phenyl)piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and 1-(2-methoxy-5-phenylphenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound. yield: 77%

m.p.: 122-123°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.38(4H,t) 3.86(4H,t), 3.97(3H,s), 4.18(3H,s), 7.05(2H,m), 7.34-7.45(6H,m), 7.50(1H,t), 7.56(2H,d), 7.71(2H,d), 7.78(2H,d), 8.88(1H,s)

#### Example 96

25 1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(5-methoxy-2-methyl phenyl)piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)carbamate and 1-(5-methoxy-2-methylphenyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

30 yield: 82%

m.p. : 128-130°C ...

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.30(3H,s), 3.37(4H,t), 3.84(4H,t), 3.78(3H,s), 3.97(3H,s), 7.05(2H,m), 7.13(1H,d), 7.38(3H,m), 7.62(1H,d), 7.80(1H,s), 8.88(1H,s)

35

Example 97

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(1-naphthyl)piperazine: Phenyl N-(2-methoxyquinolin-3-yl)carbamate and 1-(1-naphthyl)piperazine were reacted by the same way with the example 81 to obtain the titled compound.

5 yield: 68%

m.p.: 158-160℃

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.22(4H,t), 3.86(4H,t), 4.20(3H,s), 7.13(1H,d), 7.38(2H,m), 7.43(1H,t), 7.53(3H,m), 7.62(1H,d), 7.72(1H,d), 7.80(1H,d), 7.86(1H,d), 8.24(1H,d), 8.84(1H,s)

10

## Example 98

1-[N-(2-Methoxyquinolin-3-yl)-N-methylaminocarbonyl]-4-(3,5-dimethoxyphenyl) piperazine:

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)

piperazine(106mg, 0.25mmol) was dissolved in dimethylformamide(15ml) and sodium hydride(6.0mg, 0.25mmol) was added and the solution was stirred at room temperature for 15 min. Iodomethane(35mg, 0.25mmol) was added to the above solution. The mixture was stirred at room temperature for 16 hours and concentrated under the reduced pressure

20 to remove dimethylformamide. The concentrate was purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

yield: 93%

m.p.: 88-89°C

25 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.93(4H,t), 3.17(3H,s), 3.34(4H,t), 3.72(6H,s), 4.15(3H,t), 5.95(2H,s), 5.98(1H,s), 7.40(1H,t), 7.61(2H,m), 7.73(1H,s), 7.84(1H,d)

Mass(EI) m/z: Calcd for C24H28N4O4 436.2110, found 436.2105

# 30 Example 99

1-[N-Ethyl-N-(2-methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethox yphenyl)piperazine:

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl) piperazine(106mg, 0.25mmol) was dissolved in dimethylformamide(15ml) and was sodium hydride(6.0mg, 0.25mmol) was added and the solution was stirred at room temperature for 15 min. Iodoethane(35mg.

0.25mmol) was added to the above solution. The mixture was stirred at room temperature for 16hours and concentrated under the reduced pressure to remove dimethylformamide. The concentrate was purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

yield: 91%

m.p.: 118-120°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  1.16(3H,t), 2.89(4H,t), 3.30(4H,t), 3.63(2H,m), 3.71(6H,s), 4.13(3H,s), 5.93(2H,s), 5.98(1H,s), 7.41(1H,t), 7.60(1H,t),

7.66(1H,d), 7.71(1H,s), 7.84(1H,d)

Mass(EI) m/z: Calcd for C25H30N4O4 450.2227, found 450.2206

### Example 100

15

1-[N-Isopropyl-N-(2-methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)phenyl:

- 1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl) piperazine(106mg, 0.25mmol) was dissolved in dimethylformamide(15ml) and sodium hydride(6.0mg, 0.25mmol) was added and the reaction solution was stirred at room temperature for 15 min.
- 2-Propyliodide(42mg, 0.25mmol) was added to the above solution. The mixture was stirred at room temperature for 16 hours and concentrated under the reduced pressure to remove the dimethylformamide. The concentrate was purified by column chromatography(ethylacetate hexane = 1:2) to obtain the titled compound.

25 yield: 87%

m.p.: 123-125°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.21(6H,d), 2.79(4H,t), 3.29(4H,t), 3.70(6H,s), 4.08(3H,s), 4.41(1H,m), 5.90(2H,s), 5.96(1H,s), 7.43(1H,t), 7.69(1H,d), 7.75(1H,s), 7.83(1H,d)

# Example 101

30

- 1-[N-Cyclopropylmethyl-N-(2-methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:
- 1-[(2-methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)
  35 piperazine(106mg, 0.25mmol) was dissolved in dimethylformamide(15ml)
  and sodium hydride(6.2mg, 0.26mmol) was added and the solution was

5

15

stirred at room temperature for 15 min. Bromomethylcyclopropane(22mg, 0.26mmol) was added to the above solution. The mixture was stirred at room temperature for 16 hours and concentrated under the reduced pressure to remove dimethylformamide. The concentrate was purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

yield: 78%

m.p.: 118-120℃

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 8 0.41(2H,m), 0.85(2H,m), 1.28(1H,m), 2.88(4H,t),

3.24(4H,t), 3.42(2H,d), 3.71(6H,s), 4.13(3H,s), 5.94(3H,s), 7.44(1H,d), 10 7.62(1H,d), 7.78(3H,m)

## Example 102

1-[N-Benzyl-N-(2-methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5dimethoxyphenyl)piperazine:

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl) piperazine(114mg, 0.27mmol) was dissolved in dimethylformamide(15ml) and sodium hydride(6.6mg, 0.27mmol) was added and the solution was stirred at room temperature for 15 min. Benzylbromide(46mg, 0.27mmol)

was added to the above solution. The mixture was stirred at room 20 temperature for 16 hours and concentrated under the reduced pressure to remove dimethylformamide. The concentrate was purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

25 yield: 90%

m.p.: oil phase

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.92(4H,t), 3.39(4H,t), 3.72(6H,s), 4.13(3H,s), 4.79(2H,s), 6.01(3H,m), 7.21(1H,m), 7.25(2H,m), 7.33(3H,m), 7.51(1H,s), 7.57(2H,m), 7.81(2H,d)

30 Example 103

> 1-[N-(2-Methoxyquinolin-3-yl)-N-methylaminocarbonyl]-4-(3,5-dimethyl phenyl)piperazine:

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)

piperazine was reacted by the same way with the example 98 to obtain 35 the titled compound.

yield: 92%

m.p: 142-143°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  2.27(6H,d), 2.90(4H,t), 3.17(3H,s), 3.34(4H,t), 4.15(3H,s), 6.41(2H,s), 6.49(1H,s), 7.40(1H,t), 7.63(1H,t), 7.65(1H,d),

7.73(1H,s), 7.84(1H,d) 5

Mass(EI) m/z: Calcd for  $C_{24}H_{28}N_4O_2$  404.2212, found 404.2225

## Example 104

10

1-[N-Ethyl-N-(2-methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethyl phenyl)piperazine:

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl) piperazine was reacted by the same way with the example 99 to obtain the titled compound.

yield: 89%

m.p.: 84-86°C 15

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  1.16(3H,t), 2.21(6H,s), 2.87(4H,t), 3.30(4H,t), 3.64(2H,q), 4.13(3H,t), 6.40(2H,s), 6.48(1H,s), 7.40(1H,t), 7.62(1H,t), 7.66(1H,d), 7.71(1H,s), 7.84(1H,d)

#### Example 105 20

dimethylphenyl)piperazine:

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl) piperazine was reacted by the same way with the example 100 to obtain the titled compound.

yield: 84%

25

30

m.p.: 114-115°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.21(6H,d), 2.20(6H,s), 2.77(4H,t), 3.28(4H,t), 4.08(3H,s), 4.39(1H,m), 6.37(2H,s), 6.46(1H,s), 7.41(1H,t), 7.63(1H,t), 7.69(1H,d), 7.75(1H,s), 7.83(1H,d)

## Example 106

1-[N-Benzyl-N-(2-methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5dimethylphenyl)piperazine:

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl) 35 piperazine was reacted by the same way with the example 102 to

obtain the titled compound.

yield: 90%

m.p.: oil phase

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  2.24(6H,s), 2.87(4H,t), 3.31(4H,t), 4.13(3H,s),

5 4.80(2H,s), 6.42(3H,s), 7.49(1H,t), 7.62(2H,m), 7.72(2H,m)

## Example 107

1-[N-(2-Methoxyquinolin-3-yl)-N-methylaminocarbonyl]-4-(3-isopropoxyphenyl)piperazine:

10 1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3-isopropoxyphenyl) piperazine was reacted by the same way with the example 98 to obtain the titled compound.

yield: 92%

m.p.: oil phase

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.28(6H,d), 2.97(4H,t), 3.18(3H,s), 3.37(4H,t), 4.14(3H,s), 4.49(1H,m), 6.41(3H,m), 7.13(1H,m), 7.40(1H,t), 7.62(1H,t), 7.66(1H,d), 7.74(1H,s), 7.84(1H,d)

### Example 108

- 20 1-[N-Ethyl-N-(2-methoxyquinolin-3-yl)aminocarbonyl]-4-(3-isopropoxyphenyl)piperazine:
  - 1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3-isopropoxyphenyl) piperazine was reacted by the same way with the example 99 to obtain the titled compound.
- 25 yield: 87%

m.p. : oil phase

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.16(3H,t), 1.34(6H,d), 2.89(4H,t), 3.30(4H,t), 3.63(2H,m), 4.13(3H,s), 4.55(1H,m), 6.49(2H,s), 7.05(1H,s), 7.20(1H,t), 7.32(1H,s), 7.37(1H,t), 7.50(1H,t), 7.70(1H,d), 7.77(1H,d), 8.80(1H,s)

30

## Example 109

1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)thiocarbamate(56mg, 0.5mmol) and 1-(3,5-dimethoxyphenyl)piperazine(111mg, 0.5mmol) were dissolved in anhydrous tetrahydrofuran and DBU(117mg, 0.75mmol) was added. The

reaction solution was stirred at room temperature for 2 hours. The above solution was concentrated under the reduced pressure to remove tetrahydrofuran and concentrated was purified by column chromatography(Hexane: ether = 5:1) to obtain the titled compound.

5 yield: 76%

m.p.: 171-172°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.41(4H,t), 3.81(6H,s), 4.17(3H,s), 4.21(4H,t), 6.12(1H,s), 6.20(1H,d), 7.38(1H,t), 7.54(1H,t), 7.74(1H,d), 7.81(1H,d), 8.96(1H,s)

10

## Example 110

1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)thiocarbamate and

15 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 109 to obtain the titled compound.

yield: 79%

m.p.: 170-171℃

<sup>3</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  2.30(6H,s), 3.38(4H,t), 4.09(3H,s), 4.17(4H,t).

20 6.63(3H,m), 7.38(1H,t), 7.54(1H,t), 7.72(1H,d), 7.81(1H,d), 8.96(1H,s)

### Example 111

1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)thiocarbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 109 to obtain the titled compound.

yield 78%

m.p.: 140-142°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 8 3.44(4H,t), 4.20(4H,t), 4.25(3H,s), 6.33(2H,m), 6.45(1H,d), 7.41(1H,t), 7.56(1H,m), 7.72(1H,m), 7.97(1H,m), 8.96(1H,s)

#### Example 112

1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3,5-dichlorophenyl)

35 piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)thiocarbamate and

1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 109 to obtain the titled compound.

yield: 62%

m.p.: 181-183°C

5 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.44(4H,t), 4.20(4H,t), 4.26(3H,s), 6.77(1H,s), 6.88(2H,t), 7.41(1H,t), 7.59(1H,t), 7.70(2H,m), 8.01(1H,t), 8.11(1H,s), 8.93(1H,s)

## Example 113

10 1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3-methoxyphenyl) piperazine:

Phenyl N-(2-methoxyquinolin-3-yl)thiocarbamate and 1-(3-methoxyphenyl)piperazine were reacted by the same way with the example 109 to obtain the titled compound.

15 yield: 81% m.p.: oil phase <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.17(4H,t), 3.89(3H,s), 4.17(4H,t), 6.90(4H,m), 7.34(1H,t), 7.48(1H,t), 7.70(1H,d), 7.77(1H,d), 8.80(1H,s)

- 20 Example 114
  1-[(2-Methylquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)
  piperazine:
  - a) Phenyl N-(2-methylquinolin-3-yl)carbamate:
- 3-amino-2-methylquinoline(4g, 25mmol) and phenyl chloroformate(4.04g, 25mmol) were dissolved in methylene chloride and then was stirred at room temperature for 2 hrs. The mixture solution was concentrated under the reduced pressure to remove methylene chloride and purified by column chromatography(ethylacetate: hexane = 1:10) to obtain the titled compound.

yield: 88%

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  2.77(3H,s), 7.30-7.53(9H,m), 8.67(1H,s)

b) 1-[(2-Methylquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)
piperazine:
Phenyl N-(2-methylquinolin-3-yl)carbamate(140mg, 0.5mmol) and

1-(3,5-dimethoxyphenyl)piperazine(112mg, 0.5mmol) were dissolved in tetrahydrofuran and DBU(117mg, 0.75mmol) was added and then the mixture was stirred at room temperature for 2 hrs. The above solution was concentrated under the reduced pressure to remove tetrahydrofuran and purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

yield: 84%

m.p.: 199-200℃

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.81(3H,s), 3.30(4H,t), 3.76(4H,t), 3.80(6H,s),

10 6.08(1H,s), 6.12(2H,d), 7.48(1H,t), 7.62(1H,t), 7.71(1H,d), 8.03(1H,d), 8.59(1H,s)

### Example 115

1-[(2-Methylquinolin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)

15 piperazine:

Phenyl N-(2-methylquinolin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 114 to obtain the titled compound.

yield: 86%

20 m.p.: 230-232°C

<sup>3</sup>H NMR (CDCl<sub>3</sub>): & 2.31(6H,s), 2.82(3H,s), 3.29(4H,t), 3.76(4H,t), 6.60(3H,s), 7.49(1H,t), 7.63(1H,t), 7.73(1H,d), 8.05(1H,d), 8.61(1H,s)

### Example 116

25 1-[(2-methylquinolin-3-yl)aminocarbonyl]-4-(2,3-dimethylphenyl) piperazine:

Phenyl N-(2-methylquinolin-3-yl)carbamate and 1-(2,3-dimethylphenyl)piperazine were reacted by the same way with the example 114 to obtain the titled compound.

30 yield: 81%

m.p. 169-170°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.28(6H,d), 2.84(3H,s), 3.00(4H,t), 3.76(4H,t), 6.94(2H,m), 7.11(1H,t), 7.49(1H,t), 7.63(1H,t), 7.72(1H,d), 8.07(1H,d), 8.64(1H,s)

### Example 117

1-[(2-Methoxyquinolin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl) piperazine:

Phenyl N-(2-methylquinolin-3-yl)carbamate and

5 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 114 to obtain the titled compound.

yield: 81%

m.p.: 238-240°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  2.81(3H,t), 3.34(4H,t), 3.77(4H,t), 6.32(1H,t),

10 6.39(2H,d), 7.49(1H,t), 7.63(1H,t), 7.72(1H,d), 8.03(1H,d), 8.58(1H,s)

### Example 118

1-[(2-Methylquinolin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl) piperazine:

Phenyl N-(2-methylquinolin-3-yl)carbamate and 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 114 to obtain the titled compound.

yield : 65%

m.p.: 247-249°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.79(3H,s), 3.33(4H,t), 3.75(4H,t), 6.78(2H,s), 6.87(1H,s), 7.49(1H,t), 7.63(1H,t), 7.72(1H,d), 8.56(1H,s)

#### Example 119

1-[(2-Methylquinolin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)

25 piperazine:

Phenyl N-(2-methylquinolin-3-yl)carbamate and

1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 114 to obtain the titled compound.

yield: 83%

m.p.: 135-136°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): 8 2.82(3H,s), 3.18(4H,t), 3.79(4H,t), 3.91(3H,s), 6.88(1H,d), 6.97(2H,s), 7.07(1H,m), 7.48(1H,t), 7.62(1H,t), 7.72(1H,d), 8.04(1H,d), 8.63(1H,s)

35 Example 120

1-[(2-Methylquinolin-3-yl)aminocarbonyl]-4-(2-fluorophenyl)piperazine:

Phenyl N-(2-methylquinolin-3-yl)carbamate and 1-(2-fluorophenyl)piperazine were reacted by the same way with the example 114 to obtain the titled compound.

yield: 84%

5 m.p.: 201-203°C

<sup>1</sup>H NMR (CDCl<sub>2</sub>): δ 2.84(3H,s), 3.20(4H,t), 3.80(4H,t), 6.99(2H,m), 7.07(2H,m), 7.49(1H,t), 7.62(1H,t), 7.71(1H,d), 8.04(1H,d), 8.62(1H,s)

## Example 121

1-[(2-Methylquinolin-3-yl)aminocarbonyl]-4-(2-chlorophenyl)piperazine:
Phenyl N-(2-methylquinolin-3-yl)carbamate and
1-(2-chlorophenyl)piperazine were reacted by the same way with the example 114 to obtain the titled compound.
yield: 72%

15 m.p.: 180-181°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.83(3H,s), 3.16(4H,t), 3.80(4H,t), 7.04(3H,m), 7.40(1H,d), 7.49(1H,t), 7.63(1H,t), 7.71(1H,d), 8.05(1H,d), 8.62(1H,s)

#### Example 122

20 1-[(2-Methylquinolin-3-yl)aminocarbonyl]-4-(2-methylthiophenyl) piperazine:

Phenyl N-(2-methylquinolin-3-yl)carbamate and 1-(2-methylthiophenyl)piperazine were reacted by the same way with the example 114 to obtain the titled compound.

25 yield: 76% m.p.: 165-166°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.45(3H,s), 2.85(3H,s), 3.11(4H,t), 3.79(4H,t), 7.05(1H,m), 7.15(3H,d), 7.49(1H,t), 7.63(1H,t), 7.69(1H,d), 8.62(1H,s)

30

### Example 123

1-[(2-Methylquinolin-3-yl)aminocarbonyl]-4-(2-methoxy-5-methyl phenyl)piperazine:

Phenyl N-(2-methylquinolin-3-yl)carbamate and

35 1-(2-methoxy-5-methylphenyl)piperazine were reacted by the same way with the example 114 to obtain the titled compound.

```
yield: 80%
     m.p.: oil phase
     <sup>1</sup>H NMR (CDCl<sub>3</sub>): \delta 2.30(3H,s), 2.72(3H,s), 3.17(4H,t), 3.70(4H,t),
     3.87(3H,s), 6.77(1H,s), 6.82(2H,s), 7.73(4H,m), 8.60(1H,s)
 5
     Example 124
     1-[(2-Methylquinolin-3-yl)aminocarbonyl]-4-(1-naphthyl)piperazine:
     Phenyl N-(2-methylquinolin-3-yl)carbamate and
     1-(1-naphthyl)piperazine were reacted by the same way with the
10 example 114 to obtain the titled compound.
    yield: 64%
    m.p.: 220-222°C
    <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.83(3H,s), 3.23(4H,t), 3.80(4H,t), 6.91(1H,s),
     7.12(1H,d), 7.44(1H,d), 7.50(3H,m), 7.61(2H,m), 7.73(1H,d), 7.86(1H,d),
     8.05(1H,d), 8.23(1H,d), 8.64(1H,s)
15
     Example 125
     1-[(2-Methylquinolin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)
     piperazine:
20
     a) Phenyl N-(2-methylquinolin-3-yl)thiocarbamate:
     3-Amino-2-methylquinoline(4g, 25mmol) and phenyl
     chlorothionoformate(4.32g, 25mmol) were dissolved in methylene chloride
     and then was stirred at room temperature for 2hours. The mixture
   solution was concentrated under reduced pressure to remove methylene
    chloride and purified by column chromatography(ethylacetate : hexane =
     1:2) to obtain the titled compound.
    yield: 78%
    <sup>1</sup>H NMR (CDCl<sub>3</sub>): \delta 2.77(3H,s), 7.09-7.90(9H,m), 9.14(1H,s)
30
     1-[(2-Methylquinolin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)
```

piperazine:

Phenyl N-(2-methylquinolin-3-yl)thiocarbamate(147mg, 0.5mmol) and 1-(3,5-dimethoxyphenyl)piperazine(112mg, 0.5mmol) were dissolved in anhydrous tetrahydrofuran and DBU(117mg, 0.75mmol) was added and then the mixture was stirred at room temperature for 2 hrs. The above solution was concentrated under the reduced pressure to remove tetrahydrofuran and purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

yield: 86%

m.p. : 211-212°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): & 2.81(3H,s), 3.35(4H,t), 3.79(6H,s), 4.14(4H,t), 6.07(3H,s), 7.49(2H,t), 7.68(2H,m), 8.01(1H,s), 8.07(1H,d)

### 10 Example 126

1-[(2-Methylquinolin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl) piperazine:

Phenyl N-(2-methylquinolin-3-yl)thiocarbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 125 to obtain the titled compound.

yield: 81%

m.p.: 196-197°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.27(6H,s), 2.81(3H,s), 3.31(4H,t), 4.11(4H,t), 6.53(2H,s), 6.58(1H,s), 7.48(2H,t), 7.67(2H,m), 7.96(1H,s), 8.04(1H,d)

20

#### Example 127

1-[(2-Methylquinolin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl) piperazine:

Phenyl N-(2-methylquinolin-3-yl)thiocarbamate and

25 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 125 to obtain the titled compound.

yield: 74%

m.p.: 211-213°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.85(3H,s), 3.43(4H,t), 4.22(4H,t), 6.33(2H,m),

30 7.49(1H,t), 7.64(1H,d), 7.72(1H,t), 8.16(2H,m)

### Example 128

1-{[2-(Pyridin-2-yl)quinolin-4-yl]aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine:

Phenyl N-[2-(pyridin-3-yl)quinolin-4-yl]carbamate(171mg, 0.5mmol) and 1-(3,5-dimethoxyphenyl)piperazine(111mg, 0.5mmol) were dissolved in

anhydrous tetrahydrofuran and DBU(117mg, 0.75mmol) was added and then the mixture was stirred at room temperature for 2hrs. The above solution was concentrated under the reduced pressure to remove tetrahydrofuran and purified by column chromatography

5 (dichloromethane: methanol=20:1) to obtain the titled compound. yield: 73%

m.p.: 97-98°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.34(4H,t), 3.79(6H,s), 3.90(4H,t), 6.07(1H,s), 6.12(2H,s), 7.43(1H,t), 7.50(1H,t), 7.68(1H,t), 7.93(1H,t), 8.26(1H,d),

10 8.59(1H,d), 8.80(1H,d), 8.98(1H,s)

Mass(EI) m/z: Calcd for  $C_{31}H_{27}N_5O_3$  517.2113, found 517.3244

## Example 129

1-{[2-(Pyridin-3-yl)quinolin-4-yl]aminocarbonyl)-4-(3,5-

15 dimethoxyphenyl)piperazine:

Phenyl N-[2-pyridin-3-yl)quinolin-4-yl]carbamate(171mg, 0.5mmol) and 1-(3.5-dimethoxyphenyl)piperazine(111mg, 0.5mmol) were dissolved in anhydrous tetrahydrofuran and DBU(117mg, 0.75mmol) was added and then the mixture was stirred at room temperature for 2 hours. The

above solution was concentrated under the reduced pressure to remove tetrahydrofuran and purified by column chromatography (dichloromethane: methanol = 20:1) to obtain the titled compound. yield: 67%

m.p.: 95-96°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): § 3.36(4H,t), 3.87(6H,s), 3.90(4H,t), 6.08(1H,s), 6.12(2H,s), 7.50(1H,t), 7.71(1H,t), 7.93(1H,t), 8.25(1H,d), 8.53(1H,d), 8.67(1H,s), 8.73(1H,d), 9.35(1H,s)

### Example 130

30 1-{[2-Thien-2-yl)quinolin-4-yl]aminocarbonyl}-4-(3,5-dimethoxyphenyl) piperazine:

Phenyl N-[2-(thien-2-yl)quinolin-4-yl]carbamate(173mg, 0.5mmol) and 1-(3.5-dimethoxyphenyl)piperazine(111mg, 0.5mmol) were dissolved in anhydrous tetrahydrofuran and DBU(117mg, 0.75mmol) was added. The resulting mixture was stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove tetrahydrofuran and

purified by column chromatography(ethylaetate: hexane = 1:1) to obtain the titled compound.

yield: 61%

m.p.: oil phase

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.37(4H,t), 3.59(6H,s), 3.97(4H,t), 7.01(3H,m), 7.49(1H,t), 7.69(1H,t), 7.93(1H,t), 8.20(1H,d), 8.52(1H,d), 8.64(1H,s), 8.71(1H,d), 9.35(1H,s)

## Example 131

10 1-([2-(Pyridin-3-yl)quinolin-4-yl]aminocarbonyl)-4-(3.5-dimethylphenyl) piperazine:

Phenyl N-[2-(pyridin-3-yl)quinolin-4-yl]carbamate(171mg, 0.5mmol) and 1-(3,5-dimethylphenyl)piperazine(95mg, 0.5mmol) were dissolved in anhydrous tetrahydrofuran and DBU(117mg, 0.75mmol) was added. The

resulting mixture was stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove tetrahydrofuran, and purified by column chromatography(ethylacetate: hexane =1:1) to obtain the titled compound.

yield: 64%

20 m.p.: 211-213°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 2.31(6H,s), 3.32(4H,t), 3.85(4H,t), 6.61(3H,s), 7.47(1H,t), 7.55(1H,t), 7.72(1H,t), 7.86(1H,t), 8.25(1H,d), 8.53(1H,d), 8.66(1H,s), 8.72(1H,d), 9.37(1H,s)

### 25 Example 132

1-[N-(5,6-Dimethyl-2-methoxypyridin-3-yl)-N-methylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine(100mg, 0.25mmol) was dissolved in

- dimethylformamide(15ml) and thereto sodium hydride(6.0mg, 0.25mmol) was added. The resulting mixture was stirred at room temperature for 15 min and thereto iodomethane(35mg, 0.25mmol) was added. The resulting mixture was stirred at room temperature for 16 hrs, concentrated under the reduced presssure to remove dimethylformamide,
- and purified by column chromatography(ethylacetate: hexane=1:2) to obtain the titled compound.

yield: 94%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.17(3H,s), 2.38(3H,s), 2.92(4H,t), 3.04(3H,s),

3.29(4H,t), 3.74(6H,s), 3.96(3H,s), 6.00(3H,m), 7.08(1H,s)

5

Example 133

1-[N-Ethyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine(100mg, 0.25mmol) was dissolved in dimethylformamide(15ml) and thereto sodium hydride(6.0mg, 0.25mmol) was added, followed by stirring at room temperature for 15 min and then iodoethane(39.2mg, 0.25mmol) was added. The resulting mixture was stirred at room temperature for 16 hrs, concentrated under the reduced pressure to remove dimethylformamide, and purified by column chromatography(ethylacetate: hexane=1:2) to obtain the titled compound.

yield: 86%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.08(3H,t), 2.04(3H,s), 2.38(3H,s), 2.90(4H,t),

20 3.26(4H,t), 3.52(2H,q), 3.74(6H,s), 5.99(3H,m), 7.06(1H,s)

#### Example 134

1-[N-Isopropyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine(100mg, 0.25mmol) was dissolved in dimethylformamide(15ml) and thereto sodium hydride(6.0mg, 0.25mmol) was added, followed by stirring at room temperature for 15 min, and then 2-iodopropane(42mg, 0.25mmol) was added. The resulting mixture was stirred at room temperature for 16 hrs, concentrated under the reduced pressure to remove dimethylformamide, purified by column chromatography(ethylacetate: hexane=1:2) to obtain the titled compound.

yield: 78%

m.p.: oil phase

35 H NMR(CDCl<sub>3</sub>) δ: 1.13(6H,d), 2.19(3H,s), 2.38(3H,s), 2.82(4H,t), 3.26(4H,t), 3.74(6H,s), 3.89(3H,s), 4.27(1H,m), 6.06(1H,s), 6.10(2H,d),

7.07(1H,s), 8.14(1H,s)

Mass(EI) m/z: Calcd for C24H34N4O4 442.2580, found 442.2538

## Example 135

5 1-[N-(5,6-Dimethyl-2-methoxypyridin-3-yl)-N-methylaminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3,5-dimethyl phenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.

10 yield: 97%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.15(6H,s), 2.23(3H,s), 2.37(3H,s), 2.89(4H,t),

3.04(3H,s), 3.30(4H,t), 3.97(3H,s), 6.46(3H,m), 7.08(1H,s)

## 15 Example 136

1-[N-(5,6-Dimethyl-2-methoxypyridin-3-yl)-N-methylaminocarbonyl]-4-(2-methoxyphenyl)piperazine:

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methoxyph enyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.

yield: 94%

m.p.: 131-132°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.16(3H,s), 2.38(3H,s), 2.80(4H,t), 3.05(3H,s),

3.35(4H,t), 3.82(3H,s), 3.97(3H,s), 6.83(4H,m), 7.08(1H,s)

## 25

### Example 137

1-[N-Ethyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methoxyph enyl)piperazine was reacted by the same way with the example 133 to obtain the titled compound.

yield: 87%

m.p.: 112-113°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.08(3H,t), 2.16(3H,s), 2.38(3H,s), 2.77(4H,t),

3.31(4H,t), 3.58(2H,q), 3.81(3H,s), 3.96(3H,s), 6.88(4H,m), 7.06(1H,s)

### Example 138

1-[N-Benzyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine(100mg, 0.27mmol) was dissolved in dimethylformamide(15ml) and thereto sodium hydride(6.5mg, 0.27mmol) was added, followed by stirring at room temperature for 1hr, and successively benzyl bromide(46.2mg, 0.27mmol) was added. The resulting mixture was stirred at room temperature for 16 hrs,

concentrated under the reduced pressure and purified by column chromatography(ethylacetate: hexane = 1: 2) to obtain the titled compound.

yield: 93%

m.p.: oil phase

15 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 2.08(3H,s), 2.35(3H,s), 2.85(4H,t), 3.32(4H,t), 3.81(3H,s), 3.96(3H,s), 4.76(2H,s), 6.96(4H,m), 7.41(5H,m)

## Example 139

1-[N-Cyclopropylmethyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)
20 aminocarbonyl]-4-(2-methoxyphenyl)piperazine:
1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine(100mg, 0.26mmol) was dissolved in dimethylformamide(15ml) and thereto sodium hydride(6.2mg, 0.26mmol) was added, followed by stirring at room temperature for 15 min, and successively bromomethylcyclopropane(21.8mg, 0.26mmol) was added. The resulting mixture was stirred at room temperature for 16 hrs, concentrated under the reduced pressure and purified by column chromatography(ethylacetate: hexane = 1: 2) to obtain the titled compound.

30 yield: 78%

m.p.: oil phase

<sup>1</sup>H NMR(CDC<sub>b</sub>)  $\delta$ : 0.34(2H,m), 0.49(2H,m), 1.35(1H,m), 2.85(4H,t), 3.28(4H,t), 3.40(2H,s), 3.89(3H,s), 3.97(3H,s), 6.97(4H,m), 7.11(1H,s)

Example 140
1-[N-(5,6-Dimethyl-2-methoxypyridin-3-yl)-N-methylaminocarbonyl]-4-

(5-methoxy-2-methylphenyl)piperazine:

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(5-methoxy-2-methylphenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.

5 yield: 74%

m.p.: 91-93°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.15(3H,s), 2.18(3H,s), 2.39(3H,s), 2.67(4H,t), 3.05(3H,s), 3.30(4H,t), 3.75(3H,s), 3.97(3H,s), 6.48(3H,m), 7.10(1H,s)

# 10 Example 141

1-[N-Ethyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(5-methoxy-2-methylphenyl)piperazine:

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(5-methoxy-2-methylphenyl)piperazine was reacted by the same way with the

15 example 133 to obtain the titled compound.

yield: 94%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.09(3H,t), 2.15(3H,s), 2.18(3H,s), 2.39(3H,s), 2.60(4H,t), 3.27(4H,t), 3.59(2H,q), 3.75(3H,s), 3.96(3H,s), 6.45(3H,m),

20 7.08(1H,s)

#### Example 142

1-[N-Benzyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(5-methoxy-2-methylphenyl)piperazine:

25 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(5-methoxy-2-methylphenyl)piperazine was reacted by the same way with the example 138 to obtain the titled compound.

yield: 97%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.25(3H,t), 2.08(3H,s), 2.14(3H,s), 2.35(3H,s), 2.60(4H,t), 3.32(4H,t), 3.74(3H,s), 3.95(3H,s), 4.66(2H,s), 6.44(4H,m), 6.96(5H,m), 7.12(1H,s)

### Example 143

35 1-[N-(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)-N-methylamino carbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.

yield: 87%

5 m.p.: 78-79°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.14(3H,t), 2.41(3H,s), 2.52(2H,q), 2.91(4H,t), 3.02(3H,s), 3.28(4H,t), 3.74(6H,s), 3.98(3H,s), 5.98(3H,m), 7.11(1H,s) Mass(EI) m/z: Calcd for C<sub>23</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub> 428.2423, found 428.2434

# 10 Example 144

1-[N-(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)-N-methylamino carbonyl]-4-(3,5-dimethylphenyl)piperazine:

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the

15 example 132 to obtain the titled compound.

yield: 84%

m.p.: 86-87°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.14(3H,t), 2.23(6H,s), 2.45(3H,s), 2.58(2H,q), 2.87(4H,t), 3.05(3H,s), 3.30(4H,t), 3.98(3H,s), 6.46(3H,m), 7.11(1H,s)

20 Mass(EI) m/z: Calcd for C23H32N4O2 396.2525, found 396.2575

# Example 145

1-[N-Ethyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl] -4-(3,5-dimethylphenyl)piperazine:

25 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 133 to obtain the titled compound.

yield: 86%

m.p.: 84-85°C

30 <sup>1</sup>H NMR(CDCl<sub>2</sub>) δ: 1.13(6H,m), 2.23(6H,s), 2.41(3H,s), 2.58(2H,q), 2.85(4H,t), 3.26(4H,t), 3.46(2H,q), 3.96(3H,s), 6.45(3H,m), 7.08(1H,s)

# Example 146

1-[N-(2-Methoxy-6-methyl-5-propylpyridin-3-yl)-N-methylamino carbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-[(2-Methoxy-6-methyl-5-propylpyridin-3-yl)aminocarbonyl]-4-

(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.

yield: 89%

m.p.: oil phase

5 <sup>1</sup>H NMR(CDCl<sub>3</sub>) δ: 1.01(3H,t), 1.78(2H,m), 2.21(3H,s), 2.78(2H,t), 3.78(6H,s), 3.86(4H,t), 3.99(3H,s), 4.00(3H,s), 4.22(4H,t), 6.01(3H,m), 7.02(1H,s)

#### Example 147

- 1-[N-(6-Ethyl-2-methoxy-5-methylpyridin-3-yl)-N-methylamino carbonyl]-4-(3,5-dimethoxyphenyl)piperazine:
  1-[(6-Ethyl-2-methoxy-5-methylpyridin-3-yl)aminocarbonyl]-4(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.
- yield: 85%
  m.p.: oil phase

  'H NMR(CDCl<sub>3</sub>) δ: 2.21(3H,t), 2.21(3H,s), 2.45(2H,q), 3.21(4H,t),
  3.40(3H,s), 3.67(4H,t), 3.77(6H,s), 4.01(3H,s), 6.07(3H,m), 6.96(1H,s),
  8.07(1H,s)

20

#### Example 148

- 1-[N-(2-Methoxy-5-methyl-6-propylpyridin-3-yl)-N-methylamino carbonyl]-4-(3,5-dimethoxyphenyl)piperazine:
- 1-[(2-Methoxy-5-methyl-6-propylpyridin-3-yl)aminocarbonyl]-4-
- 25 (3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.

yield : 86%

m.p.: 106-107°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 0.98(3H,t), 1.73(2H,q), 2.18(3H,s), 2.63(2H,t),

30 2.92(4H,t), 3.05(3H,s), 3.29(4H,t), 3.74(6H,s), 3.96(3H,s), 6.00(3H,m), 7.11(1H,s)

Mass(EI) m/z: Calcd for C24H34N4O4 442.2580, found 442.2543

#### Example 149

35 1-[N-(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)-N-methylamino carbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.

yield : 89%

5 m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.50(3H,s), 2.70(3H,s), 2.97(4H,t), 3.09(3H,s),

3.33(4H,t), 3.75(6H,s), 4.06(3H,s), 6.03(3H,m), 7.72(1H,s)

Mass(EI) m/z: Calcd for C23H30N4O5 442.2216, 442.2229

### 10 Example 150

1-[N-Ethyl-N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl ]-4-(3,5-dimethoxyphenyl)piperazine:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 133 to obtain the titled compound.

vield: 87%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.09(3H,t), 2.49(3H,s), 2.70(3H,s), 3.00(4H,t), 3.32(4H,t), 3.77(6H,s), 4.01(3H,s), 4.09(2H,q), 5.98(3H,m), 7.76(1H,s)

20

#### Example 151

1-[N-(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)-N-methylamino carbonyl]-4-(3,5-dimethylphenyl)piperazine:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-

25 (3,5-dimethylphenyl)piperazine was reacted by the same with the example 132 to obtain the titled compound.

vield: 88%

m.p.: oil phase

<sup>1</sup>H NMR(CDC<sub>3</sub>)  $\delta$ : 2.24(6H,s), 2.50(3H,s), 2.70(3H,s), 2.93(4H,t),

30 3.09(3H,s), 3.28(4H,t), 4.06(3H,s), 6.46(3H,m), 7.73(1H,s)

#### Example 152

1-{N-[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-N-methyl aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine:

35 1-[N-(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)-N-methylamino carbonyl]-4-(3,5-dimethoxyphenyl)piperazine(0.47mmol) was dissolved in

anhydrous ethanol(15ml) and thereto sodium borohydride(17.3mg) was added, then followed by stirring at room temperature for 2 hrs. The resulting mixture was concentrated under the reduced pressure to remove ethanol and purified by column chromatography(ethylacetate:

5 hexane = 2:1) to obtain the titled compound.

vield: 97%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.14(3H,d), 2.44(3H,s), 2.93(4H,t), 3.06(3H,s), 3.30(4H,t), 3.74(6H,s), 3.98(3H,s), 5.03(1H,q), 6.02(3H,m), 7.50(1H,s)

10

15

#### Example 153

1-{N-Ethyl-N-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl] aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine;

1-[N-Ethyl-N-(5-cetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl] -4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with

the example 152 to obtain the titled compound.

yield: 96%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.09(3H,t), 1.41(3H,d), 2.44(3H,s), 2.91(4H,t),

3.27(4H,t), 3.54(1H,q), 3.74(6H,s), 3.96(3H,s), 5.03(1H,q), 6.02(3H,m), 8.46(1H,s)

# Example 154

1-{N-[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-N-methylaminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:
1-[N-Methyl-N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)amino carbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 152 to obtain the titled compound.

yi**e**ld: 97%

m.p.: oil phase

H NMR(CDCl<sub>3</sub>) δ: 1.41(3H,d), 2.24(6H,s), 2.44(3H,s), 2.91(4H,t),
3.06(3H,s), 3.26(4H,t), 3.99(3H,s), 5.03(1H,q), 6.49(3H,m), 7.50(1H,s)

### Example 155

35 1-{N-[5-(1-Hydroxy-1-methylethyl)-2-methoxy-6-methylpyridin-3-yl]-N-methylaminocarbonyl)-4-(3,5-dimethoxyphenyl)piperazine:

- 76 -

1-[N-Methyl-N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)amino carbonyl]-4-(3,5-dimethoxyphenyl)piperazine(221mg, 0.5mmol) was dissolved in tetrahydrofuran(10ml) and thereto methyl magnesium bromide(0.50ml, 1.50mmol). The resulting mixture was refluxed for 15 5 hrs, concentrated under the reduced pressure to remove used solvent. extracted with ethylacetate, filtered to dryness, and purified by column chromatography(ethylacetate: hexane =1:2) to obtain the titled compound.

vield: 92%

m.p.: oil phase 10

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.59(6H,s), 2.66(3H,s), 2.93(4H,t), 3.06(3H,s), 3.30(4H,t), 3.74(6H,s), 3.99(3H,s), 6.03(3H,m), 7.45(1H,s)

# Example 156

- 1-{N-[5-(1-Hydroxy-1-methylpropyl)-2-methoxy-6-methylpyridin-3-v]] 15 -N-methylaminocarbonyl)-4-(3,5-dimethylphenyl)piperazine: 1-[N-Methyl-N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)amino carbonyl]-4-(3,5-dimethylphenyl)piperazine(213mg, 0.5mmol) was dissolved in tetrahydrofuran(10ml) and thereto methyl magnesium 20 bromide(0.50ml, 1.50mmol) was added slowly, then refluxed for 15 hrs. The resulting mixture was concentrated under the reduced pressure to remove the used solvent, extracted with ethylacetate, filtered to dryness. and purified by column chromatography(ethylacetate: hexane =1:2) to obtain the titled compound.
- yield : 88% 25 m.p.: oil phase 'H NMR(CDCl<sub>3</sub>)  $\delta$ : 0.79(3H,t), 1.58(3H,s), 1.85(2H,q), 2.61(3H,s), 2.99(4H,t), 3.07(3H,s), 3.30(4H,t), 3.76(6H,s), 6.12(3H,m), 7.47(1H,s)
- 30 Example 157 1-{N-[2-Methoxy-5-(1-methoxyethyl)-6-methylpyridin-3-yl]-N-methyl aminocarbonyl}-4-(3.5-dimethoxyphenyl)piperazine: 1-(N-[5-(1-Hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]amino carbonyl)-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound. yield: 95%

m.p.: 117-119℃

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.34(3H,t), 2.43(3H,s), 2.94(4H,t), 3.06(3H,s), 3.18(3H,s), 3.30(4H,t), 3.74(6H,s), 3.99(3H,s), 4.44(1H,q), 6.02(3H,m), 7.37(1H,s)

5

# Example 158

1-[N-(2-Methoxy-6-methyl-5-vinylpyridin-3-yl)-N-methylamino carbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-[(2-Methoxy-6-methyl-5-vinylpyridin-3-yl)aminocarbonyl]-4-

10 (3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.

yield: 94%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.46(3H,s), 2.93(4H,t), 3.07(3H,s), 3.30(4H,t),

3.73(6H,s), 3.99(3H,s), 5.25(1H,d), 5.48(1H,d), 6.01(3H,m), 6.78(1H,s), 7.43(1H,s)

# Example 159

1-[N-(2-Methoxy-6-methyl-5-vinylpyridin-3-yl)-N-methylamino

20 carbonyl]-4-(3,5-dimethylphenyl)piperazine:

1-[(2-Methoxy-6-methyl-5-vinylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.

vield: 89%

25 m.p.: oil phase <sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.24(6H,s), 2.43(3H,s), 2.90(4H,t), 3.04(3H,s), 3.27(4H,t), 3.99(3H,s), 5.23(1H,d), 5.45(1H,d), 6.05(3H,m), 6.77(1H,s),

7.40(1H,s)

### 30 Example 160

1-[N-Ethyl-N-(2-methoxy-6-methyl-5-vinylpyridin-3-yl)aminocarbonyl] -4-(3,5-dimethoxyphenyl)piperazine:

1-[(2-Methoxy-6-methyl-5-vinylpyridin-3-yl)aminocarbonyl]-4-(3.5-dimethoxyphenyl)piperazine was reacted by the same way with the example 133 to obtain the titled compound.

vield: 92%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.09(3H,t), 2.43(3H,s), 2.94(4H,t), 3.28(4H,t), 3.77(6H,s), 4.01(3H,s), 4.11(2H,q), 5.25(1H,d), 5.49(1H,d), 5.98(3H,m), 6.77(1H,s), 7.44(1H,s)

5

## Example 161

1-[N-(5-Isopropenyl-2-methoxy-6-methylpyridin-3-yl)-N-methylamino carbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-[(5-Isopropenyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-10 (3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.

yield: 92%

m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.98(3H,s), 2.43(3H,s), 2.92(4H,t), 3.06(3H,s),

3.29(4H,t), 3.74(6H,s), 3.99(3H,s), 4.84(1H,s), 5.30(1H,s), 6.01(3H,m), 7.10(1H,s)

### Example 162

20

1-[N-(5-Isopropenyl-2-methoxy-6-methylpyridin-3-yl)-N-methylamino carbonyl]-4-(3,5-dimethylphenyl)piperazine:

1-[(5-Isoprophenyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 132 to obtain the titled compound.

yield: 91%

25 m.p.: oil phase

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.98(3H,s), 2.24(6H,s), 2.43(3H,s), 2.90(4H.t), 3.06(3H.s), 3.28(4H,t), 4.00(3H,s), 4.84(1H,s), 5.19(1H,s), 6.46(3H,m), 7.10(1H,s)

#### 30 Example 163

Ethyl 2-(([4-(3,5-dimethoxyphenyl)piperazino]carbonyl)(5-acetyl-2-methoxy-6-methylpyridin-3-yl)amino)acetate:

1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine(200mg, 0.5mmol) was dissolved in

dimethylformamide(15ml) and thereto sodium hydride(18.5mg, 0.5mmol) was added, then followed by stirring at room temperature for 15 min.

and ethylbromoacetate(83.5mg, 0.5mmol) was added. The resulting mixture was stirred at room temperature for 3 hrs, concentrated under the reduced pressure to remove the used solvent, and purified by column chromatography(ethylacetate: hexane =1:2) to obtain the titled compound.

yield: 84%

m.p.: oil phase

 $^{1}$ H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.26(3H,t), 2.51(3H,s), 2.69(3H,s), 3.04(4H,t), 3.43(4H,t), 3.75(6H,s), 4.05(3H,s), 4.15(2H,q), 4.19(2H,s), 6.08(3H,s),

10 7.96(1H,s)

Example 164

Ethyl 2-({[4-(3,5-dimethylphenyl)piperazino]carbonyl)(5-acetyl-2-methoxy-6-methylpyridin-3-yl)amino)acetate:

15 1-[(5-Acetyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 163 to obtain the titled compound.

yield: 80%

m.p. : oil phase

<sup>1</sup>II NMR(CDCl<sub>3</sub>)  $\delta$ : 1.25(3H,t), 2.56(3H,s), 2.69(3H,s), 3.00(4H,t), 3.29(4H,t), 3.78(6H,s), 4.06(3H,s), 4.18(2H,s), 5.99(3H,m), 7.98(1H,s)

Example 165

25

2-({[4-(3,5-Dimethoxyphenyl)piperazino]carbonyl}(5-acetyl-2-methoxy-6-methylpyridin-3-yl)amino)acetic acid:

Ethyl ({[4-(3,5-dimethoxyphenyl)piperazino]carbonyl}(5-acetyl-2-methoxy-6-methylpyridin-3-yl)amino)acetate(200mg, 0.38mmol) was dissolved in mixed solvent of dioxane: distilled water =4:1(15ml), and lithium hydroxide hydrate(48.1mg, 1.14mmol) was added, then followed by

30 stirring at room temperature for 3 hrs. The resulting mixture was made acidic with 1N-HCl, extracted with ethylacetate, filtered to dryness, concentrated under the reduced pressure and purified by column chromatography(ethylacetate: hexane = 1:2) to obtain the titled compound.

35 yield: 94%

m.p.: 135-137°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 2.52(3H,s), 2.69(3H,s), 3.11(4H,t), 3.49(4H,t), 3.74(6H,s), 4.05(3H,s), 4.24(2H,s), 6.15(3H,m), 7.83(1H,s)

#### Example 166

Ethyl 2-(([4-(3,5-dimethoxyphenyl)piperazino]carbonyl)[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]amino)acetate:

Ethyl 2-(([4-(3,5-dimethoxyphenyl)piperazino]carbonyl)(5-acetyl-2-methoxy-6-methylpyridin-3-yl)amino)acetate was reacted by the same way with the example 152 to obtain the titled compound.

10 yield: 97%

m.p.: 125-127°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.26(3H,t), 1.42(3H,d), 2.44(3H,s), 3.04(4H,t), 3.31(4H,t), 3.75(6H,s), 3.97(3H,s), 4.16(2H,q), 4.19(2H,s), 6.15(3H,m), 7.69(1H,s)

15

#### Example 167

Ethyl 2-({[4-(3,5-dimethoxyphenyl)piperazino]carbonyl)[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]amino)acetate: Ethyl 2-({[4-(3,5-dimethoxyphenyl)piperazino]carbonyl)[5-

20 (1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]amino)acetate was reacted by the same way with the example 164 to obtain the titled compound.

yield: 92%

m.p.: oil phase

25 <sup>1</sup>H NMR(CDC<sub>3</sub>) δ: 1.41(3H,d), 2.44(3H,s), 2.98(4H,t), 3.36(4H,t), 3.74(6H,s), 3.98(3H,s), 4.40(2H,s), 5.00(1H,q), 6.08(3H,m), 7.69(1H,s)

# Example 168

Ethyl 2-(([4-(3,5-dimethylphenyl)piperazino]carbonyl)[5-30 (1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]amino)acetate:
Ethyl 2-(([4-(3,5-dimethylphenyl)piperazino]carbonyl)(5-acetyl-2-methoxy-6-methylpyridin-3-yl)amino)acetate was reacted by the same way with the example 152 to obtain the titled compound.

yield: 94%

35 m.p.: 68-70°C

'H NMR(CDCl<sub>3</sub>) δ: 1.13(3H,t), 1.47(3H,d), 2.33(6H,s), 2.44(3H,s),

2.95(4H,t), 3.30(4H,t), 3.98(3H,s), 4.10(2H,q), 5.01(1H,q), 6.46(3H,m), 7.71(1H,s)

#### Example 169

5 2-({[4-(3,5-Dimethylphenyl)piperazino]carbonyl}{5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]amino)acetic acid:
Ethyl 2-({[4-(3,5-dimethylphenyl)piperazino]carbonyl}{5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]amino)acetate was reacted by the same way with the example 165 to obtain the titled compound.

vield: 92%

m.p.: 114-116°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>)  $\delta$ : 1.40(3H,d), 2.23(6H,s), 2.40(3H,s), 2.91(4H,t), 3.21(4H,t), 3.98(3H,s), 4.06(2H,s), 4.90(1H,q), 6.50(3H,m), 6.51(1H,s)

15

# Example 170

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-phenylpiperazine a) 3,4-Dimethyl anisole:

To 3,4-dimethylphenol(19.3g, 0.16mol), methanol(150ml) and KOH(9.65g, 0.25mol) were added and then refluxed for 2hrs. Methyl iodide(36.5g, 0.25mol) was added thereto, refluxed for 3 hours and then followed by addition of water(150ml). The resulting mixture was extracted with ethylacetate and purified by column chromatography to obtain the titled compound.

25 yield: 81%

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.24(3H,s), 3.77(3H,s), 6.71(2H,m), 6.97(1H,s)

b) 4,5-Dimethyl-2-nitroanisole:

Trifluoroacetic acid(250ml) was added into 3,4-dimethylanisole(17.1g, 0.13mol), successively sodium nitrite(16.6g, 0.24mol) was added slowly in water bath, and stirred at room temperature for 14 hrs. After trifluoroacetic acid was removed and water was added thereto, the resulting mixture was extracted with ether, and purified by column chromatography to obtain the titled compound.

35 yield: 55%

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.25(3H,s), 2.32(3H,s), 3.94(3H,s),

PCT/KR97/00128 WO 98/00402

- 82 -

6.85(1H,s), 7.70(1H,s)

c) 4,5-Dimethyl-2-methoxyaniline:

Tetrahydrofuran(100ml) and ethanol(40ml) were added into 4,5-dimethyl-2-nitroanisole(7.80g, 0.043mol) and then added 10%

5 Pd/activated carbon(0.57g) slowly, hydrogenated for 5 hrs. The reaction was completed by the same way with the above and the resulting product was purified by column chromatography to obtain the titled compound.

yield: 82%

- <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.23(3H,s), 2.27(3H,s), 3.90(3H,s), 10 6.80(1H,s), 7.68(1H,s)
  - d) Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate: To 4,5-dimethyl-2-methoxyaniline(4.50g, 0.03mol), methylene chloride(100ml) was added and phenyl chloroformate(4.80g, 0.03mol) was
- added slowly. The resulting solution was stirred for 2 hrs and thereto 15 water(150ml) was added, and extracted with methylene chloride and purified by column chromatography to obtain the titled compound. yield: 98%

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.24(3H,s), 2.27(3H,s), 3.89(3H,s),

20 6.85(1H,s), 7.20(5H,m), 7.90(1H,s)

- e) 1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-phenylpiperazine: Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate(5.422g, 0.02mol) and 1-phenylpiperazine(3.44g, 0.02mol) were dissolved in tetrahydrofuran(10ml). After DBU(3.04g, 0.02mol) was added, the
- 25 resulting solution was stirred at room temperature for 2 hrs. concentrated and purified by column chromatography to obtain the titled compound.

yield: 85%

m.p.: 143-144°C

30 'H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.20(3H,s), 2.21(3H,s), 3.25(4H,t), 3.67(4H,t), 3.85(3H,s), 6.64(1H,s), 6.94(3H,m), 6.99(1H,s), 7.29(1H,t), 7.91(1H,s)

Example 171

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-

(3,5-dimethoxyphenyl)piperazine: Phenyl N-(4.5-dimethyl-2-methoxyphenyl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 85%

m.p.: 119-120°C

5 <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.21(3H,s), 3.27(4H,t), 3.70(4H,t), 3.79(6H,s), 3.85(3H,s), 6.17(2H,m), 6.65(1H,s), 6.98(1H,s), 7.90(1H,s) Mass(EI) m/z : Calcd for C<sub>22</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> 399.2158, found 399.2168

# Example 172

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4(3,5-dimethylphenyl)piperazine:
Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and
1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

15 yield: 88%

m.p.: 177-178°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.20(3H,s), 2.21(3H,s), 2.29(6H,s), 3.23(4H,t), 3.66(4H,t), 3.85(3H,s), 6.58(2H,m), 6.65(1H,s), 6.99(1H,s), 7.92(1H,s)

20 Mass(EI) m/z: Calcd for C<sub>22</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub> 367.2259, found 367.2290

#### Example 173

1-[4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(2,3-dimethylphenyl) piperazine:

25 Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and 1-(2,3-dimethylphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 95%

m.p.: 140-142°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.21(3H,s), 2.22(3H,s), 2.27(3H,s), 2.29(3H,s), 2.95(4H,t), 3.67(4H,t), 3.85(3H,s), 6.65(1H,s), 7.01(3H,m), 7.93(1H,s)

#### Example 174

35 1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(2,3,5,6-tetramethylphenyl)piperazine:

WO 98/00402 PCT/KR97/00128

- 84 -

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and 1-(2,3,5,6-tetramethylphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 93%

5 m.p.: oil phase

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.20(9H,s), 2.21(9H,s), 3.17(4H,t), 3.63(4H,t), 3.84(3H,s), 6.64(1H,s), 6.84(1H,s), 7.95(1H,s)

#### Example 175

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-difluorophenyl) piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

15 yield: 89%

m.p.: 102-103°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.20(3H,s), 2.22(3H,s), 3.29(4H,t), 3.68(4H,t), 3.85(3H,s), 6.65(1H,s), 6.97(3H,m), 7.89(1H,s)

#### 20 Example 176

1-[(4.5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(2-chlorophenyl) piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and

1-(2-chlorophenyl)piperazine were reacted by the same way with the 25 example 170 to obtain the titled compound.

yield: 90%

m.p.: 176-177°C

'H NMR(500MHz, CDC $_3$ ):  $\delta$  2.21(3H,s), 2.22(3H,s), 3.10(4H,t,J=5.0Hz), 3.69(4H,t,J=5.0Hz), 3.85(3H,s), 6.65(1H,s), 7.02(2H,m), 7.24(1H,m),

7.39(1H,d,J=4.0Hz), 7.92(1H,s)30

### Example 177

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3-chlorophenyl) piperazine:

35 Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and 1-(3-chlorophenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 84%

m.p.: 75-76℃

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.20(3H,s), 2.22(3H,s), 3.27(4H,t,J=5.0Hz),

5 3.68(4H,t,J=5.0Hz), 3.85(3H,s), 6.65(1H,s), 6.90(3H,m), 7.21(1H,t), 7.90(1H,s)

Mass(EI) m/z: Calcd for C20H24N3O2Cl1 373.1557, found 373.1590

Example 178

10 1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(2-hydroxyphenyl) piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and 1-(2-hydroxyphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

15 yield: 87%

m.p.: 197-199°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.21(3H,s), 2.98(4H,t), 3.72(4H,t), 3.84(3H,s), 6.65(1H,s), 6.89(1H,t), 7.00(2H,m), 7.13(2H,m), 7.89(1H,s)

20 Example 179

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3-hydroxyphenyl) piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and 1-(3-hydroxyphenyl) were reacted by the same way with the example 170 to obtain the titled compound.

vield: 88%

m.p.: 177-178℃

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.19(3H,s), 2.21(3H,s), 3.24(4H,t), 3.68(4H,t), 3.85(3H,s), 6.41(3H,m), 6.65(1H,s), 6.98(1H,s), 7.13(1H,t), 7.88(1H,s)

30

Example 180

1-[(4.5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3-thiophenyl) piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and

35 1-(3-thiophenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 79%

m.p.: 108-110°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.20(3H,s), 2.21(3H,s), 3.26(4H,t), 3.65(4H,t), 3.84(3H,s), 6.64(1H,s), 6.97(4H,m), 7.05(1H,s), 7.89(1H,s)

5

# Example 181

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(2-acetoxyphenyl) piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and

10 1-(2-acetoxyphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 84%

m.p.: 129-131°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.21(3H,s), 2.32(3H,s),

15 3.05(4H,t), 3.63(4H,t), 3.85(3H,s), 6.64(1H,s), 6.99(1H,s), 7.04(1H,m), 7.17(2H,m), 7.22(1H,m), 7.90(1H,s)

#### Example 182

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3-acetoxyphenyl)

20 piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and 1-(3-acetoxyphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 87%

25 m.μ.: 154-156°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.21(3H,s), 2.29(3H,s), 3.27(4H,t), 3.68(4H,t), 3.85(3H,s), 6.64(1H,s), 6.66(2H,m), 6.82(1H,m), 6.98(1H,s), 7.90(1H,s)

### 30 Example 183

1-[(4,5-Dimethyl+2-methoxyphenyl)aminocarbonyl]-4-(2-methoxyphenyl) piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 90%

m.p.: 144-145℃

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.20(3H,s), 2.22(3H,s), 2.26(3H,s), 2.95(4H,t, J=5.0Hz), 3.65(4H,t,J=5.0Hz), 3.78(3H,s), 3.85(3H,s), 6.59(1H,s), 6.65(1H,s), 7.00(1H,s), 7.11(1H,s), 7.93(1H,s)

5

# Example 184

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(5-methoxy-2-methylphenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and

10 1-(5-methoxy-2-methylphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 88%

m.p.: 140-141°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): 8 2.20(3H,s), 2.22(3H,s), 2.26(3H,s), 2.95(4H,t,

15 J=5.0Hz), 3.65(4H,t,J=5.0Hz), 3.78(3H,s), 3.85(3H,s), 6.59(1H,s), 6.65(1H,s), 7.00(1H,s), 7.11(1H,s), 7.93(1H,s)

#### Example 185

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(2-methoxy-5-

20 methylphenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and 1-(2-methoxy-5-methylphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 80%

25 m.p.: 107-108℃

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.20(3H,s), 2.21(3H,s), 2.29(3H,s), 3.10(4H,t, J=5.0Hz), 3.69(4H,t,J=5.0Hz), 3.85(3H,s), 3.86(3H,s), 6.55(1H,s), 6.79(2H,m), 7.01(1H,s); 9.94(1H,s)

#### 30 Example 186

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(2-methoxy-5-phenylphenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and

1-(2-methoxy-5-phenylphenyl)piperazine were reacted by the same way

35 with the example 170 to obtain the titled compound.

yield: 91%

m.p.: 139-140°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.21(3H,s), 2.22(3H,s), 3.20(4H,t), 3.74(4H,t), 3.85(3H,s), 3.94(3H,s), 6.65(1H,s), 7.02(2H,m), 7.32(2H,m), 7.42(2H,t), 7.55(2H,d), 7.93(1H,s)

5

#### Example 187

1-[(4.5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(2-isopropenyl phenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and

10 1-(2-isopropenylphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 80%

m.p.: 134-135°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.21(6H,s), 3.10(4H,t), 3.64(4H,t),

15 3.85(3H,s), 5.08(1H,s), 5.14(1H,s), 6.64(1H,s), 7.05(3H,m), 7.70(1H,m), 7.92(1H,s)

#### Example 188

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(1-naphthyl)

20 piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and 1-(1-naphthyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 92%

25 m.p.: 160-162℃

<sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>):  $\delta$  2.20(3H,s), 2.24(3H,s), 3.31(4H,t,J=5.0Hz), 3.83(3H,s), 4.04(4H,t), 6.39(2H,m), 6.69(1H,s), 7.13(1H,t), 7.30(1H,s), 7.46(1H,s)

#### 30 Example 189

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(1-anthranyl) piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)carbamate and 1-(1-anthranyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound. vield: 94%

m.p.: 74-75°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.22(3H,s), 3.24(4H,t), 3.70(4H,t), 3.86(3H,s), 6.70(1H,s), 7.05(3H,m), 7.45(5H,m), 8.00(2H,m)

# 5 Example 190

1-[N-(4,5-Dimethyl-2-methoxyphenyl)-N-methylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

1-[(4,5-dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine(0.2g, 0.5mmole) was dissolved in

dimethylformamide(15ml), sodium hydride(12mg, 0.5mmole) was added thereto slowly, and then the resulting mixture was stirred at room temperature for 15 min, then followed by addition of iodomethane(71mg, 0.5mmole) and subsequently at room temperature for 16 hours. The resulting mixture was concentrated under the reduced pressure to

remove the used solvent, extracted with methylene chloride, dried, filtered and purified by column chromatography to obtain the titled compound.

yield: 92%

m.p.: 86-88°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.21(3H,s), 2.24(3H,s), 2.92(4H,t), 3.06(3H,s), 3.31(4H,t), 3.75(6H,s), 3.83(3H,s), 6.00(3H,m), 6.71(1H,s), 6.83(1H,s)

Mass(EI) m/z: Calcd for C22H31N3O4 413.2314, found 413.2293

# 25 Example 191

1-[N-(4,5-Dimethyl-2-methoxyphenyl)-N-methylaminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-dimethyl phenyl)piperazine was reacted by the same way with the example 190 to obtain the titled compound.

yield: 90%

30

m.p.: 137-138°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.15(3H,s), 2.24(9H,s), 2.88(4H,t), 3.06(3H,s), 3.29(4H,t), 3.83(3H,s), 6.45(3H,m), 6.71(1H,s), 6.83(1H,s)

35 Mass(EI) m/z: Calcd for C<sub>22</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub> 381.2416, 381.2436

- 90 -

#### Example 192

1-[N-(4,5-Dimethyl-2-methoxyphenyl)-N-methylaminocarbonyl]-4-(3.5-difluorophenyl)piperazine:

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-difluorophenyl)

piperazine was reacted by the same way with the example 190 to obtain the titled compound.

yield: 87%

m.p.: 98−100°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.16(3H,s), 2.25(3H,s), 2.92(4H,t).

3.06(3H,s), 3.29(4H,t), 3.83(3H,s), 6.23(3H,m), 6.72(1H,s), 6.83(1H,s) 10

# Example 193

1-[N-Ethyl-N-(4,5-dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3.5-dimethoxyphenyl)piperazine:

- 1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-dimethoxyphen 15 yl)piperazine(0.2g, 0.5mmole) was dissolved in dimethylformamide(15ml), and thereto sodium hydride(12mg, 0.5mmole) was added slowly. The resulting mixture was stirred at room temperature for 15 min. After iodoethane(78mg, 0.5mmol) was added, the resulting mixture was stirred at room temperature for 16 hours. The resulting mixture was 20
- concentrated under the reduced pressure to remove the used solvent, extracted with methylene chloride, dryed, filtered and purified by column chromatography to obtain the titled compound.

yield: 89%

m.p.: oil phase

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 1.09(3H,t), 2.16(3H,s), 2.24(3H,s), 2.75(4H,t), 3.28(4H,t), 3.52(2H,q), 3.75(6H,s), 3.81(3H,s), 5.98(3H,m), 6.70(1H,s), 6.80(1H.s)

#### Example 194 30

1-[N-(4,5-Dimethyl-2-methoxyphenyl)-N-ethylaminocarbonyl]-4-(3.5-dimethylphenyl)piperazine:

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-dimethyl phenyl)piperazine was reacted by the same way with the example 193 to obtain the titled compound.

vield: 93%

m.p.: 80-82°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  1.21(3H,t), 2.15(3H,s), 2.23(9H,s), 2.90(4H,t), 3.25(4H,t), 3.59(2H,q), 3.81(3H,s), 6.45(3H,m), 6.69(1H,s), 6.81(1H,s)

# 5 Example 195

1-[N-(4,5-Dimethyl-2-methoxyphenyl)-N-ethylaminocarbonyl]-4-(3,5-difluorophenyl)piperazine:

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-difluorophenyl) piperazine was reacted by the same way with the example 193 to obtain the titled compound.

yield: 87%

m.p.: oil phase

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 1.09(3H,t), 2.16(3H,s), 2.25(3H,s), 2.90(4H,t), 3.27(4H,t), 3.52(2H,q), 3.81(3H,s), 6.24(3H,m), 6.70(1H,s), 6.81(1H,s)

15

10

# Example 196

1-[N-Isopropyl-N-(4,5-dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-difluorophenyl)piperazine:

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-difluorophenyl)
piperazine(0.2g, 0.52mmole) was dissolved in dimethylformamide(15ml)
and thereto sodium hydride(12.48mg, 0.52mmole) was slowly added. The
resulting mixture was stirred at room temperature for 15 min. After
2-iodopropane(87.88mg, 0.52mmole) was added thereto, the resulting
mixture was stirred at room temperature for 16 hours. The resulting
mixture was concentrated under the reduced pressure to remove the
used solvent, extracted with methylene chloride, dryed, filtered and
purified by column chromatography to obtain the titled compound.
yield: 84%

m.p.: oil phase

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 1.10(3H,s), 1.26(3H,s), 2.20(3H,s), 2.25(3H,s), 2.86(4H,t), 3.26(4H,t), 3.77(3H,s), 4.25(1H,m), 6.17(3H,m), 6.68(1H,s), 6.82(1H,s)

#### Example 197

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

(a) Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate: To 3,4-dimethyl-2-methoxyaniline(4.50g, 0.03mol), methylene chloride(100ml) was added and then phenyl chlorothionoformate(5.16g. 0.03mol) was added slowly. The resulting mixture was stirred for 2 hours, and thereto water(150ml) was added. The resulting mixture was extracted with methylene chloride and purified by column chromatography to obtain the titled compound.

yield: 92%

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.21(3H,s), 2.25(3H,s), 3.85(3H,s),

6.80(1H,s), 6.93(5H,m), 7.31(1H,s)

(b) 1-[(4,5-Dirnethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(3.5-dimethoxyphenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate(0.2g, 0.7mmol) and 1-(3,5-dimethoxyphenyl)piperazine(0.16g, 0.7mmol) were dissolved in tetrahydrofuran(10ml) and thereto DBU(0.11g, 0.7mmole) was added. followed by stirring at room temperature for 2 hours. The resulting product was concentrated and purified by chromatography to obtain

yield: 84%

the titled compound.

15

20

m.p.: 128-129℃ <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.20(3H,s), 2.24(3H,s), 2.32(6H,s), 3.37(4H,t), 3.83(3H,s), 4.08(4H,t), 6.69(3H,m), 7.39(1H,m), 7.47(1H,s) Mass(EI) m/z: Calcd for C22H29N3O3S1 415.1929, found 415.1912

#### Example 198 25

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(3.5-dimethylphenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and 1-(3,5-dimethylphenyl)perazine were reacted by the same way with the 30 example 197 to obtain the titled compound.

yield: 90%

m.p.: 164-165°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.20(3H,s), 2.24(3H,s), 2.32(6H,s), 3.37(4H,t), 3.83(3H,s), 4.08(4H,t), 6.69(3H,m), 7.39(1H,m), 7.47(1H,s)

Mass(EI) m/z: Calcd for C2H28N3O1S1 383.2031, found 383.2086

#### Example 199

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(2,3-dimethylphenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and

5 1-(2,3-dimethylphenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

yield: 89%

m.p.: 151-152°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.21(3H,s), 2.24(3H,s), 2.29(6H,s),

10 3.03(4H,t), 3.83(3H,s), 4.10(4H,t), 6.69(1H,s), 6.97(2H,m), 7.11(1H,t)

#### Example 200

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(3,5-difluorophenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

yield: 92%

m.p.: 167-168°C

20 <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.24(3H,s), 2.27(3H,s), 2.32(3H,s), 3.39(4H,t,J=5.0Hz), 3.83(3H,s), 4.14(4H,t), 6.70(1H,s), 6.80(2H,m), 7.36(1H,s), 7.44(1H,s)

#### Example 201

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(3,5-dichlorophenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

30 yield: 85%

m.p.: 188-189°C 🔍

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.24(3H,s), 3.35(4H,t,J=5.0Hz), 3.83(3H,s), 4.04(4H,t,J=5.0Hz), 6.70(2H,m), 6.83(1H,s), 7.30(1H,s), 7.48(1H,s)

35 Mass(EI) m/z: Calcd for C20H24N3O2Cl1 423.0938, 423.0956

#### Example 202

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(2-fluorophenyl) piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and

5 1-(2-fluorophenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

yield: 87%

m.p.: 139-140℃

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.21(3H,s), 2.24(3H,s), 3.40(4H,t).

10 3.83(3H,s), 4.25(4H,t), 6.70(1H,s), 7.13(3H,m), 7.37(2H,m)

### Example 203

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(2-chlorophenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and 1-(2-chlorophenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

yield: 85%

m.p.: 115-116°C

20 <sup>1</sup>H NMR(500MHz, CDCl<sub>2</sub>): δ 2.21(3H,s), 2.24(3H,s), 3.18(4H,t), 3.83(3H,s), 4.09(4H,t), 6.69(1H,s), 7.05(2H,m), 7.33(1H,s), 7.41(2H,m)

## Example 204

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-

25 (2-methoxyphenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

yield: 90%

30 m.p.: oil phase

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.23(3H,s), 3.14(4H,t,J=5.0Hz),
3.82(3H,s), 3.88(3H,s), 4.06(4H,t,J=5.0Hz), 6.69(1H,s), 6.94(3H,m),
7.30(1H,s), 7.40(1H,s)

# 35 Example 205

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-

(2-methylthiophenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and 1-(2-methylthiophenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

5 yield: 93%

m.p.: 136-137°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.26(3H,s), 2.45(3H,s), 3.33(4H,t), 3.82(3H,s), 4.39(4H,t), 6.74(1H,s), 7.16(3H,m), 7.47(2H,m)

10 Example 206

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(3-hvdroxyphenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and 1-(3-hydroxyphenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

yield: 77%

15

m.p.: Decomposed(200℃)

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.17(3H,s), 2.23(3H,s), 3.31(4H,t), 3.82(3H,s), 4.03(3H,t), 6.37(2H,m), 6.47(1H,d), 6.69(1H,s), 7.13(1H,t),

20 7.45(1H,s)

Example 207

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(2-phenoxyphenyl)piperazine:

25 Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and 1-(2-phenoxyphenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

yield: 86%

m.p.: oil phase

30 <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.17(3H,s), 2.24(3H,s), 3.19(4H,t), 3.80(3H,s), 3.85(4H,t), 6.66(1H,s), 6.91(2H,m), 6.98(1H,m), 7.05(3H,m), 7.13(1H,m), 7.23(1H,m), 7.31(2H,m), 7.36(1H,s)

Example 208

35 1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(2-isopropenylphenyl)piperazine:

Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and 1-(2-isopropenylphenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

yield: 75%

5 m.p.: 157-158°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.21(3H,s), 2.24(3H,s), 3.19(4H,t), 3.82(3H,s), 4.05(4H,t), 5.07(1H,s), 5.16(1H,s), 6.69(1H,s), 7.11(3H,m), 7.33(1H,s), 7.45(1H,s)

# 10 Example 209

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4(2-methoxy-5-methylphenyl)piperazine:
Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and
1-(2-methoxy-5-methylphenyl)piperazine were reacted by the same way
with the example 197 to obtain the titled compound.
yield: 87%

m.p.: oil phase

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.23(3H,s), 2.29(3H,s), 3.13(4H,t), 3.83(3H,s), 3.85(3H,s), 4.05(4H,t), 6.69(1H,s), 6.83(2H,m),

20 7.30(1H,s), 7.40(1H,s)

### Example 210

1-[(4,5-Dimethyl-2-methoxyphenyl)aminothiocarbonyl]-4-(1-naphthyl) piperazine:

25 Phenyl N-(4,5-dimethyl-2-methoxyphenyl)thiocarbamate and 1-(1-naphthyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

yield: 87%

m.p.: 139-140°C

30 H NMR(500MHz, CDCl<sub>3</sub>): δ 2.23(3H,s), 2.24(3H,s), 3.21(4H,t), 3.84(3H,s), 4.09(4H,t), 6.70(1H,s), 7.10(1H,d), 7.48(5H,m), 7.85(1H,m), 8.22(1H,d)

#### Example 211

35 1-[(5-Acetyl-2-methoxy-4-methylphenyl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-4-methylphenyl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 91%

5 m.p.: 103-105℃

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.54(3H,s), 2.59(3H,s), 3.27(4H,t), 3.70(4H,t), 3.79(6H,s), 3.94(3H,s), 6.13(3H,m), 6.70(1H,s), 7.05(1H,s), 8.72(1H,s)

# Example 212

1-[(5-Acetyl-2-methoxy-4-methylphenyl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-4-methylphenyl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

15 yield: 88%

m.p.: 140-142°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.30(3H,s), 2.54(3H,s), 2.59(3H,s), 3.26(4H,t), 3.70(4H,t), 3.97(3H,s), 6.61(3H,m), 6.70(1H,s), 7.06(1H,s), 8.72(1H,s)

20

#### Example 213

1-[(5-Acetyl-2-methoxy-4-methylphenyl)aminocarbonyl]-4-(3,5-dichlorophenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-4-methylphenyl)carbamate and

1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 170 to obtain the titled compound.

yield: 78%

m.p.: 170-172°C

 $^{1}$ H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.54(3H,s), 2.59(3H,s), 3.32(4H,t), 3.74(4H,t),

3.94(3H,s), 6.69(1H,s), 6.86(3H,m), 7.04(1H,s), 8.69(1H,s)

#### Example 214

1-([5-(1-Hydroxyethyl)-2-methoxy-4-methylphenyl]aminocarbonyl}-4-(3,5-dimethoxyphenyl)piperazine:

35 1-[(5-Acetyl-2-methoxy-4-methylphenyl)aminocarbonyl]-4-(3.5-dimethoxyphenyl)piperazine(0.2g, 0.47mmol) was dissolved in anhydrous ethanol(15ml), and sodium borohydride(17mg) was added thereto, and then the resulting mixture was stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove ethanol, and purified by column chromatography(ethylacetate:hexane = 1:2) to obtain the titled compound.

yield: 96%

m.p.: 152-154°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 1.41(3H,d), 2.32(3H,s), 3.27(4H,t), 3.71(4H,t), 3.79(6H,s), 3.87(3H,s), 5.04(1H,q), 6.10(3H,m), 6.63(1H,s),

10 7.01(1H,s), 8.22(1H,s)

# Example 215

1-([5-(1-Hydroxyethyl)-2-methoxy-4-methylphenyl]aminocarbonyl)-4-(3,5-dimethylphenyl)piperazine:

15 1-[(5-Acetyl-2-methoxy-4-methylphenyl)aminocarbonyl]-4(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 214 to obtain the titled compound.

yield: 96%

m.p.: 140-142°C

20 <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 1.48(3H,d), 2.33(3H,s), 3.26(4H,t), 3.68(4H,t), 3.87(3H,s), 5.06(1H,q), 6.61(3H,m), 6.64(1H,s), 7.01(1H,s), 8.22(1H,s)

# Example 216

- 25 1-[(2-Methoxy-4-methyl-5-vinylphenyl)aminocarbonyl]-4-(3.5-dimethoxyphenyl)piperazine:
  - 1-([5-(1-Hydroxyethyl)-2-methoxy-4-methylphenyl]aminocarbonyl)-4-(3,5-dimethoxyphenyl)piperazine(0.2g, 0.47mmol) was dissolved in chloroform(15ml), pyridium p-toluenesulfonate(0.12g, 0.47mmol) was
- added thereto, and the resulting mixture was refluxed for 16 hours, and concentrated under the reduced pressure to remove chloroform and purified by column chromatography(ethylacetate:hexane=1:2) to obtain the titled compound.

yield: 84%

35 m.p.: 163-165°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.31(3H,s), 3.23(4H,t), 3.58(4H,t), 3.77(6H,s),

3.87(3H,s), 5.20(1H,d), 5.62(1H,d), 6.59(3H,m), 6.63(1H,s), 6.88(1H,t), 6.99(1H,s), 8.32(1H,s)

# Example 217

5 1-[(2-Methoxy-4-methyl-5-vinylphenyl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

1-{[5-(1-Hydroxyethyl)-2-methoxy-4-methylphenyl]aminocarbonyl}-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 216 to obtain the titled compound.

10 yield: 82%

m.p.: 201-203°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.29(6H,s), 2.34(3H,s), 3.24(4H,t), 3.68(4H,t), 3.87(3H,s), 5.22(1H,d), 5.66(1H,d), 6.59(3H,m), 6.63(1H,s), 6.86(1H,t), 7.02(1H,s), 8.32(1H,s)

15

# Example 218

1-[(5-Acetyl-2-methoxy-4-methylphenyl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

Phenyl N-(5-acetyl-2-methoxy-4-methylphenyl)thiocarbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

vield: 82%

m.p.: 163-165°C

 $^{1}$ H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.16(3H,s), 2.56(3H,s), 3.35(4H,t),

25 3.91(6H,s), 4.03(3H,s), 4.13(4H,t), 6.06(3H,m), 6.73(1H,s), 8.62(1H,s)

#### Example 219

1-[(5-Acetyl-2-methoxy-4-methylphenyl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

30 Phenyl N-(5-acetyl-2-methoxy-4-methylphenyl)thiocarbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

yield: 79%

m.p.: 180-182°C

35 <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.29(6H,s), 2.57(6H,s), 3.32(4H,t), 3.92(3H,s), 4.12(4H,t), 6.56(3H,m), 6.72(1H,s), 7.39(1H,s), 8.63(1H,s)

WO 98/00402 PCT/KR97/00128

- 100 -

# Example 220

1-[(5-Acetyl-2-methoxy-4-methylphenyl)aminothiocarbonyl]-4-(3,5-dichlorophenyl)piperazine:

5 Phenyl N-(5-acetyl-2-methoxy-4-methylphenyl)thiocarbamate and 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 197 to obtain the titled compound.

yield: 79%

m.p.: 201-203°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.20(3H,s), 2.57(3H,s), 3.46(4H,t), 3.92(3H,s), 4.25(4H,t), 6.64(1H,s), 6.88(3H,m), 7.72(1H,s), 8.57(1H,s)

#### Example 221

1-{[5-(1-Hydroxyethyl)-2-methoxy-4-methylphenyl]aminothiocarbonyl}-4

-(3,5-dimethoxyphenyl)piperazine: 15

> 1-[(5-Acetyl-2-methoxy-4-methylphenyl)aminothiocarbony]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 214 to obtain the titled compound.

yield: 94%

m.p.: 146-148°C 20

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  1.44(3H,d), 2.32(3H,s), 3.35(4H,t), 3.78(6H,s), 3.84(3H,s), 4.11(4H,t), 5.06(1H,q), 6.13(3H,m), 6.66(1H,s), 7.41(1H,s), 7.77(1H,s)

#### Example 222 25

1-{[5-(1-Hydroxyethyl)-2-methoxy-4-methylphenyl]aminothiocarbonyl}-4 -(3,5-dimethylphenyl)piperazine:

1-[(5-Acetyl-2-methoxy-4-methylphenyl)aminothiocarbony]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 214 to obtain the titled compound.

yield: 93%

30

m.p.: 150-152°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  1.44(3H,d), 2.29(6H,s), 2.32(3H,s), 3.30(4H,t), 3.84(3H,s), 4.07(4H,t), 5.06(1H,q), 6.61(3H,m), 6.66(1H,s),

7.38(1H,s), 7.79(1H,s) 35

# Example 223

1-{[5-(1-Hydroxyethyl)-2-methoxy-4-methylphenyl]aminothiocarbonyl}-4 -(3,5-dichlorophenyl)piperazine:

1-[(5-Acetyl-2-methoxy-4-methylphenyl)aminothiocarbony]-4-

5 (3,5-dichlorophenyl)piperazine was reacted by the same way with the example 214 to obtain the titled compound.

yield: 77%

m.p.: 166-168°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  1.45(3H,d), 2.33(3H,s), 3.35(4H,t),

3.84(3H,s), 4.03(4H,t), 5.07(1H,q), 6.68(3H,m), 6.83(1H,s), 7.37(1H,s), 7.82(1H,s)

### Example 224

Ethyl 2-(([4-(3,5-dimethoxyphenyl)piperazino]carbonyl)-2-methoxy-4,5-dimethylanilino)acetate:

- 1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-dimethoxy phenyl)piperazine(0.2g, 0.5mmol) was dissolved in dimethylformamide(15ml), sodium hydride(18.5mg, 0.5mmol) was added thereto, and the resulting mixture was stirred at room temperature.
- Then, ethyl bromoacetate(83.5mg, 0.5mmol) was added thereto and the resulting mixture was stirred for 3 hours, concentrated under the reduced pressure to remove the used solvent and purified by column chromatography(ethylacetate:hexane=1:2) to obtain the titled compound. yield: 79%
- 25 m.p.: oil phase

  <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 1.36(3H,t), 2.15(3H,s), 2.23(3H,s), 2.91(4H,t), 3.22(4H,t), 3.82(6H,s), 4.12(3H,s), 4.18(2H,s), 5.98(3H,m), 6.69(1H,s), 7.03(1H,s)

#### 30 Example 225

Ethyl 2-({[4-(3,5-dimethylphenyl)piperazino]carbonyl}-2-methoxy-4,5-dimethylanilino)acetate:

1-[(4,5-Dimethyl-2-methoxyphenyl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 224 to obtain the titled compound.

yield: 78%

m.p.: oil phase

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  1.26(3H,t), 1.56(6H,s), 2.17(3H,s), 2.24(3H,s), 3.32(4H,t), 3.52(4H,t), 3.82(3H,s), 4.15(2H,q), 4.18(2H,s), 6.70(3H,m), 6.94(1H,s), 7.46(1H,s)

5

# Example 226

2-({[4-(3,5-Dimethoxyphenyl)piperazino]carbonyl}-2-methoxy-4,5-dimethylanilino)acetic acid:

Ethyl 2-({[4-(3,5-dimethoxyphenyl)piperazino]carbonyl}-2-methoxy-4,5-dimethylanilino)acetate(200mg, 0.41mmole) was dissolved in dioxane:distilled water(4:1, 15ml), lithium hydroxide monohydrate(50.7mg, 1.23mmol) was added thereto, and then the resulting mixture was stirred at room temperature for 3 hours, acidified with 1N-hydrochloric acid, extracted with ethylacetate, filtered to dryness, concentrated under

the reduced pressure to remove the used solvent, and purified by column chromatography(ethylacetate:hexane=1:2) to obtain the titled compound.

yield: 80%

m.p.: 188-189℃

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.14(3H,s), 2.23(3H,s), 2.93(4H,t), 3.35(4H,t), 3.75(6H,s), 3.87(3H,s), 4.18(2H,s), 5.96(3H,m), 6.71(1H,s), 7.71(1H,s)

#### Example 227

2-({[4-(3,5-Dimethylphenyl)piperazino]carbonyl}-2-methoxy-4,5-

25 dimethylanilino)acetic acid:

Ethyl 2-(([4-(3,5-dimethylphenyl)piperazino]carbonyl}-2-methoxy-4,5-dimethylanilino)acetate was reacted by the same way with the example 226 to obtain the titled compound.

yield: 78%

30 m.p.: 170-171℃

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.13(3H,s), 2.24(9H,s), 2.91(4H,t), 3.35(4H,t), 3.83(3H,s), 4.18(2H,s), 6.45(3H,m), 6.70(2H,s), 6.80(1H,s)

### Example 228

35 1-[(2-Hydroxy-4,5-dimethylphenyl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

- (a) 4.5-Dimethyl-2-nitrophenol:
- To 3,4-dimethylphenol(12.1g, 0.1mol), trifluoroacetic acid(250ml) was added, and in water bath sodium nitrite(12.4g, 0.18mol) was added slowly. The resulting mixture was stirred at room temperature for 14 hours and concentrated under the reduced pressure to remove trifluoroacetic acid, followed by addition of water(150ml), extracted with ether and purified by column chromatography to obtain the titled compound.
- 10 yield: 80%

  <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.23(3H,s), 2.29(3H,s), 6.93(1H,s), 7.84(1H,s)
  - (b) 4.5-Dimethyl-2-hydroxyaniline:
- To 4,5-dimethyl-2-nitrophenol(11.7g, 0.07mol), tetrahydrofuran(100ml) and ethanol(40ml) were added, and 10% palladium/activated carbon(0.57g) was added slowly, and then the mixture was hydrogenated for 5 hours. The reaction mixture was concentrated and chromatographed by the same way above to obtain the titled compound.
- 20 yield: 77%

  <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.11(6H,s), 6.56(2H,s)
- (c) Phenyl N-(4,5-dimethyl-2-hydroxyphenyl)carbamate:
  To 4,5-dimethyl-2-hydroxyaniline(6.80g, 0.05mole), methylene
  chloride(100ml) was added and then phenyl chloroformate(8.0g, 0.05mole)
  was added slowly. After stirring for 2 hours, addition of water(150ml),
  extraction with methylene chloride and column chromatography gave
  the titled compound.
  vield: 92%
- 30 <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.17(6H,s), 6.74(1H,s), 7.15(5H,m), 7.31(1H,s)
- (d) Phenyl N-[2-(t-butyldimethylsilyloxy)-4,5-dimethylphenyl]carbamate: To a mixture of phenyl N-(4,5-dimethyl-2-hydroxyphenyl)carbamate (7.72g, 0.03mol) and imidazole(2.2g, 33mmol), methylene chloride(100ml) was added, and with stirring t-butyldimethylsilylchloride(5.0g, 33mmole)

WO 98/00402 PCT/KR97/00128

- 104 -

was added. Then the mixture was stirred for 2 hours, and water(150ml) was added thereto. The resulting mixture was extracted with methylene chloride, dried, concentrated under the reduced pressure and purified by column chromatography to obtain the titled compound.

5 yield: 83%

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 0.27(6H,s), 0.98(9H,s), 2.17(6H,s), 7.12(5H,m), 7.30(2H,s)

- (e) 1-[(2-Hydroxy-4,5-dimethylphenyl)aminocarbonyl]-4-
- 10 (3,5-dimethoxyphenyl)piperazine:

Phenyl N-[2-(t-butyldimethylsilyloxy)-4,5-dimethylphenyl]carbamate (0.17g, 0.5mmole) and 1-(3,5-dimethoxyphenyl)piperazine(0.13g. 0.6mmole) were dissolved in tetrahydrofuran(10ml), and thereto with stirring DBU(0.09g, 0.6mmole) was added, and the resulting mixture

15 was stirred for 2 hours, concentrated and chromatographed to obtain the titled compound.

yield: 87%

m.p.: 145-146°C

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.14(3H,s), 2.18(3H,s), 3.26(4H,t), 3.67(4H,t), 20 3.79(6H,s), 6.07(3H,m), 6.40(3H,m), 6.67(1H,s), 6.82(1H,s), 8.87(1H,s)

### Example 229

1-[(2-Hydroxy-4,5-dimethylphenyl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

25 Phenyl N-[2-hydroxy-4,5-dimethylphenyl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 228 to obtain the titled compound.

yield: 84%

m.p.: 160-162°C

'H NMR(500MHz, CDCl<sub>3</sub>):  $\delta$  2.13(3H,s), 2.17(3H,s), 2.31(6H,s). 3.26(4H,t), 3.75(4H,t), 6.73(3H,m), 6.81(1H,s), 8.86(1H,s)

### Example 230

1-[(2-Hydroxy-4,5-dimethylphenyl)aminocarbonyl]-4-(3,5-difluorophenyl)

35 piperazine:

Phenyl N-[2-hydroxy-4,5-dimethylphenyl)carbamate and

1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 228 to obtain the titled compound.

yield: 80%

m.p.: 152-154°C

5 <sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.17(3H,s), 2.20(3H,s), 3.30(4H,t), 3.70(4H,t), 6.40(3H,m), 6.70(1H,s), 6.82(1H,s), 6.98(1H,s)

# Example 231

1-[(2-hydroxy-4,5-dimethylphenyl)aminocarbonyl]-4-(3,5-dichlorophenyl)
10 piperazine:

Phenyl N-(2-hydroxy-4,5-dimethylphenyl)carbamate and 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 228 to obtain the titled compound.

yield: 77%

m.p.: oil phase

<sup>1</sup>H NMR(500MHz, CDCl<sub>3</sub>): δ 2.15(3H,s), 2.20(3H,s), 3.32(4H,t), 3.69(4H,t), 6.29(3H,m), 6.69(1H,s), 6.81(1H,s), 8.65(1H,s)

20

25

30

WO 98/00402 PCT/KR97/00128

Antitumor activities of compounds of the present invention were tested in vitro against 5 kinds of human tumor cell lines and 2 kinds of leukemia tumor cell lines. The method and result of in vitro tests is as follows.

5

10

Experimental 1: In vitro antitumor effect against human tumor cell lines.

A. Tumor cell line: A549 (human non-small lung cell)

SKOV-3 (human ovarian)

HCT-15 (human colon) XF 498 (human CNS)

SKMEL-2 (human melanoma)

15 B. SRB Assay Method.

a. Human solid tumor cell lines, A549(non-small lung cell), SKMEL-2(melanoma), HCT-15(colon), SKOV-3(ovarian), XF-498(CNS) were cultured at 37°C, in 5% CO<sub>2</sub> incubators using the RPMI 1640 media containing 10% FBS, while they were transfer-cultured successively once or twice per week. Cell cultures were dissolved in a solution of 0.25% trypsin and 3 mM CDTA PBS(-) and then cells were separated from media which the cells were sticked on.

25

- b.  $5 \times 10^3 \sim 2 \times 10^4$  cells were added into each well of 96-well plate and cultured in 5% CO<sub>2</sub> incubator, at 37°C, for 24 hours.
- c. Each sample drug was dissolved in a little DMSO and diluted with the used medium to a prescribed concentration for experiments, wherein the final concentration of DMSO was controlled below 0.5%.
- d. Medium of each well cultured for 24 hours as above b. was removed by aspiration. Each 200 µl of drug samples prepared in c. was added into each well and the wells were cultured for 48 hours. Tz(time zero) plates were collected at the point of time drugs were added.

e. According to the SRB assay method, cell fixing with TCA, staining with 0.4% SRB solution, washing with 1% acetic acid and elution of dye with 10mM Tris solution were carried out on Tz plates and culture-ended plates, and then, OD values were measured at 520 nm.

5

### C. Calculation of result

a. Time zero(Tz) value was determined with measuring the SRB protein value at the point of time drugs were added.

10

- b. Control value(C) was determined with the OD value of an well untreated with drug.
- c. Drug-treated test value(T) was determined with the OD value of drug-treated well.
  - d. Effects of drugs were estimated with growth stimulation, net growth inhibition, net killing etc. calculated from Tz, C and T.
- 20 e. If  $T \ge Tz$ , cellular response function was calculated by 100x(T-Tz)/(C-Tz), and if T < Tz, by  $100 \times (T-Tz)/Tz$ . The results are shown in the next table 1.

#### \* REFERENCE

- P. Skehan, R. Strong, D Scudiero, A. Monks, J. B. Mcmahan, D. T. Vistica, J. Warren, H. Bokesh, S. Kenny and M. R. Boyd: Proc. Am. Assoc. Cancer Res., 30, 612(1989)
  - 2) L. V. Rubinstein, R. H. Shoemaker, K. D. Paull, R. M. simon, S. Tosini, P. Skehan, D. Scudiero, A. Monks and M. R. boyd.; J. Natl.
- 30 Cancer Inst., 82, 1113(1990)
  - 3) P. Skehan, R. Strong, D. Scudiero, A. monks, J. B. Mcmahan, D. T. Vistica, J. Warren, H. Bokesh, S. Kenny and M. R. Boyd.; J. Natl. Cancer Ins., 82, 1107(1990)

#### 35 D. Results.

It was found that compounds of the present invention have the

superior antitumor activities than those of cisplatin, one control, and equal to or higher antitumor activities than those of adriamycin, another control, against human solid cancer cell lines.

5	Table	1.

 $ED_{50}=\mu g/ml$ 

-						
į	Ex. No.	<b>A54</b> 9	SK-OV-3	SK-MEL-2	XF-498	HCT 15
	4	0.007	0.022	0.007	0.94	0.093
1	5	0.71	0.96	0.60	>10.0	0.96
10	9	0.15	0.07	0.21	0.11	0.11
	11	0.91	0.56	0.62	0.73	0.71
	14	0.022	0.02	0.001	0.16	0.007
	15	0.002	0.05	0.052	0.035	0.038
15	16	0.008	0.04	0.038	0.005	0.061
	17	0.018	0.01	0.021	0.077	0.008
	22	0.0009	0.006	0.027	0.0053	0.01
20	23	0.09	0.04	0.09	0.092	0.05
20	24	0.03	0.006	0.01	0.234	0.01
	27	0.02	0.11	0.01	0.046	0.165
	28	0.06	0.07	0.001	0.41	0.05
05	46	0.21	0.12	0.08	0.14	0.16
25	47	0.92	0.62	0.47	0.64	0.81
	53	0.47	0.47	0.64	0.67	0.71
	56	0.017	0.0027	0.01	0.013	0.045
	57	0.27	0.15	0.18	0.22	0.25
30	63	0.04	0.1	0.11	0.03	0.07
	64	0.42	0.56	0.52	0.23	0.37
	73	0.01	0.0054	0.02	0.013	0.012
35	74	27         0.02         0.11         0.01         0.046         0.165           28         0.06         0.07         0.001         0.41         0.05           46         0.21         0.12         0.08         0.14         0.16           47         0.92         0.62         0.47         0.64         0.81           53         0.47         0.47         0.64         0.67         0.71           56         0.017         0.0027         0.01         0.013         0.045           57         0.27         0.15         0.18         0.22         0.25           63         0.04         0.1         0.11         0.03         0.07           64         0.42         0.56         0.52         0.23         0.37           73         0.01         0.0054         0.02         0.013         0.012           74         0.016         0.0138         0.02         0.026         0.021	0.021			
33	75	0.19	0.09	0.09	0.13	0.12

Ex. No. 81	A549 0.0032	SK-OV-3	SK-MEL-2	XF 498	HCT 15
	U.UU3Z I	0.0007	0.0107	0.0007	-
		0.0007	0.0107	0.0097	0.0054
82	0.0676	0.0249	0.0754	0.0479	0.0346
85	0.048	0.117	0.039	0.104	0.10
88	0.014	0.043	0.02	0.009	0.011
99	0.43	0.41	0.40	0.52	0.36
100	4.54	3.02	3.47	0.66	4.21
103	0.52	0.46	0.49	0.36 •	0.33
109	0.47	0.91	0.86	0.53	0.49
110	0.52	1.06	0.97	0.81	0.69
112	0.56	6.43	0.22	2.07	0.61
128	0.40	0.37	0.42	0.44	0.51
132	0.03	0.01	0.03	0.04	0.04
133	0.57	0.94	0.53	0.61	0.57
134	0.0009	0.0091	0.0086	0.002	0.0065
135	0.056	0.092	0.102	0.06	0.066
140	0.33	0.47	0.56	0.54	0.49
142	0.015	0.011	0.021	0.026	0.017
143	0.0004	0.0095	0.0121	0.0009	0.0108
147	0.031	0.092	0.024	0.466	0.18
148	0.01	0.07	0.03	0.05	0.05
151	0.004	0.008	0.007	0.007	0.037
152	0.18	0.37	0.2	0.26	0.44
156	0.06	0.10	0.09	0.06	0.07
157	0.000002	0.000002	0.000043	0.000245	0.000211
-	0.05	0.10	0.07	0.21	0.17
	99 100 103 109 110 112 128 132 133 134 135 140 142 143 147 148 151 152 156	99 0.43 100 4.54 103 0.52 109 0.47 110 0.52 112 0.56 128 0.40 132 0.03 133 0.57 134 0.0009 135 0.056 140 0.33 142 0.015 143 0.0004 147 0.031 148 0.01 151 0.004 152 0.18 156 0.06 157 0.000002	99         0.43         0.41           100         4.54         3.02           103         0.52         0.46           109         0.47         0.91           110         0.52         1.06           112         0.56         6.43           128         0.40         0.37           132         0.03         0.01           133         0.57         0.94           134         0.0009         0.0091           135         0.056         0.092           140         0.33         0.47           142         0.015         0.011           143         0.0004         0.0095           147         0.031         0.092           148         0.01         0.07           151         0.004         0.008           152         0.18         0.37           156         0.06         0.10           157         0.000002         0.000002	99         0.43         0.41         0.40           100         4.54         3.02         3.47           103         0.52         0.46         0.49           109         0.47         0.91         0.86           110         0.52         1.06         0.97           112         0.56         6.43         0.22           128         0.40         0.37         0.42           132         0.03         0.01         0.03           133         0.57         0.94         0.53           134         0.0009         0.0091         0.0086           135         0.056         0.092         0.102           140         0.33         0.47         0.56           142         0.015         0.011         0.021           143         0.0004         0.0095         0.0121           147         0.031         0.092         0.024           148         0.01         0.07         0.03           151         0.004         0.008         0.007           152         0.18         0.37         0.2           156         0.06         0.10         0.00002      <	99         0.43         0.41         0.40         0.52           100         4.54         3.02         3.47         0.66           103         0.52         0.46         0.49         0.36           109         0.47         0.91         0.86         0.53           110         0.52         1.06         0.97         0.81           112         0.56         6.43         0.22         2.07           128         0.40         0.37         0.42         0.44           132         0.03         0.01         0.03         0.04           133         0.57         0.94         0.53         0.61           134         0.0009         0.0091         0.0086         0.002           135         0.056         0.092         0.102         0.06           140         0.33         0.47         0.56         0.54           142         0.015         0.011         0.021         0.026           143         0.0004         0.0095         0.0121         0.0009           147         0.031         0.092         0.024         0.466           148         0.01         0.07         0.03

	Ex. No.	A549	SK-OV-3	SK-MEL-2	XF 498	HCT 15
	171	0.000645	0.00372	0.003233	0.000572	0.001809
	172	0.0047	0.0097	0.0233	0.0086	0.0180
5	174	0.54	0.56	0.27	0.49	0.33
	1 <b>7</b> 7	0.52	0.39	0.17	0.12	0.09
	179	1.04	0.98	0.72	0.74	0.63
	183	0.42	2.27	1.17	1.41	2.09
10	184	0.28	0.34	0.17	0.12	0.20
i	190	0.004	0.008	0.002	0.443	0.017
	191	0.09	0.28	0.06	0.47	0.40
	198	0.021	0.068	0.008	0.072	0.56
15	200	0.50	0.53	0.26	1.01	0.44
	201	0.014	0.053	0.049	0.026	0.071
	202	0.57	1.26	0.48	2.09	0.64
20	206	0.47	0.54	0.52	0.70	0.38
	Cisplatin	0.8184	0.7134	0.7147	0.7771	3.0381
	Adriamycin	0.0168	0.0176	0.0108	0.0250	1.6689

## Experimental 2.

In vitro antitumor effects against animal leukemia cells.

### A. Materials:

30

Tumor cell lines: L1210(mouse leukemia cell)
P388 (mouse lymphoid neoplasma cell)

- B. Method: Dye Exclusion Assay.
- 1) The concentrations of L1210 and P388 cells being cultured in 35 RPMI 1640 media containing 10% FBS were regulated to  $1\times10^6$  cells/ml.

- 2) Sample drugs of respective concentrations diluted in the ratio of log doses were added into cell media, and cultured at 37°C, for 48 hours, in 50% CO<sub>2</sub> incubator, and then viable cell number was 5 measured by dye exclusion test using trypan blue.
  - 3) The concentration of sample compounds showing 50 % cell growth inhibition(IC<sub>50</sub>) compared with the control were determined and listed in the table 2 below.

## \* REFERENCE

- 1) P. Skehan, R. Strong, D. Scudiero, A. Monks, J. B. Mcmahan, D. T. Vistica, J. Warren, H. Bokesh, S. Kenney and M. R. Boyd.: Proc. Am. Assoc. Cancer Res., 30, 612(1989).
- 2) L. V. Rubinstein, R. H. Shoemaker, K. D. Paull, R. M. Simon, S. Tosini, P. Skehan, D. Scudiero, A. Monks, J. Natl. Cancer Inst., 82, 1113(1990)
- P. Skehan, R. Strong, D. Scudiero, J. B. Mcmahan, D. T. Vistica, J. Warren, H. Bokesch, S. Kenney and M. R. Boyd. : J. Natl. Cancer
   Inst., 82, 1107(1990)

## C. Results

As the results of measurement of antitumor activities of compounds of the present invention against L1210 and P388 mouse cancer cells, it was found that the compounds tested have equal to or higher antitumor activities than those of the control drug, mitomycin C.

	Ex. No.	L1210	P388
	8	0.9	0.4
	12	0.2	
5	13	0.5	
	14	0.3 -	-
	15	0.3	0.4
	16	0.5	0.3
10	17	1.2	0.8
	24	0.5	0.5
	49	1.5	_
•	56	0.2	0.2
15	57	1.8	1.2
	60	1.1	<u>-</u>
	63	0.5	0.3
	. 64	1.9	1.4
20	69	-	0.5
	71	-	0.07
	72	-	0.9
0.5	73	0.2	0.04
25	74	0.5	0.4
	76	-	0.4
	77	-	0.5

	Ex. No.	L1210	P388
	132	0.4	0.4
5	134	0.5	0.2
	140	1.8	1.6
	143	0.5	0.4
	144	1.2	0.5
	148	1.6	-
10	149	1.0	0.6
ļ	151	-	1.2
	152	0.3	0.3
	154	, <del>-</del>	0.1
15	157	1.7	. 1.0
	158	0.5	0.2
	170	0.4	0.4
_	173	0.5	0.2
20	178	1.8	1.6
	181	0.5	0.4
	182	1.2	0.5
05	186	1.6	-
25	187	1.0	0.6
	190	0.3	0.3
	195	1.7	1.0
200	196	0.5	0.2
30	Mitomycin	1.6	1.1

# 35 Experimental 3.

<sup>\*</sup> In vivo antitumor effects against mouse leukemia P388 cells.

WO 98/00402 PCT/KR97/00128

- 114 -

- A. Material of experiment
   BDF1 mice were used.
- B. Method of experiment
- Leukemia P388 cells being transfer-cultured successively in
   DBA/2 mouse, were grafted into each mouse of a group comprising 8 mice of 6 week old BDF1 mouse with the dose of 1×10<sup>6</sup>cells/0.1ml.
- 2) Sample drugs were dissolved in PBS or suspended in 0.5% tween 80, and then injected into abdominal cavity of mouse at each prescribed concentration on days 1, 5, 9, respectively.
- 3) With observation everyday, survival times of tested mice were measured. Antitumor activities was determined in such a manner that the increasing ratio(T/C%) of average survival days of drug-treated groups compared with the control group was calculated using the mean survival times of each tested groups.
  The results are shown at the next table 3.

20

25

- 115 -

	Ex. No.	Dose(mg/kg)	T/C(%)	Interval of administration
	8	200 100	140.9 104.5	on days 1, 5, 9
5	15	25 10	150 110	nine everyday
	16	50 25	165 110	nine everyday
10	22	100 50 25	150 140 110	nine everyday
15	56	200 100 50	227.3 140.9 118.2	on days 1, 5, 9
20	56	50 25 10	165.0 145.0 140.0	nine everyday
20	73	50 25 10	180.0 150.0 140.0	nine everyday
25	74	50 25 10	250.0 150.0 140.0	nine everyday

	Ex. No.	Dose(mg/kg)	T/C(%)	Interval of adminstration
		200	218.2	
	81	100	145.5	on day 1, 5, 9
5	·	50	127.3	
		50	210.0	
	81	25	140.0	nine everyday
		10	140.0	
	82	100	127.3	on days 1, 5, 9
10	32	50	100.0	on days 1, 5, 9
		100	150.0	
	98	50	110.0	nine everyday
		25	110.0	
		100	150.0	
15	135	50	110.0	nine everyday
•		25	100.0	
		200	125.0	·
	144	100	110.0	nine everyday
20		50	110.0	
		100	140.0	
	171	50	100.0	on days 1, 4, 8
		. 25	100.0	
05		200	190.9	
25	172	100	127.3	on days 1, 4, 8
		50	118.2	

- 117 -

# \* REFERENCE

A. Goldin et al.: Euro. J. Cancer, 17, 129 (1981).

### 5 C. Result

Through in vivo experiments using P388 mouse cancer cells, significant antitumor effect of the compounds of examples were observed.

10

### Experimental 4.

Acute toxicity test (LD50): Litchfield-Wilcoxon method.

- 6 weeks old ICR mice(male 30±2.0g) were fed freely with solid feed and water at room temperature, 23±1°C and at humidity 60±5%. Sample drugs were injected into the abdominal cavities of mice, while each group comprises 6 mice. Observed during 14 days, external appearances and life or dead were recorded, and then, visible
- pathogenies were observed from dead animals by dissection. LD<sub>50</sub> value was calculated by Litchfiled-wilcoxon method.

  The results are shown at the next table 4.

25

	Ex. No.	LD <sub>50</sub> (mg/kg)(i.p)
	8	707
_	12	165
5	13	284.8
	15	190
	16	282.8
10	22	>2,000
	28	>2,000
	56	410
	57	455
15	73	250
	74	361.4
	81	1,600
20	82	700
	170	573
	172	723
	182	348
25	184	309
	186	>2,000
	187	417.6
30	Cisplatin	9.7

As described above, it was found that the compounds of the present invention are more safer and have superior antitumor activities to cisplatin, and accordingly have solved the problems of drugs by the prior art such as restriction of dosage, toxicity, etc.

WO 98/00402 PCT/KR97/00128

- 119 -

#### What is claimed:

35

#### 1. A compound of the general formula(I)

wherein R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C2-C8 unsaturated alkyl, ketone, substituted or unsubstituted aryl, substituted or unsubstituted C<sub>1</sub>-C<sub>4</sub> alkoxy, substituted or unsubstituted arylhydroxy, substituted or unsubstituted amino, C1-C4 lower ester, C1-C4 lower thioester, thiol, substituted or unsubstituted carboxyl, epoxy, substituted or unsubstituted C<sub>1</sub>-C<sub>4</sub> lower thioalkoxy; or R<sub>1</sub> and R<sub>2</sub> are fused to form C<sub>3</sub>-C<sub>4</sub> saturated or unsaturated chain: R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are independently hydrogen, halogen, hydroxy, nitro, C<sub>1</sub>-C<sub>4</sub> lower ester, C<sub>1</sub>-C<sub>4</sub> lower alkyl, C<sub>1</sub>-C<sub>4</sub> lower thioalkyl, substituted or unsubstituted C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>4</sub> lower alkoxy, C<sub>1</sub>-C<sub>4</sub> lower thioalkoxy, substituted or unsubstituted aryl, substituted or unsubstituted lower arylalkoxy, substituted or unsubstituted lower alkylamino, or lower alkyl substituted or unsubstituted carbamate; or among R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub>, two adjacent groups are bonded with each other to form 1,2-phenylene or 2,3-naphthylene; X is oxygen, sulfur, or substituted or unsubstituted imino; Y is bonded at the 3-position or 4-position of the aromatic ring part wherein Y is oxygen or -NR<sub>8</sub>- (wherein, R<sub>8</sub> is the same with the above-mentioned R<sub>3</sub>.); Z is hydroxy, C<sub>1</sub>-C<sub>4</sub> lower alkoxy, C<sub>1</sub>-C<sub>4</sub> lower thioalkoxy, substituted or unsubstituted aryloxy, C1-C4 lower alkylamino, substituted or unsubstituted cycloamino containing 1-5 nitrogen atoms; A is nitrogen or -CH=; and pharmaceutically acceptable acid addition salts thereof.

2. A process for the preparation of compound of the general formula(I) or a pharmaceutically acceptable acid addition salt thereof comprising reacting a compound of the general formula(a) with a -C(=X)-group-providing agent in the presence of organic solvent to obtain a compound of the general formula(b) and reacting the compound of the general formula(c).

10 
$$R_2$$
  $R_3$   $R_4$   $R_5$   $R_7$   $R_8$   $R_9$   $R$ 

wherein,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ , A, X, Y and Z are as defined above and Lie is a leaving group.

3. A process for the preparation of compound of the general formual(Ib) by introducing R<sub>8</sub> providing agent into a compound of the general formula(Ia).

30

35

wherein, R1, R2, R3, R4, R5, R6, R7, R8, A, X and Z are as defined above.

#### INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 97/00128

#### A. CLASSIFICATION OF SUBJECT MATTER

IPC<sup>6</sup>: C 07 D 213/65, 213/68, 295/108, 295/13, 409/04

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>6</sup>: C 07 D 213/00, 295/00, 409/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AT; Chem. Abstr.

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Questel: DARC, CAS; EPO: WPI

#### C. DOCUMENTS CONSIDERED TO BE RELEVANT

Further documents are listed in the continuation of Box C.

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 96/21 648 A1 (SAMJIN PHARMACEUTICAL CO., LTD.) 18 July 1996 (18.07.96), claims 1,2.	1-3
A	Chemical Abstracts, Vol.110, No.4, 23 January 1989 (Columbus, Ohio, USA), page 499, column 1, abstract No.31325d, YOSHIMOTO, S. et al.: "Silver halide photographic material giving stable magenta color images", & Jpn. Kokai Tokkyo Koho JP 63,115,167 [88,115,167].	1-3
A	US 5 461 047 A (HANSEN) 24 October 1995 (24.10.95), claims; example 43.	1-3
A	AT 336 030 B (RHONE-POULENC) 12 April 1977 (12.04.77), claims.	1-3
A	EP 0 547 517 Al (THOMAE) 23 June 1993 (23.06.93), claims.	1-3
		,

سا		ننا	
-4-	Special categories of cited documents:  document defining the general state of the art which is not considered to be of particular relevance.	-T-	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" "L" "O" "P"	cartier document but published on or after the international filling date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another cluston or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filling date but later than the priority date claimed	"X" "Y"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
Date	e of the actual completion of the international search	Date	of mailing of the international search report
o	3 September 1997 (03.09.97)	0	5 September 1997 (05.09.97)
	ne and mailing address of the ISA/AT AUSTRIAN PATENT OFFICE KOhlmarkt 8-10 A-1014 Vienna nimile No. 1/53424/535		Hammer Hone No. 1/53424/374

X See patent family annex.

Form PCT/ISA/210 (second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT Information on patent family members

International application No.

PCT/KR 97/00128

angeführte Patent in sea Document	erchenbericht is Patentdokument document cited urch report de brevet cité opport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mituliedler) der Pafentfamilie Patent family aember(s) Hembre(s) de la familie de brevets	Datum der Veröffent i Ichung Publication date Date de publication
WO A1	9621.648	18-07-96	A1 440054 C77945294564 C1845294564 C1845294564 C1845294564 C1945294564 C19464 C	31-07-96 18-07-96 19-07-96 19-03-97 27-12-96 10-09-96 10-09-96 11-11-96 20-07-96
US A	5461047	24-10-95	AU A1 71387/94 CA AA 2165159 EP A1 703908 JP T2 9500107 US A 5354747 WO A1 9429286	03-01-95 22-12-94 03-04-96 07-01-97 11-10-94 22-12-94
AT B	336030	12-04-77	116414103178009965579990255899174220194777674141122577737764688875111915755557754044119947777674141122904860222111736666577976668870445587046100400288778884977888388788055851114444 22511	77-6475777995478666995858685755524997677967887775336 

7-44-4077 7887-77-788-7	INTERNATIONAL SEARCH REPORT Information on patent family members	International application No. PCT/KR 97/00128
	EP A1 547517 23-06-93	77777788897889777018871171016975571771688007727927 554887873777888777788877778887777888777788877778887777

# INTERNATIONAL SEARCH REPORT Information on patent family membe.s

International application No. PCT/KR 97/00128

ABAACTAABTAAA	29 29 29 29 29 29 29 29 29 29 29 29 29 2	17-04-99333-64-999333-64-9999999999999999999
HILLPODYAGG	4455445554 10738648808080 10802245558 692245658 9222554	28-02-95 04-95 04-96 -04-96 22-92 11-12-95 24-102-95 26-105 21-10